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Tissue ischemia is a major cause of morbidity contributing to disease processes 
such as cardiovascular diseases, stroke, cancer, and traumatic injury and may lead to 
death. Failure to quickly reestablish flow to ischemic tissue results in tissue death. 
However, even timely return to normal flow has a downside in that the reintroduction of 
oxygen to ischemic tissue results in ischemia/reperfusion (I/R) injury that produces an 
oxidant stress. This pathological process requires new therapeutic strategies and agents to 
reduce the personal, social and economic loss. One of the most generally accepted 
mechanisms for the pathology of I/R injury is the production of the reactive oxygen 
species (ROS), suggesting antioxidants may ameliorate I/R injury.  
 
 vii
Caffeic acid phenethyl ester (CAPE), a plant derived polyphenolic compound, has 
been shown to protect organs from I/R induced damage in vivo, and this effect has been 
attributed to its antioxidant activity. To better understand the mechanism of CAPE 
protection, a model using menadione-induced oxidative stress in human endothelial cells 
to simulate I/R injury in vitro was developed.  Gene expression analysis was performed 
with microarrays undergoing cytoprotection with CAPE. The dose-dependent 
cytoprotection of CAPE has been related to its induction of heme oxygenase-1 (HO-1).  
With the aim of improving the beneficial effect of CAPE and understanding 
structure activity relationship, six new catechol ring-fluorinated CAPE derivatives were 
synthesized and evaluated in the menadione-endothelial cell model. The data suggest 
good cytoprotective effects of CAPE and some analogues and indicate important 
structural features for cytoprotection. Further investigation of the mechanism of 
cytoprotection showed that cytoprotection profiles of CAPE and derivatives correlate 
better to their ability to induce HO-1 in human endothelial cells than free radical 
scavenging activity.  
One CAPE derivative (FCAPE) with cytoprotective effects similar to CAPE in 
vitro exhibited better stability in rat plasma. A validated ultra-performance liquid 
chromatography/tandem mass spectrometric method was developed that allowed for 
quantification of CAPE and FCAPE in plasma samples. Pharmacokinetic studies in male 
Sprague Dawley rats following intravenous bolus administration of 5, 10, and 20 mg/kg 
CAPE and 20 mg/kg FCAPE were performed. The results indicate that dose 
proportionality for CAPE does not exist in the dose range studied. Although the 
elimination half life was found not to be significant different between CAPE and FCAPE, 
significant difference was observed between the total body clearance of FCAPE and 
CAPE which may due to the difference in volume of distribution.    
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Statement of Objectives and Significance of Research 
 
This dissertation is the result of an effort directed towards drug development for 
ameliorating ischemia/reperfusion (I/R) injury using CAPE and its fluorinated derivatives 
as model drugs to establish structure cytoprotection relationships, understand the 
mechanism of cytoprotection, and characterize the pharmacokinetic profiles of CAPE and 
the most cytoprotective derivative (FCAPE) in male Sprague Dawley rats. 
 
The following specific aims were proposed in order to: 
 
1. Establish an in vitro cytoprotection assay of CAPE against oxidative stress in   
    human umbilical vein endothelial cells that simulates I/R injury; 
 
2. Synthesize six new CAPE derivatives fluorinated in the catechol ring; 
 
3. Determine structure activity relationships between CAPE and its fluorinated 
    derivatives and cytoprotection; 
 
4. Investigate the cytoprotection mechanism of CAPE and its fluorinated  
    derivatives: evaluate the role of heme oxygenase-1 induction and  
    antioxidant activity; 
 
5. Quantitatively determine CAPE and FCAPE in rat plasma using liquid   
    chromatography with electrospray ionization tandem mass spectrometry; 
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6. Characterize the pharmacokinetic profiles of CAPE and FCAPE following 
    intravenous bolus administration to male Sprague Dawley rats. 
 
Ischemia is a restriction in blood supply, generally due to factors in blood vessels, 
with resultant damage or dysfunction to tissue. Restoration of blood flow after a period of 
ischemia can actually be more damaging than the ischemia. Reintroduction of oxygen 
causes a greater production of damaging free radicals, resulting in reperfusion injury. 
With reperfusion injury, cellular damage can be greatly accelerated. Ischemia and 
subsequent reperfusion injury occurs in many situation. Traumatic injury, heart disease 
and ultimately aging, are failures of the endothelial cell of the circulatory system to 
present a nonthrombogenic surface to circulating blood, leading to clot formation that 
may block downstream vessels leading to ischemia/ reperfusion injury. Alteplase, 
recombinant tissue plasminogen activator, approved by the Food and Drug 
Administration 1987 was a major achievement in eliminating the clot before too severe 
ischemia leads to tissue death. Alteplase is indicated for the treatment of acute 
myocardial infarction, pulmonary embolism, and acute ischemic stroke, but few other 
treatments are available. 
There is a large body of information indicating oxidant stress accompanies 
ischemia reperfusion injury and that application of antioxidants before or shortly after 
removal of the blockage reduces the degree of injury and aids in a more rapid recovery.  
A significant number of studies indicate that administration of CAPE, a plant-derived 
antioxidant, benefits outcome of I/R injury in vivo as well as cytoprotective effects in 
vitro. CAPE and its fluorinated derivatives are the subjects of the current series of 
studies.  
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The hypothesis was tested that induction of heme oxygenase-1(HO-1) played a 
major role in the protection by CAPE and its fluorinated derivatives against oxidative 
injury and that selective structural modifications of CAPE could improve its 
pharmacological activity in vitro and in vivo. The hypothesis was based on the following 
observations. First, the induction of heme oxygenase-1 and its heme-catalyzing products 
ameliorates I/R injury in different organs in vivo. Second, the suppression of heme 
oxygenase-1 enhanced apoptosis in lung I/R injury both in vitro and in vivo in an organ-
specific manner. Third, CAPE was shown to be a novel class of HO-1 inducers in vitro. 
A comprehensive understanding of CAPE and its structure activity relationships 
following derivatization with fluorine to cytoprotection, the mechanism of 
cytoprotection, and the in vivo fate after intravenous administration may facilitate 













Chapter I: Introduction and Literature Review 
 
1.1 ISCHEMIA, REPERFUSION, AND ISCHEMIA/REPERFUSION (I/R) INJURY 
 
1.1.1 The Definition and Significance of Ischemia, Reperfusion, and I/R Injury 
 
Ischemia (Greek ισχαιμία, isch- restriction, hema or haema- blood) refers to the 
prolonged interruption of blood supply to a tissue or organ leading to a deprivation of 
oxygen and nutrients to the constituent cells, which may result in cell damage, and 
subsequent cell, tissue, or organ death. Reperfusion is required to restore oxygen and 
nutrients for normal metabolic function. However, the reintroduction of oxygen to 
ischemic tissue generates reactive oxygen species (ROS) that worsen vascular and 
cellular injury.  
Ischemia reperfusion (I/R) injury is a potentially serious pathologic state involved 
in a number of cardiovascular diseases such as myocardial infarction and stroke, and also 
occurs following septic or circulatory shock, surgery, organ transplantations, and 
traumatic injury which cause great economic loss and may lead to death. The National 
Heart, Lung, and Blood Institute (NHLBI) has requested proposals to investigate new 
therapeutic strategies and agents to ameliorate I/R induced injury in cardiovascular 
diseases, hemostatic and thrombotic diseases [1]. Understanding I/R injury and 
corresponding mechanism will help achieve this goal. 
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1.1.2 The Mechanism of I/R Injury 
 
A generally accepted mechanism for the pathology of I/R injury is the production 
of ROS such as superoxide anion (O2•-), hydrogen peroxide (H2O2) and hydroxyl radical 
(OH•). Under normal conditions, oxygen reduction to water may go through two 
pathways. In the mitochondria, 95% of oxygen is tetravalently reduced to H2O by the 
corresponding cytochrome oxidase without the production of any free radical 
intermediates. The remaining 5% of oxygen, however, is transformed by a univalent 
mechanism with the formation of free radicals such as superoxide anion and hydrogen 
peroxide. The superoxide anion is generated when one oxygen molecule accepts one 
electron. The protonated form is favored in acidic environments such as acidosis that 
occurs in ischemia and quite toxic capable of oxidative injury to fatty acids of cell 
membranes. Superoxide is detoxified by dismutation to form H2O2 mainly through 
superoxide dismutase (SOD). SOD is the most abundant anti-oxidant enzyme in animals, 
consisting of Cu/Zn-SOD in cytoplasm and Mn-SOD in mitochondria. Although 
hydrogen peroxide is toxic at high concentrations, the normal cell defense system 
converts it into water via catalase (CAT) or the glutathione system. Glutathione is a 
tripeptide containing cysteine, glycine, and glutamic acid, and it is the major intracellular 
antioxidant. Glutathione exists in reduced form (GSH) and oxidized form (GSSG). The 
enzyme glutathione peroxidase can neutralize hydrogen peroxide by converting two GSH 
into one GSSG molecules, and glutathione reductase could regenerate GSH from GSSG 
with NADPH as a source of hydrogen [2, 3].  
During ischemia, hypoxanthine and xanthine are produced and accumulate by 
catabolizing large amount of ATP, and their normal metabolizing enzyme xanthine 
dehydrogenase is converted to xanthine oxidase activated by increased level of 
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intracellular Ca2+ and through a protease. Following reperfusion, this xanthine oxidase 
can use oxygen, instead of NAD+ for xanthine dehydrogenase as the final electron 
acceptor to generate superoxide as a byproduct in the metabolism of hypoxanthine and 
xanthine to uric acid. This reaction doesn’t occur until reperfusion supplies the necessary 
oxygen [4-6]. The well-orchestrated redox homeostasis of normal cells is upset and the 
most reactive and toxic radical among these three oxygen species, hydroxyl radicals, can 
be produced from the other two radicals through Fenton reaction and Haber-Weiss 
reaction with the participation of ischemia-induced iron [7-10]. Under normal 
physiological conditions, almost all iron ions are sequestered by various proteins such as 
transferrin in plasma, ferritin within cells, hemoglobin in red blood cells, and myoglobin 
in muscle. The amount of “free iron” is, therefore, very limited. “Free iron” refers to at 
least one out of six iron coordination sites open or associated with some low molecular 
weight compounds such as citrate and ATP. In the pathological situation like I/R, 
however, the overproduction of O2•- and H2O2 increases the release of “free ion” and 
activates the cell uptake of iron, facilitating the production of OH• [11]. These ROS, 
especially hydroxyl radicals attack bases in nucleic acids, amino acid side chains in 
proteins and double-bonds in unsaturated fatty acids, therefore, damaging DNA, protein, 
lipid, membrane, and eventually the whole cell [11]. The half-life of the highly reactive 
hydroxyl radicals is only one nanosecond, which indicates that it reacts with any 
molecule it first bumps into. It can cause covalent cross-linking or free-radical 
propagation in many biological macromolecules. The proposed mechanism of xanthine 










Figure 1.1:   Proposed mechanism of xanthine oxidase mediated free radical injury, 
modified from Granger et al. [4]. Under the hypoxic conditions of ischemia, 
xanthine dehydrogenase is converted to xanthine oxidase. It utilizes oxygen 
reintroduced from following reperfusion producing superoxide, hydrogen 






1.1.3 Potential Therapeutic Antioxidants 
 
Because ROS-induced oxidative stress plays an important role in I/R injury, 
compounds with antioxidant activity could be beneficial and protective. Figure 1.2 shows 
the process of how I/R causes tissue damage and where antioxidants could exert 
therapeutic effects. Tempol, a membrane-permeable radical scavenger, attenuates hepatic 
I/R injury in rat by reacting with free radicals to abolish their reactivity [12]. Melatonin, 
an antioxidant and an efficient neutralizer of hydroxyl radical, has been shown to be 
protective against renal I/R injury in rats [13].  N-acetylcysteine, a low molecular weight 
thiol antioxidant, can react with hydrogen peroxide, thereby decreasing the production of 
highly reactive hydroxyl radical, and increasing the cytoplasmic supply of reduced 
glutathione, which accounts for its beneficial effect in rat hepatic I/R injury during 
hemorrhagic shock [14].  
Recently, plant-derived polyphenolic compounds have been shown to improve 
I/R-induced injury, that has been attributed to their antioxidant activity. Epigallocatechin 
gallate, a green tea polyphenol, reduces superoxide concentration significantly after 
ischemia and reperfusion in vivo, suggesting its therapeutical potential [15]. 
Procyanidins, a mixture of polyphenolic antioxidants, reduced the sequela of myocardial 
I/R damage in rats by elevating plasma antioxidant activity [16]. Other polyphenolic 
compounds such as curcumin, the intense yellow pigment found in turmeric, and 
resveratrol, a component of red wine and grapes, also exhibited cytoprotective effects 
against I/R-induced myocardia impairment and blood-brain barrier disruption, possibly 
through their free radicals scavenging abilities [17, 18].  
In addition to direct interaction with free radicals, other experimental data have 
demonstrated that polyphenol antioxidants may benefit I/R injury indirectly by inducing 
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antioxidant enzymes and modulating signaling pathways. The induction of nitric oxide 
(NO), a signaling molecule and key biological messenger, seems to play a key role in the 
protection mechanism of resveratrol preconditioning [19, 20]. Epigallocatechin gallate 
also showed stimulation of NO through the Phosphoinositide 3-kinase (PI 3-kinase) 
pathway, which may explain its cardiovascular protection. The ability of epigallocatechin 
gallate to inhibit the NF-κB and AP-1 transcriptional pathways, may also partially 
explain this beneficial effect [21, 22]. Finally, it has been suggested that curcumin may 
be cytoprotective in I/R injury via induction of heat shock protein 70 or regulation of 

























Figure 1.2:   The general procedure of ROS-involved I/R injury and where antioxidants 







1.1.4 The Beneficial Effect of Caffeic Acid Phenethyl Ester (CAPE) in I/R Injury  
 
Numerous reports in the literature indicate that caffeic acid phenethyl ester 
(CAPE), a plant-derived polyphenolic compound (Figure 1.3), ameliorates I/R induced 
injury in various organs and tissues in vivo. CAPE was first reported protecting rat 
intestine [24] and rabbit spinal cord [25] in 1999. CAPE alleviated torsion/detorsion I/R 
induced injury in rat testis [26] and ovary [27]. The beneficial effect of CAPE against I/R 
damage has also been observed in rat skeletal muscle [28] and brain due to focal cerebral 
ischemia [29, 30]. The cardioprotective effect of CAPE has been documented to relieve 
myocardial I/R induced injuries in vivo by reducing apoptosis and arrhythmias [31-35]. In 
addition, CAPE improved myocardial I/R induced oxidative stress in rat testis and kidney 
[36, 37]. Compared to another antioxidant α-tocopherol (Vitamin E), CAPE showed 
greater activity of ameliorating I/R injury in rat brain and kidney [38, 39]. The suggested 
mechanism for CAPE protection in I/R injury has focused on its antioxidant activity and 
related anti-inflammatory and anti-apoptosis effects. The major experimental evidence 
cited were reduced histopathological changes and improved biochemical profile 
including reduced end products of lipid peroxidation malondiadehyde, increased 
production of antioxidant enzymes (superoxide dismutase, catalase, and glutathione 
reduced form GSH), and decreased level of nitric oxide and xanthine oxidase.  However, 
the mechanisms of these beneficial effects have not been defined and further 



















Figure 1.3:   The structure of caffeic acid phenethyl ester (CAPE). CAPE is a natural 
polyphenolic compound, the two adjacent hydroxyl groups on the catechol 


















CAPE is present in relatively high amounts in honeybee propolis. Propolis is a 
natural resinous material collected by bees from various plant sources, and is used by 
bees to seal the hives, reinforce the borders of their combs, and it may protect against 
pathogenic microorganisms. Propolis has been used as a folk medicine since antiquity in 
many cultures to treat various diseases and has been demonstrated to exhibit antibacterial, 
antifungal, antiviral, antioxidant, anti-inflammatory, and other beneficial activities [40]. 
The chemical compositions and biological activities of propolis, however, vary directly 
from the local flora and phenology of the host plants and indirectly from the geographic 
regions and season of collection. CAPE has been reported to be high in propolis from 
European and non-tropic Asian countries such as the Netherlands, China, and Korea 
where there are numerous popular trees that bees have been observed to visit [41-44].  A 
recent study by Kumazawa et al has produced a comprehensive picture of the presence 
and relative quantity of CAPE in propolis from all over the world [45]. CAPE can be 
extracted from propolis with ethanol and their results showed that the amount of CAPE is 
more than 10 mg/g of propolis in extracts from Australia, China, Hungary, New Zealand, 
Uruguay, and Uzbekistan. Propolis from Argentina, Bulgaria, Chile, Ukraine, and the 
United States contained less than 10 mg/g CAPE, whereas CAPE was not detectable in 
ethanolic extracts of propolis from Brazil, South Africa, and Thailand. Propolis from 
China had the most CAPE content (up to 29 mg/g).  
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1.2.2 Properties  
 
CAPE or phenethyl caffeate presents as an off-white powder with melting point 
128 to 129°C. Its molecular formula is C17H16O4 and molecular weight 284.31. CAPE is 
hydrophobic and dissolves in organic solvent such as DMSO, acetonitrile, methanol, 
acetone and ethanol. The partition coefficient LogP of CAPE determined using 
ChemDraw Ultra software is 3.43 compared to its much-more-hydrophilic analogue 
caffeic acid which is 1.15. It needs to be protected from light in order to prevent photo-
oxidation due to its catechol ring during the process of storage and application.  Synthetic 
CAPE was first made by Dr. Koji Nakanishi and Dr. Dezider Grunberger and they hold a 
patent on its synthesis and application as anti-inflammatory and anti-carcinogenic agents 
[46]. 
Numerous pharmacological activities have been reported for CAPE: 
1) Anticancer/tumor: CAPE at a low dose of 1 µg/ml induced apoptosis in 
adenovirus-transformed rat fibroblasts, while the same dose of CAPE only inhibited the 
proliferation of untransformed fibroblasts [47]. Topical application of CAPE to mouse 
skin inhibited 12-o-tetradecanoylphorbol-13-acetate-induced tumor promotion. CAPE in 
the range of 0 to 12 µg/ml reduced the viability of mouse colon cancer cells up to 60% 
and ameliorated pulmonary metastasis induced in BALB/c male mice by the same tumor 
cell lines at the dose of 10 mg/kg/day, which may be through inhibition of matrix 
metalloproteinase activity and reduction of vascular endothelial growth factor level in 
vitro and in vivo [48]. CAPE also prevented the growth of rat C6 glioma cell line, human 
breast cancer MCF-7 cells, and human hepatoma HepG2 cell line and HepG2 tumor 
xenografts in nude mice [49-51].    
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2) Anti-inflammatory: CAPE decreased the cell viability of leukocytes involved 
in the process of inflammation by inducing apoptosis both in vitro and in a rat model of 
carrageenin-induced subcutaneous inflammation [52]. CAPE was shown to be cytotoxic 
to inflammatory-related rat macrophage and colonic epithelial cells and to ameliorate 
bacterial peptidoglycan polysaccharide (PG-PS)-triggered colitis in rats [53]. CAPE 
attenuated inflammatory stress induced by paw edema, carrageenin pleurisy, and adjuvant 
arthritis in rats [54], and it suppressed the interferon-γ plus lipopolysaccharide-stimulated 
cerebral inflammatory response in rat organotypic hippocampal cultures [55]. 
3) Antiviral: In 1993, CAPE was identified as a potent inhibitor of human 
immunodeficiency virus (HIV) integrase [56]. It selectively suppressed the integration or 
strand-transfer step rather than the initial neucleolytic cleavage reaction of the enzyme 
reaction. Furthermore, the same research group indicated CAPE not only selectively 
inhibited the integration step but also suppressed the dinucleotide cleavage step if 
preincubation of CAPE with HIV integrase was performed [57]. The relationship 
between CAPE structure and inhibition on HIV integrase was investigated and the results 
demonstrated the indispensable role of the ortho dihydroxylation for high suppressive 
potency of CAPE against HIV integrase [58].  
4) Antioxidant: CAPE was shown to be beneficial in oxidative stress-related 
pathological states. CAPE was first described as a 5-lipoxygenase inhibitor by a non-
competitive mechanism with free radical scavenging ability in both phorbol-12-myristate 
13 acetate-activated neutrophils and cell-free superoxide-producing xanthine/xanthine 
oxidase enzyme system during the investigation of its anti-inflammatory activity [59]. 
CAPE attenuated oxidative stress-induced cyclosporine A-stimulated cardiotoxicity in 
rats both morphologically and chemically by reducing matrix metalloproteinase 2 
expression, increasing level of its inhibitors, elevating endogenous antioxidant enzyme 
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cytochrome-c-oxidase activity, and decreasing cardiac level of ROS [60]. CAPE 
alleviated lipid peroxidation mediated cerebral vasospasm induced by experimental 
subarachnoidal hemorrhage, resulting in the improved basilar artery vasoconstriction and 
increased level of reduced glutathione and nitric oxide in rat brain [61]. CAPE 
ameliorated experimentally-triggered hyperthyroidism-generated oxidative stress in rat 
plasma and organs (liver, heart, and brain) by decreasing the level of thiobarbituric acid 
reactive substances which refers to the lipid peroxidation and bringing back the cellular 
antioxidant capacity to the hyperthyroid group [62].  
Besides these major activities, CAPE has been reported to have 
immunomodulatory effects in vivo related to decreasing immune organ weight, 
increasing T lymphocyte blastogenesis and CD4(+) T cell subpopulation, and inducing 
the production of cytokines IL-2, IL-4 and IFN-γ at higher dose [63]. CAPE may possess 
neuron- and cardio-protective potential by activating TREK-1 background potassium 
channels [64]. CAPE was reported to exert its protective effect in variety of drugs or 
toxic chemicals-induced organ damage such as antibiotics amikacin [65], vancomycin 
[66], gentamycin [67], and doxorubicin [68, 69]-induced renal and cardiac impairment, 
antitumor drug methotrexate-caused neuron and cerebullar injury [70-72], antimanic 
medication lithium carbonate-mediated lung and kidney toxicity [72, 73], and toxic 
environment pollutant cadmium-induced cardiac damage [74].  
 
1.2.3 Purported Mechanism of Action  
 
Several mechanisms have been proposed for the beneficial effects of CAPE that 
depend on the test system used.  
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Anticancer/tumor: 1). By altering redox balance in tumor or transformed cells, 
CAPE reduces or induces oxidative stress. The resulting effect depended on the dose of 
CAPE and cell type examined [47, 75]. 2). It inhibited angiogenic enzyme activity of 
matrix metalloproteinase-2/9 in cancer cells [50, 76]. 3). It modulated signal transduction 
such as inhibition of transcription factor NF-κB and activation of Fas although not 
through an effect on Fas ligand. Some evidence also suggests that activation of 
extracellular signal-regulated kinase (ERKs) and p38 mitogen-activated protein kinase 
(p38 MAPK) with the involvement of tumor suppressor protein p53 and down-regulation 
of β-catenin may be involved [49-51, 76, 77].  
Anti-inflammatory: 1). CAPE may exert its anti-inflammatory activity by 
blocking prostaglandin (PG) and leukotriene synthesis by inhibiting cyclooxygenase 
(COX) enzyme activity through down-regulating COX gene expression both in vitro and 
in vivo, which may also account for CAPE chemoprevention activity since the 
overproduction of PG favors malignant growth [78, 79]. 2). The involvement of nuclear 
factor kappa B (NF-κB) has been cited as the mechanism for CAPE anti-inflammatory 
effects.  
NF-κB is a transcription factor discovered in the production of kappa light chain 
of immunoglobulins in B cells [80]. NF-κB regulates host inflammatory and immune 
responses by inducing the expression of proinflammatory cytokines, chemokines, 
adhesion molecules, matrix metalloproteinases, cyclooxygenase-2, and inducible nitric 
oxide synthase. Proinflammatory mediators TNF-α and IL-1β are regulated by NF-κB. 
TNF-α and IL-1β can also directly activate the NF-κB pathway, thus establishing a 
positive autoregulatory loop that can amplify the inflammatory response and increase the 
duration of chronic inflammation. In the cytoplasm, NF-κB exists in an inactive form 
associated with regulatory proteins called inhibitors of κB (IκB). Upstream activating 
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signal such as binding of TNF to its receptor may cause phosphorylation of IκB by IκB 
kinase (IKK). This triggers the degradation of IκB through the ubiquitin system, where 
the target molecule is tagged by a chain of ubiquitins for degradation by the 26 
protesome. The free NF-κB (a heterodimer consisting of p50 and p65 proteins) can then 
translocate to the nucleus and activate transcription of proinflammatory genes. NF-κB 
activation has been found in many inflammatory diseases such as rheumatoid arthritis 
[81] and inflammatory bowel disease [82]. Therefore, it is considered as a novel target for 
treating inflammatory diseases. 
In 1996, Natarajan et al reported that CAPE was a potent and specific inhibitor of 
NF-κB activation in U937 cells, providing an explanation for the anti-inflammatory 
effect of CAPE [83]. In this report, CAPE was shown to suppress the binding of NF-κB 
to its target DNA during NF-κB activation by many inflammatory agents such as TNF, 
phorbol ester, ceramide, hydrogen peroxide, and okadaic acids. This inhibition of CAPE 
was specific to NF-κB since the binding of some other transcription factors such as AP-1, 
TFIID, and Oct-1 to the DNA were not affected. The suppression of NF-κB activation by 
CAPE was also confirmed in rat macrophage, colonic epithelial cells, and PG-PS-induced 
colitis [53]. CAPE also modulated other transcriptional factors such as elevating anti-
inflammatory factor cAMP-response element binding protein (CREB) activity in rat 
cerebral organotypic  hippocampal slices [55], down-regulating nuclear factor of 
activated T-cells in stimulated Jurkat cells [84], and suppressing Helicobacter pylori-
induced activator protein-1 expression in gastric epithelial cells [85].  
Antioxidant: The catechol ring configuration of CAPE may account for its free 
radical scavenging ability. The presence of the electron donating hydroxyl groups on the 
catechol ring not only stabilize oxygen free radicals by the formation of a more stable 
aroxyl radical through intramolecular hydrogen bonding but can also chelate of metal 
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ions as well [86, 87]. This may account for the cytoprotective effect of CAPE against 
cellular oxidative stress induced by tert-butylhydroperoxide and hydrogen peroxide in 
U937 cells [88]. The main evidence for CAPE antioxidant activity comes from cell-free 
in vitro assays such as the 2,2’-diphenyl-picrylhydrazyl radical (DPPH) free radical 
scavenging assay, peroxynitrite-scavenging assay, 2,2’-azobis(2-
amidinopropane)dihydrochloride (AAPH)-induced lipid peroxidation system, Rancimat 
test (lipid oxidation), and corn oil-in-water emulsion system for antioxidative activity 
examination [89-91]. These tests, however, may not accurately reflect the oxidation-
reduction environment of a live cell. 
In addition to direct antioxidant activity, CAPE was recently shown to induce 
antioxidant or detoxifying phase II enzymes. The phase II system exerts protective effects 
through enzymes such as NAD(P)H: quinine oxidoreductase (NQO1) and heme 
oxygenase-1 [92, 93] that may be activated through transcriptional factor NF-E2 related 
factor-2 (Nrf2)/antioxidant-responsive element (ARE) signaling pathway [94]. 
Considering that CAPE may undergo extensive biotransformation and metabolism in 
liver and intestine such as glucuronidation, sulfation, and methylation, its true in vivo 
concentration may be much lower than what it needed to scavenge free radicals directly 
[95, 96]. Therefore a role for CAPE in cytoprotection mechanisms involving activation of 
detoxifying enzymes, modulating cell signaling, or altering gene expression at doses too 
low to counteract the deleterious effects of oxidative stress directly becomes more 
attractive.   
Recent studies have identified CAPE as a novel inducer of heme oxygenase-1 
(HO-1) in astrocytes, the cytoprotective component of cellular defense system protecting 
organs from I/R insult. This result supports the hypothesis on the mechanism of CAPE 
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protection involving the induction of HO-1 as a key component in CAPE protection 
against I/R induced oxidative stress [93, 97, 98].  
 
1.3 HEME OXYGENASE-1 (HO-1) 
 
1.3.1 Heme Oxygenase System 
 
Heme oxygenase (HO) was first identified for its ability to catalyze the 
degradation of heme to bilirubin in hepatic microsomes by Tenhunen and Schmid in 1968 
[99], and this enzymatic activity was later clarified to be independent of cytochrome P-
450 [100]. The metalloporphyrins heme (Fe-protoporphyrin IX) is integral to life. It 
promotes most biological oxidative reactions and electron transfer processes, transports 
molecular oxygen to cells, and participates in mitochondrial respiration and signal 
transduction [101]. Heme is also a potentially toxic substance that contains iron that can 
lead to ROS generation and causing lipid peroxidation damaging cellular membranes and 
other cell structures [102]. Therefore, the metabolism of heme by the HO system plays a 
key role in maintaining the cellular heme homeostasis. The HO enzyme catalyzes the first 
and rate-limiting step in the oxidative decomposition of heme. This enzymatic reaction 
utilizes three moles of molecular oxygen per heme molecule degraded and requires a 
reducing agent to activate O2 and reduce heme-chelating iron from Fe3+ to Fe2+, where 
NADPH: cytochrome P450 reductase is applied to provide the reducing equivalents and 
electron transfer as well. HO specifically breaks the α-methene bridge of the heme 
molecule to generate the open-chain tetrapyrrole α-isomer of biliverdin. Biliverdin-IXα 
(BV) is then rapidly converted to bilirubin-IXα (BR) by NAD(P)H: biliverdin reductase. 
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The breakdown of heme releases its chelated iron in the ferrous form which is 
subsequently sequestered to iron-binding protein ferritin and disposing of the α-methene 
bridge carbon as carbon monoxide (CO). The pathway of heme catabolism by HO action 











In mammals, two different forms of HO have been characterized so far. The first 
isozyme HO-1 is the inducible isoform, which was identified about 3 decades ago [100]. 
The other form, HO-2 was initially purified from rat testes in 1986 and has been reported 
to exist constitutively in multiple tissues [103-106]. HO-1 is also referred to as the stress 
protein HSP32 [107] with the molecular weight of about 32 kDa, while HO-2 has a 
relatively larger molecular weight (~42 kDa). These two isozymes of HO have been 
defined as different gene products with differences in gene organization, structure, 
chromosomal localization, cell type, subcellular localization, and tissue distribution [108, 
109]. Despite these differences, both enzymes catalyze the same heme-degrading reaction 
with similar substrate specificity and cofactor requirements.  
Not too long ago, the HO system was only considered as the catabolic enzyme in 
the category of maintaining the internal balance of cellular heme, and its downstream 
products were thought to be waste or cytotoxic materials. Nowadays, the induction of 
HO-1 has being considered  as an important component in a cell defense system 
mediating cellular and tissue protection against a variety of stimuli and agents resulting in 
oxidative stress and pathological conditions. HO-1 inducers can be subcategorized into 
1). ROS or ROS inducer such as H2O2, peroxynitrite, menadione, and UVA radiation; 2). 
heavy metals like cadmium and cobalt; 3). metalloporphyrins such as heme, CoPPIX, and 
ZnPPIX; 4). pro-inflammatory cytokines like interleukin and tumor necrosis factor; and 
5). phenolic antioxidants such as curcumin, carnosol, quercetin, resveratrol, and CAPE. 
Other inducers include prostaglandin family members, tumor promoter 12-O-
tetradecanoylphorbol 13-acetate (TPA), hypoxia/hyperoxia, angiotensin, and non 
phenolic phase II enzyme inducers such as sulfurophane. Investigations of the 
mechanisms of HO-1 induction have revealed two major signaling pathways including 
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protein phosphorylation-depenent signaling transductions and redox sensitive signaling 
regulations [108, 109].  
Activation of mitogen-activated protein kinases (MAPKs) has been implicated as 
participating in HO-1 induction by various physical and chemical stresses through using 
the chemical inhibitors for MAPKs. The MAPKs superfamily consists of three major 
signaling cascades: the extracellular signal regulated kinases (ERK), the c-Jun NH2-
terminal kinases (JNK), and the p38 MAPKs. HO-1 activation has been reported 
involving one or a combination of these MAPK pathways to achieve better HO-1 gene 
expression. Among these MAPK pathways, p38 and ERK seems to play major roles in 
HO-1 activation. Additional evidence from the expression of dominant negative mutants, 
wild-type, and activated forms of various MAPKs further implicates MAPKs in HO-1 
gene activation. Other kinases potentially contributing to induction include 
phosphatidylinositol 3-kinase (PI3K), protein kinases A and C, and tyrosine kinase [109].  
The Nrf2/ARE pathway, a redox-sensitive signaling cascade activated by cells 
when faced with electrophils, oxidative toxicants, or physiological injury also has been 
implicated in HO-1 induction. Under normal conditions, Nrf2 is sequestered in cytoplasm 
by a cytoplasmic factor Keap1, which represses Nrf2 transactivation activity. During 
oxidative stress, electrophils and ROS can directly react with the sulfhydryl groups from 
two (C273 and C288) cysteine residues of Keap1, facilitating the formation of disulfide 
bonds and resulting in the dissociation of Nrf2/Keap1 complex. The “free” Nrf2 can then 
translocate to the nucleus, where it could bind to ARE to initiate the expression of 
antioxidant genes such as HO-1 [110]. Other transcriptional factors that have been 
reported to modulate HO-1 expression include Bach 1 as a repressor of HO-1 induction, 
heat shock factor 1, NF-κB, and AP-1 [111, 112].   
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The beneficial effects of HO-1 induction have been reported [113-115] and 
confirmed with HO-1 knockout mice [116, 117] and one human case with HO-1 
deficiency [118]. In addition to degrading the prooxidant heme, the cytoprotective 
mechanism of HO-1 induction has been recently attributed to the end products of HO-1 
action (CO and BV) and BR. CO is a colorless and odorless gas first discovered in the 
late 18th century and considered only a toxic air pollutant mainly from incomplete 
combustion of organic molecules. Its strong affinity to hemoglobin (Hb) (about 240 times 
more than that of oxygen) leads to its harmful effects which could result in displacement 
of O2 from Hb and eventually tissue hypoxia. The major source of endogenous CO comes 
from the HO-catalyzed hemoglobin turnover. The protective effects of CO demonstrated 
so far include anti-inflammation, cell or tissue-specific suppression of apoptosis, 
proliferation, and vasodilation mainly through activating the soluble guanylate cyclase 
(sGC)/ cyclic 3’,5’-guanosine monophosphate (cGMP) pathway and MAPKs signaling 
cascades [119]. BV and BR are primarily generated from hemoglobin degradation in vivo 
[120]. BV is a hydrophilic and nontoxic greenish pigment, which is rapidly converted to 
BR, an insoluble yellowish pigment. The endogenous BR used to be considered a toxic 
waste product eliminated from cells and tissues via blood and exclusively metabolized by 
liver UDP:glucuronyltransferases. Excessive accumulation of unconjugated BR in the 
blood causes neonatal jaundice and neurotoxicity [121]. The landmark studies by Stocker 
et al [121] first confirmed the strong antioxidant role of BV and BR at physiological 
micromolar concentrations, which could scavenge the chain-carrying peroxyl radical 
either by donating a hydrogen atom (BR) or directly react to form stable addition product. 
In addition, The conversion from BV to BR by BV reductase may contribute to 
amplifying the protective effect of BR. Baranano et al [122] indicated that 10 nM BR 
could protect against up to 100 µM H2O2-induced oxidative stress, which is feasible 
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through the powerful redox cycle of BR being oxidized to BV which is recycled back to 
BR. This BV-BR redox process that protects the membrane components is comparable to 
that of GSH-GSSG conversion to protect cytoplasmic components from ROS insult. 
Besides CO and BV, iron is also released by heme degradation. Since free iron could 
facilitate ROS production through Fenton reaction, it possesses prooxidant activity and is 
itself toxic. Some studies suggest that HO-1 induced cytoprotection could be linked to 
either exporting iron out of the cells mediated by an iron-transporting ATPase [123] or 
sequestering iron into ferritin, the intracellular iron-binding protein [124].  
 
1.3.2 HO-1 and I/R Injury 
 
The production of HO-1 stimulated either by its chemical inducer hemin [125] or 
by physiological stimuli such as hypoxia preconditioning [126] has been shown to 
directly correlate with amelioration of I/R injury in vivo. Further investigation into the 
protective role of HO-1 activation in I/R injury was recently confirmed by repressing 
HO-1 production [127] with HO-1 siRNA and showing enhanced apoptosis in endothelial 
cells in mouse lung during I/R injury. In addition, overexpression of HO-1 with or 
without the incorporation of erythropoietin hypoxia response elements regulating the HO-
1 expression by a preemptive adeno-associated vector-carried HO-1 gene delivery system 
reduced various tissue damage triggered by I/R [128, 129]. Exogenous administration of 
heme-degrading end products by HO-1 enzymatic activity also provides beneficial effects 
in the deleterious situation of I/R through different mechanisms. Antioxidant BR and BV 
at micromolar level, signaling molecular CO exposure, and overexpression of heavy 
chain Ferritin with iron-sequestering ability protected I/R injury in vitro, ex vivo, and in 
vivo [130-135].   
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1.4 HUMAN ENDOTHELIAL CELLS 
 
1.4.1 The Importance of Endothelial Cells in I/R Injury 
 
Endothelial cells (EC), as an important component of the blood vessel wall, play a 
critical role in the preservation of normal vessel wall structure and function, and regulate 
vessel growth. Rather than just being a passive barrier, EC also maintain several 
important physiological functions such as modulating microvascular substance exchange, 
metabolizing circulating molecules, regulating vascular tone and blood flow, controlling 
leukocyte trafficking, and mediating angiogenesis [136]. I/R injury begins within EC in 
blood vessels. Endothelial injury at the initial site of tissue damage is inevitable and plays 
a key role in the tissue dysfunction and organ failure after ischemia and reperfusion.  
EC have been identified as a source of oxygen free radical production when 
subjected to hypoxia and reoxygenation simulating ischemia and reperfusion in vitro 
[137, 138]. When confronted by oxidative stress induced by ROS generated from I/R 
injury, EC are activated, expressing proinflammatory properties, recruiting and 
accumulating neutrophils facilitated by the expression of adhesion molecules (P-selectin, 
E-selectin). Collateral damage can occur to endothelial cells by ROS produced by 
neutrophils at a site of injury. These neutrophil products damage EC directly by reacting 
with membrane lipids, nucleic acids, and polyunsaturated fatty acids, which result in the 
disruption of cellular integrity [139].  
Damage to endothelial cells following I/R injury leads to delays in recovery due 
to poor delivery of nutrients, removal of waste products, and reduction in the ability of 
mononuclear cell immigration to repair injured tissue. Damage to endothelial cells can 
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also lead to secondary tissue injury as a consequence of diminished vascular function and 
more severe impairment of a variety of organs leading to multiple organ failure. 
Therefore, endothelial cells provide an important cell target for modeling of 
cytoprotectants against I/R injury in vitro.   
  
1.4.2 The Human Umbilical Vein Endothelial Cells (HUVEC) Model 
 
The umbilical cord, discarded after birth, has provided a readily available source 
of human endothelial cells that are probably the best characterized model of the 
endothelium. The isolation of HUVEC could be achieved using enzyme like collagenase 
to remove the cells from the internal lining of umbilical veins, which provides good yield 
and high purity of HUVEC. To minimize variation caused by harvesting from different 
individuals, HUVEC are usually pooled from several umbilical cords. During cell culture, 
the cells are grown to confluence for at least two days before experiments to mimic the in 
vivo situation where endothelial are relatively proliferatively inactive. In general, only 
passages from 1 to 5 were used in the experimental treatments to avoid characteristic 
cellular changes known to occur with long in vitro culture which may consequently affect 
the integrity of experimental results.  
HUVEC in vitro have been used to simulate the I/R situation in vivo [140-142]. 
Because oxygen free radical generation play a major role in I/R injury and the burst of 
ROS has been identified produced from HUVEC mitochondria after 
hypoxia/reoxygenation, the application of menadione to induce oxidative stress in 
HUVEC could simulate I/R triggered oxidative injury in vitro. Menadione (MD) is one of 
the simplest quinones (Figure 1.5), and it belongs to the vitamin K family. It has been 
widely studied as a model for evaluating the cellular effects of oxidative stress in 
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endothelial cells (EC), including induction of apoptosis [143, 144]. The major mechanism 
of EC cytotoxicity caused by menadione is the stimulated production of ROS by redox 
cycling, where one electron reduction of O2 by the semiquinone form of menadione 
generates superoxide. Superoxide dismutates to form hydrogen peroxide either 
spontaneously or enzymatically through superoxide dismutase, which then participates in 
the Fenton reaction producing hydroxyl radicals. Therefore, MD has been proposed to 
initiate a cascade of ROS formation in EC. Note that, when treated with MD, different 
passages and batches of HUVEC respond differently to a given dose of menadione, 
therefore the dose required to reduce survival by 90% had to be determined prior to a 
study. The pattern of cell damage caused by MD toxicity compared to normal HUVEC 


















Figure 1.6:   Oxidative stress-induced apoptosis and damage in HUVEC after 24-hr MD 
exposure. Cultured confluent HUVEC were treated with either vehicle 
control (A) or 25 µM MD (B).  The rounded up cells in B are endothelial 




1.5 SYNTHESIS OF CAPE FLUORINATED DERIVATIVES 
 
Despite the wide variety of biological activities associated with CAPE, only 
limited structural analogs have been examined [145-147], especially those incorporating 
modifications to the caffeic acid catechol ring [148-150]. We are unaware of any 
fluorinated CAPE derivatives in the literature. Ring-fluorinated derivatives of other 
catechol-containing drugs may display a “fluorine-effect,” in which the position of the 
fluorine ring substituent has a profound impact on binding or selectivity of the receptor 
[151, 152]. The introduction of fluorine into the catechol ring exerts a negative inductive 
effect, increases the electronic density in this conjugated system, strengthens the ester 
bond, and can diminish interactions with catechol methyltransferase [153-155]. 
With the aim of studying structure activity relationship of CAPE, new CAPE 
derivatives fluorinated in the catechol ring were synthesized through the Wittig reaction. 
This reaction was discovered by Georg Wittig, a German chemist who won the Nobel 
Prize in 1979. The Wittig reaction is an important method for the preparation of alkenes 
with specific introduction of carbon carbon double bond in a known location through the 
reaction of an aldehyde or ketone with a phosphorus ylide [156]. CAPE analogues were 
prepared through the reaction between various fluorinated benzaldehydes and a triphenyl 
phosphonium halide. The necessary fluorinated benzaldehydes were either commercially 
available or easily obtained through demethylation reaction with boron tribromide [157]. 
The Wittig reagent phosphonium salt was obtained from the reaction between 





1.6 PHARMACOKINETICS OF CAPE AND FCAPE 
 
Pharmacokinetics (PK) is what the body does to the drug and it is indispensable in 
both preclinical and clinical phases of new drug development. The ultimate purpose of 
studying PK and pharmacodynamics (PD), which is what the drug does to the body, and 
corresponding PK/PD modeling is to optimize drug dose regimen for clinical trials. 
Although many preclinical studies have demonstrated primary safety and biological 
activities of CAPE in animal and in vitro models, the pharmacokinetics of CAPE has not 
been reported in the literature. It will be useful to obtain preliminary data on 
pharmacokinetics of CAPE and its most cytoprotective fluorinated derivative (FCAPE) in 
animal model.  
Prior to pharmacokinetic characterization, the integrity of target compounds in 
collected samples must be maintained because further degradation could confound the 
results. As an aryl ester, CAPE is liable to enzymatic hydrolysis in vivo by the action of 
plasma esterases. Therefore, the determination of the stability of CAPE and FCAPE in 
plasma was critical for evaluating their effects, understanding the protection mechanism, 
and studying their pharmacokinetic behavior in vivo. The application of the esterase 
inhibitor sodium fluoride and pH adjustment were investigated to avoid further 
hydrolysis of CAPE and FCAPE [158]. 
In addition, the quantitative determination of CAPE and FCAPE in biological 
matrix is essential for establishing their pharmacokinetic profiles. A review of the 
literature showed that a limited number of quantitative CAPE assays are available [159-
161]. With the objective of studying pharmacokinetics of CAPE and FCAPE, a 
quantitative method using ultra-performance liquid chromatography with electrospray 
ionization tandem mass spectrometry was developed and validated for CAPE and 
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FCAPE. The main advantages of ultra-performance liquid chromatographic system are to 
provide better resolution and sensitivity, reduce analytical time, and minimize carryover 
effect compared to traditional HPLC system. 
Finally, pharmacokinetic profiles of CAPE and FCAPE were established 
following intravenous administration to Sprague Dawley rats. Non-compartmental 





















Chapter II: Cytoprotection of Human Endothelial Cells from 





Caffeic acid phenethyl ester (CAPE) has been reported to ameliorate 
ischemia/reperfusion (I/R) injury in vivo [24-39]. The mechanism of cytoprotection, 
however, has not been determined. Without clear understanding of its mechanism of 
action and potential side effects, it is unlikely that it will be applied in the clinical setting.  
With the aim of understanding the mechanisms of action of CAPE for using CAPE as a 
model drug for treating I/R injury, an in vitro assay simulating I/R injury was established.  
Menadione (MD)-induced oxidative stress in human umbilical vein endothelial 
cells (HUVEC) was used to simulate I/R injury in vitro for assessing the ability of CAPE 
as a cytoprotectant. Although the cytoprotective activity of CAPE has been attributed to 
its known antioxidant ability, CAPE has been shown to also affect transcriptional 
activity, which may contribute to its cytoprotective effect. Some other polyphenolic 
antioxidants such as curcumin and resveratrol have also been reported to effect 
transcriptional activity [93, 162, 163]. The results presented here indicate that 
cytoprotection in human endothelial cells by CAPE involved transcriptional activation of 
heme oxygenase-1 (HO-1).  
The purpose of this study was to develop a CAPE cytoprotection model in vitro 
and investigate the mechanism of CAPE protection against ROS-mediated injury. We 
hypothesized that HO-1 induction is the key component in CAPE protection against 
oxidative stress. 
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CAPE was purchased from Cayman Chemical (Ann Arbor, MI). Bilirubin (BR), 
menadione sodium bisulfite (MD), and DMSO were purchased from Sigma (Saint Louis, 
MO). Biliverdin hydrochloride (BV) and Sn(IV) protoporphyrin IX dichloride (SnPPIX) 
were purchased from Frontier Scientific (Logan, UT).  
 
2.2.2 Cell Culture 
 
First passage HUVEC (Cascade Biologics, Portland, OR) were cultivated on 1% 
gelatin-coated 75-cm2 culture flasks (Corning Incorporated, Corning, NY) in Medium 
200 supplemented with 2% fetal calf serum, penicillin (100 units/ml), streptomycin (100 
units/ml), and Fungizone (0.25μg/ml) supplied by Cascade Biologics [164]. The cells 
were cultivated at 37 ºC in a humidified atmosphere of 95% air and 5% CO2 with 
medium changes every 2 days until confluent. Prior to an experiment, HUVEC were 
subcultivated with Trypsin/EDTA onto 1% gelatin-coated 48- or 6-well Costar® 
multiplates (Corning Incorporated, Corning, NY) at 5000 cells/cm2 and grown to 
confluence (3-4 days), and kept for 72 hrs to produce a quiescent cell layer. On the day 
before the experiment, the medium was changed. Only the second through fifth 
population doublings of cells were used. 
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2.2.3 Cell Viability Assay 
 
Cell viability was assessed at 24 hours after initiation of treatment using Alamar 
Blue™ (Biosource International, Camarillo, CA), which is converted to a fluorescent 
compound in amounts proportional to the number of viable cells [165]. The cells were 
incubated for two hours at 37 °C with culture medium containing 10% Alamar Blue™. 
After incubation, fluorescence was measured at 545 nm excitation and 590 nm emissions 
using SpectraMAX® M2 microplate reader (Molecular Devices, Sunnyvale, CA). 
HUVEC were regularly observed under phase contrast microscopy and images were 
captured with a digital camera.  
 
2.2.4 MD Cytotoxicity 
 
MD was dissolved in phosphate buffered saline (PBS) to produce a 0.5 M solution 
[166] and diluted with medium before being added to the plate wells. Due to differences 
in responses to menadione, each group of pooled HUVEC was initially assessed for a 
dose of menadione which is close to its maximum toxicity producing 90% cell death. 
Cells were incubated in 5 to 38 µM MD depending on the sensitivity of a given set of 
cells for 24 hrs followed by Alamar Blue viability assay. 
 
2.2.5 In Vitro Cytoprotection Assay 
 
CAPE, BV, and BR were dissolved in DMSO and diluted 1000-fold with medium 
before addition of serial dilutions to 48-well culture plates. To assess protection against 
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oxidative stress, confluent HUVEC were initially pretreated with CAPE, BV, and BR at 
various concentrations for 6 hrs to allow transcriptional response to occur. The cytotoxic 
dose of menadione chosen from MD cytotoxicity assay was then given to the HUVEC in 
the presence of testing compounds. After 24 hrs incubation, cell viability was measured 
using the Alamar Blue assay. 
 
2.2.6 Total RNA Isolation 
 
Total RNA was extracted from cultured HUVEC in 6-well culture plates with 
TRITM reagent according to the manufacture’s instructions (Molecular Research Center, 
Cincinnati, OH). RNA yield was quantified using a NanoDrop® ND-1000 
Spectrophotometer (NanoDrop Technologies, Wilmington, DE), and the quality was 
assessed by 1% agarose gel electrophoresis containing 1:1000 SYBR Gold nucleic acid 






















Figure 2.1:   Intact total RNA on a 1% agarose gel. The quality was assured by the 









2.2.7 Protein Extraction 
 
Protein was extracted from the HUVEC grown on 24-well multiplates. After 
incubation with 5 μg/ml (17.5 µM) of CAPE or 0.1% DMSO for 24 hrs, protein for gel 
electrophoresis was obtained by  incubating them in 100 μl of lysis Buffer (NOVEX, San 
Diego, CA) containing 1% β-mercaptoethanol (Sigma) at 70°C for 10 min. 
 
2.2.8 Gel Electrophoresis, Total Protein Determination and Western Blotting 
 
Ten microliters, containing approximately 10 μg of protein, from each treatment 
were run on NuPage 4-12% Bis-Tris Gels (NOVEX) for 1 hr at 125 volts. The protein 
was then transferred to a PVDF membrane (NOVEX) for 5 hrs at 95 mA (Semi-Dry 
Blotter II, Kem En Tec, Flander, NJ). Membranes were hydrated in a 50% 
methanol/water solution for 10 min, then incubated three times, 15 minutes each, in a 
blocking solution of 0.2% I-Block (Tropix, Bedford, MA), 0.1% Tween-20 (Sigma) and 
0.1% thimerosal (Sigma) in PBS (Sigma). The blots were then incubated with a rabbit 
anti-rat HO-1 primary antibody (1:5000 dilutions) for 2 hrs, which was purchased from 
Stressgen Biotechnologies Inc. (San Diego, CA). Blots were then washed another three 
times in blocking solution for 15 minutes each, and incubated in biotin labeled antibody 
against rabbit (Vector Laboratories) and 1:4,000 dilution of alkaline-phosphatase labeled 
secondary antibody. Finally, the blots were washed three times in PBS, 15 minutes each, 
before staining. Following staining for HO-1, the blots were stripped and restain with 
mouse anti-actin. The blots were stained in a 10% NBT-BCIP solution (Invitrogen) until 
the bands developed. Quantitative analysis was performed NIH Images (NIH) on blots 
scanned into the computer. 
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2.2.9 Gene Expression Analysis 
 
Microarrays containing ~ 22,000 human genes per array were produced by 
spotting oligonucleotides (Qiagen/Operon Human ArrayReady Oligo Set V 2.0, 
Alameda, CA) onto epoxy-coated slides (Cel Associates, Pearland, TX). A 
GeneMachines Omni Accent Gridder (GeneMachines, San Carlos, CA) and SMP-3 pins 
from Telechem International were applied to print the microarrays. Microarrays were 
blocked with 1% BSA in 3X SSC and 0.1% SDS for 1 hr at 50 °C before use. For gene 
expression analysis, sample RNA was extracted from 5 µg/ml CAPE and 0.1% DMSO-
treated HUVEC for 6 hrs, while reference RNA was human universal reference RNA 
(Stratagene, La Jolla, CA). cDNA targets were then generated with the 3DNA Array 900 
kit (Genisphere Inc., Hatfield, PA) according to the manufacture’s instructions. The high-
resolution scans were acquired with a GenePix scanner 4000B (Axon Instruments, Inc., 
Union City, CA) and tabulated with GenePix pro 5.1 software.  To determine intra-assay 
variability, each condition (3 replicates) was individually labeled and compared to a 
universal reference of pooled RNA that was labeled as a pool sufficient for 6 
microarrays. Following washing and scanning, the microarray data analysis and statistical 
comparison were performed using BRB Array Tools (Biometric Research Branch, 






2.2.10 Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction 
(qRT-PCR) 
 
One μg of total RNA from the same samples used for microarray analysis was 
converted to cDNA using random primers and Superscript III reverse transcriptase 
according to the manufacture’s instruction (Invitrogen TM life Technology, Carlsbad, CA).   
Real-time PCR was performed on a LightCyclerTM thermal cycler (Idaho Technology, 
Salt Lake City, UT) with Roche LightCycler® TaqMan Master for HO-1 and β-actin 
(Roche Diagnostics, Indianapolis, IN). HO-1 and β-actin primer sets were from TaqMan® 
Gene Expression Assays (Applied Biosystems, Foster City, CA). HO-1 gene was 
normalized to the expression level of β-actin gene for each sample. Relative 
quantification was acquired by comparative CT method. 
 
2.2.11 HO-1 Inhibition with SnPPIX 
 
HUVEC were pretreated with 5 μg/ml CAPE plus different doses (10, 20, and 30 
μM) of HO-1 inhibitor SnPPIX [167], respectively, for 6 hrs before exposing to MD for 
24 hrs. SnPPIX was dissolved in 0.1 M NaOH and dilute 1000-fold with medium before 








2.2.12 Carbon Monoxide (CO) Exposure 
 
HUVEC were exposed to 1% CO and 5% CO2 in air (Matheson-TriGas, Kyle, 
TX) in sealed incubator chambers (Billups-Rothenberg Inc, Del Mar, CA). Cultures 
identically treated but exposed to 95% air 5% CO2 served as control. After a 10 minute 
purging of either CO or air, HUVEC were incubated for 2 hrs. Various concentrations of 
MD were then added to the culture media and the culture plates were returned to the 
chambers. After 10 minutes of purging with 1% CO or air, HUVEC were incubated for 
additional 24 hrs in sealed chambers. The cell culture chambers were humidified and 
maintained at 37 °C. Cell viability was measured using the Alamar Blue assay.  Control 
cultures were identically treated but with 95% air and 5% CO2 
 
2.2.13 Statistical Analysis 
 
Data are presented as the mean ± standard deviation. Differences between or 
among the groups were analyzed using the independent samples T test or one-way 
analysis of variance combined with Tukey (equal variances assumed) or Games-Howell 
(equal variances not assumed) test through SPSS statistical software. A difference of p 
value < 0.05 was considered significant. Each experiment was repeated at least 3 times 
and a representative experiment is presented. For microarray analysis through BRB Array 
Tools (http://linus.nci.nih.gov/BRB-ArrayTools.html), genes were first excluded if both 
intensities of red and green signals <100, spot sizes <10, and spot flag contained numeric 
values other than 0. Then, lowess smooth normalization was applied to balance the 
difference in labeling intensities of the red and green dyes. Genes considered non-
informative were filtered out if less than 20 % of expression data had at least a 1.5 -fold 
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change in either direction from the gene's median value and percent of data missing or 
filtered out exceeds 50%. Two-class or multiple-class comparison was performed to 
identify genes that were differentially expressed using a random-variance t or F-test. 
Genes were considered statistically significant with p value < 0.001. The common genes 




2.3 RESULTS AND DISCUSSION 
 
2.3.1 Protective Effects of CAPE against MD-Induced Oxidative Stress in HUVEC 
 
I/R injury may occur in cardiovascular disease, surgical procedures and following 
traumatic injury. Natural polyphenolic compounds such as CAPE may provide some 
relief from I/R injury. To better understand the potential protective mechanism of CAPE, 
an in vitro model of MD-induced oxidative stress in HUVEC was developed.  
MD-induced cytotoxicity in HUVEC is shown in Figure 2.2. MD induced a dose-
dependent decrease in the viability of HUVEC as determined by the Alamar Blue assay. 
CAPE cytotoxicity was examined at 5, 10, and 15 μg/ml and is shown in Figure 2.3. 
Because 15 μg/ml of CAPE caused more than 10% cell death, the maximum dose of 
CAPE used for cytoprotection testing was 10 μg/ml. CAPE protected HUVEC against 
MD-induced I/R-like injury in a dose-dependent fashion (Figure 2.4). At 5 μg/ml, CAPE 
exhibited the maximum cytoprotective effect against MD-induced toxicity, recovering 
65% HUVEC compared to about 15% HUVEC viability after MD exposure alone.  
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The morphology of HUVEC is shown in Figure 2.5. The control HUVEC (Figure 
2.5A, 0.1% DMSO for 24 hrs) exhibited normal mitotic cells. MD-treated HUVEC 
(Figure 2.5B, 30 µM menadione for 24 hrs) displayed significant shrinkage and 
fragmentation, morphological characteristics of apoptosis. HUVEC pretreated with 5 
µg/ml CAPE for 6 hrs before MD treatment exhibited relatively normal cell morphology 
with few cells undergoing apoptosis (Figure 2.5C). 
This study demonstrated that CAPE provided dose-dependent cytoprotection of 























Figure 2.2:   Cytotoxicity of MD to HUVEC. MD caused a dose-dependent reduction of 
viability in HUVEC. Values are presented as means with standard 
deviations (n=3). The dose of MD at 25 μM was used in CAPE 
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Figure 2.3:   Cytotoxicity of CAPE to HUVEC. Values are presented as means with 
standard deviations (n=3). Cell viability is shown as percent of control, and 
less than 90% was considered toxic. CAPE at 15 μg/ml was considered 





































Figure 2.4:   CAPE cytoprotection against MD-induced injury in HUVEC. MD was used 
at 25 µM. Values are presented as means with standard deviations (n=3). 
CAPE showed dose-dependent cytoprotection against MD. CAPE at 5 
μg/ml recovered HUVEC significantly to about 65% from MD-induced 
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Figure 2.5:   Morphology of HUVEC treated with 0.1% DMSO (A), 30 µM MD alone 
(B), or pretreated with 5 µg/ml CAPE for 6 hrs before incubation with 30 
µM MD (C) for 24 hrs. In panel A, HUVEC undergoing normal mitosis are 
indicated with an arrow. In panels B and C, apoptotic cells are indicated by 
arrows. HUVEC were protected by CAPE pretreatment against MD toxicity, 
as shown by much less cell damage and fewer apoptotic cells. 
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2.3.2 HO-1 Induction by CAPE in HUVEC 
 
The mechanism for the beneficial effects of CAPE has been proposed result from 
its free radical scavenging ability due to 3, 4-dihydroxyl configuration on its catechol 
ring. Several recent studies suggested polyphenolic antioxidants such as curcumin and 
resveratrol altered transcriptional events to exert their beneficial effects, which provides 
an alternative explanation to antioxidant effects. To investigate the mechanism for CAPE 
cytoprotection at the transcriptional level, we performed gene expression analysis using 
oligonucleotide microarrays. The data showed that out of the 22,000 human genes 
examined from two independent experiments, 23 genes were statistically significantly up-
regulated early (within 6 hrs) to CAPE (Table 2.1). Among them, HO-1 was highly 
induced (8.25 fold) by CAPE compared to the DMSO control. To validate this 
microarray screening result, qRT-PCR and western blotting were performed to identify 
HO-1 mRNA and protein level in HUVEC after 6-hr and 24-hr preincubation with 
CAPE, respectively. The results confirmed that HO-1 mRNA and protein product level 
were elevated about 29-fold (Figure 2.6) and 6-fold (Figure 2.7), respectively. 
HO-1 induction has been shown to be beneficial in I/R injury in vivo [125, 128]. 
Several mechanisms of HO-1 protection against I/R injury have been proposed: 1) 
metabolism of heme, the toxic cellular component from disposed heme proteins; 2) 
consumption of excessive O2 during I/R injury in the process of heme degradation by 
HO-1; and 3) cytoprotection through heme catabolizing products such as BV/BR, ferrous 









Table 2.1: CAPE-regulated significant alteration of gene expression in HUVEC 
Gene category Gene description Fold change
Detoxification Heme oxygenase (decycling) 1 8.245 
Molecular 
chaperone 
Heat shock protein 90kDa beta (Grp94), member 1 
Heat shock 70kD protein 5 (glucose-regulated protein, 78kD) 
2.832 
3.954 
Growth factor KIT ligand 
Prostate differentiation factor 




Transporter Solute carrier family 3, member 2 
Solute carrier family 30 (zinc transporter), member 1 
Solute carrier family 39 (zinc transporter), member 14 
START domain containing 4, sterol regulated 






Binding  Selenoprotein K (selenium binding) 
Nucleobindin 2 (calcium ion binding) 
Asp (abnormal spindle)-like (calmodulin binding) 








DNA-damage-inducible transcript 3 (P38 MAPK signaling 
pathway) 
4.717 
Apoptosis BCL2/adenovirus E1B 19kD interacting protein 3 3.490 
Cytokine Interleukin 8 3.479 
Kinase Eukaryotic translation initiation factor 2-alpha kinase 3 2.914 
Transferase  Phosphatidylinositol glycan, class A 2.942 
Others Spindle pole body component 25 homolog (S. cerevisiae) 
Transmembrane protein 50B 





















Figure 2.6:   HO-1 mRNA induction by CAPE at 5 μg/ml for 6 hr in HUVEC by relative 
quantitative real-time RT-PCR. HO-1 expression was highly increased 
(29.24 fold) in CAPE group compared to DMSO control. Values are 













































Figure 2.7:   Effect of CAPE on HO-1 protein expression in HUVEC by western blotting. 
The induction of HO-1 protein was determined in HUVEC after incubating 









2.3.3 HO-1 Inhibitor SnPPIX Effects on CAPE Cytoprotection 
 
To further elucidate the role of HO-1 induction in CAPE cytoprotection, HO-1 
activity was suppressed by HO-1 enzyme competitive inhibitor SnPPIX. Coincubating 
with various non-toxic concentrations of SnPPIX and optimal cytoprotective dose of 
CAPE (5 µg/ml), the cytoprotective effect of CAPE against MD-induced cytotoxicity 
was abrogated in a concentration-dependent fashion (Figure 2.8). This result indicated 
that HO-1 induction may play an important role in CAPE cytoprotection.  
 
2.3.4 The Effects of BV, BR, and CO 
 
Heme degradation by HO-1 results in BV, BR, and CO production. All of them 
have been reported to ameliorate I/R induced injury in different organs in vivo [133, 169, 
170]. The cytoprotective activities of BV, BR, and CO were examined in the HUVEC-
MD model. BV and BR were reported as potent antioxidants against linoleic acid peroxyl 
radicals [171], which may contribute to the protective effect of HO-1. BR as low as 10 
nM can protect cells against oxidative stress induced by 100 µM hydrogen peroxide, 
which seems to function through the conversion from BV to BR by the action of BV 
reductase [122]. Therefore, the cytoprotective effects of BV and BR ranging from 0.01 to 
1 µM were tested, but no protection was observed compared to CAPE (Figure 2.9A and 










Figure 2.8:   The effect of HO-1 inhibitor SnPPIX on CAPE cytoprotection against MD-
mediated oxidative injury in HUVEC. Values are presented as means with 
standard deviations (n=3). SnPPIX exerted dose-dependent suppression on 5 
μg/ml CAPE protection against 25 μM MD-induced oxidative injury. CAPE 
plus 30 μM SnPPIX alone was not toxic. *:  P<0.01 versus CAPE + MD 


































Figure 2.9:   BR (A) and BV (B) cytoprotection testing compared to 5 μg/ml CAPE in 
HUVEC against oxidative stress induced by 30 μM MD. Values are 
presented as means with standard deviations (n=3). Neither BV nor BR from 
0.01 μM to 1 μM showed cytoprotection. ♣: P<0.01 versus MD alone. BV 




































































































































Brouard et al have shown that 1% CO treatment suppressed apoptosis and 
improved survivability of endothelial cells [172]. Mishra recently reported that CO 
provided cytoprotection in ischemic lungs by interrupting mitogen activated protein 
kinase expression of early growth response 1 genes and their downstream target genes 
[173]. To determine if CO could account for the cytoprotective effect of HO-1, HUVEC 
were exposed to various concentrations of MD in the presence or absence of 1% CO and 
cell viability was assessed by the Alamar Blue assay. HUVEC in the presence of CO 


























Figure 2.10: The cytoprotective effect of 1% CO against low doses of MD-induced 
oxidative damage in HUVEC. Values are represented as means with 
standard deviation (n=3). About 20% more cell viability was observed in 
1% CO-treated HUVEC (black column) than control (white column). ♣: 
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The observation that 1% CO (10,000 ppm) only provided partial protection at low 
doses of MD challenge but not at higher doses (data not shown) plus the fact that no 
cytoprotective effect could be demonstrated for BR and BV suggests that further 
investigations to clarify the role of the products of heme oxygenase enzymatic activity 
are needed. One possibility is that delivering carbon monoxide to the environment in the 
gas phase rather than generating it intracellularly in the appropriate cellular compartment 
where HO-1 is located may explain the fact that complete cytoprotection was not 
obtained compared to CAPE. In addition, the amount of heme proteins in non-erythroid 
cells available as the substrate for HO-1 action, may limit the generation of heme 
catabolic products. Two recent studies have demonstrated that non-heme induction of 
HO-1 or overexpression of mutated HO-1 incapable of heme catalytic activity still 
provided protection against ROS-induced oxidative stress [174, 175]. Therefore CAPE 















An in vitro model simulating I/R-induced damage in endothelium was developed, 
where MD triggered oxidative stress in HUVEC and induced apoptosis. CAPE displayed 
cytoprotective ability in a dose-dependent manner increasing cell survivability up to 65% 
against MD toxicity at the optimal cytoprotective dose of 5 μg/ml. The alteration in 
HUVEC transcriptional activity especially the induction of HO-1 by CAPE provided 
information about the mechanism of cytoprotection. The loss of CAPE cytoprotection in 
the presence of HO-1 enzyme inhibitor SnPPIX indicated the important role of HO-1 
induction in providing the beneficial effect of CAPE. The partial protection by CO, the 
end product of HO-1 action does not explain the direct effect in CAPE cytoprotection. 
















Chapter III: Synthesis and Cytoprotective effects of Caffeic Acid 





The cytoprotective effect of caffeic acid phenethyl ester (CAPE) has been 
demonstrated in a model of oxidative stress produced by treatment of human endothelial 
cells with a cytotoxic dose of menadione (MD), and the induction of heme oxygenase-1 
(HO-1) enzyme may play an important role in this cytoprotection (Chapter II). 
Understanding the chemical basis of CAPE in cytoprotection will further elucidate its 
mechanism of action and may improve cytoprotection with proper chemical modification 
of CAPE. This effort may eventually lead to better candidate drugs for ameliorating 
ischemia/reperfusion (I/R) injury.  
In this chapter, the synthesis of six new fluorinated CAPE derivatives and their 
evaluation as cytoprotectants in the recently established HUVEC-MD model will be 
described. In addition to providing structure-activity information, these fluorinated CAPE 
derivatives may display altered metabolic liability, thereby extending their protection 
potency in vivo. Since the number of the hydroxyl groups within CAPE catechol moiety 
may also play an important role in antioxidant activity [176, 177], we also examined the 
effect of replacing one of these hydroxyl groups with a fluorine or hydrogen, or 




3.2 MATERIALS AND METHODS 
 
3.2.1 Materials and Apparatus 
 
Chemical reagents 6-fluoroveratraldehyde (2d), 3-fluoro-4-hydroxy-5-
methoxybenzaldehyde (2a), 3-fluoro-4-methoxybenzaldehyde (1), boron tribromide, 
chloroacetyl chloride, phenethyl alcohol, and triphenylphosphine were purchased from 
Aldrich (Milwaukee, WI). Phenethyloxycarbonylmethyl-triphenyl-phosphonium chloride 
(4) was prepared from triphenylphosphine and chloroacetic acid phenethyl ester as 
described in the literature [148]. All solvents were of analytical grade and distilled prior 
to experiments. Thin-layer chromatography (TLC) was performed on precoated silica gel 
60 F254 aluminum plates made from EM Science (Gibbstown, NJ). Flash chromatography 
was performed on silica gel column (230-400 mesh, 40-63 μm) from Fisher Scientific 
(Pittsburgh, PA). 
Melting points were calculated following differential scanning calorimetry using 
TA Instruments Model 2920 (New Castle, DE) with a heating range of 10 °C /min and 
rounded to whole numbers. 1H and 13C NMR spectra were recorded on a Bruker AMX-
500 or Varian Inova 500 nuclear magnetic resonance spectrometer, using CD3OD or 
CDCl3 as solvents. Chemical shifts are reported in ppm (δ) relative to tetramethylsilane 
(TMS) as internal standard for 1H NMR and in ppm relative to the solvent for 13C NMR.  
Elemental analyses were performed on a 2400 Perkin-Elmer Elemental Analyzer by 
Quantitative Technologies Inc (Whitehouse, NJ). Low-resolution MS data were obtained 
using Finnigan MAT TSQ700 (San Jose, CA). High-resolution MS data were acquired on 
Micromass ZABE (Manchester, England). 
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3.2.2 Synthesis of CAPE Derivatives 
 
3.2.2.1 General procedure for demethylation 
 
2-Fluoro-4,5-dihydroxy-benzaldehyde (2e). Compound 2d, 2-fluoro-4,5-
dimethoxybenzaldehyde (500 mg, 2.715 mmol), was dissolved in 12 ml of CH2Cl2 and 
cooled to –70 °C in a dry ice/acetone bath under argon. A 1 M solution of BBr3 in 
CH2Cl2 (8.15 ml, 8.15 mmol) was added slowly with vigorous stirring. The reaction 
mixture was stirred overnight without further cooling. After 24 hrs, MeOH (10 ml) was 
added to the reaction mixture to quench excess BBr3 and the solvent was evaporated.  
This process was repeated two additional times and the crude product 2e was used in the 
next step without further purification. 
 
3.2.2.2 General procedure for Wittig reaction 
 
3-(2-Fluoro-4,5-dihydroxy-phenyl)-acrylic acid phenethyl ester (3e, CAPE-1). 
The crude 2-fluoro-4,5-dihydroxybenzaldehyde (2e) was dissolved in 7.5 ml of 1,4-
dioxane.  The phosphonium chloride 4 (1.7 g, 3.7 mmol), 7.5 ml CHCl3, and KHCO3 
(815 mg, 8.15 mmol) were added. The reaction was heated under reflux in a 110 °C oil 
bath with vigorous stirring under argon for 18 hrs. The resulting mixture was filtered, 
washed with CH2Cl2, and concentrated on a rotary evaporator. Column chromatography 
(EtOAc/CH2Cl2 (2:3, v/v)) afforded 456 mg (55 % yield) of 3e as a white solid:  mp 157 
ºC; TLC (Silica gel, EtOAc/CH2Cl2 (2:3, v/v)), Rf 0.45; 1H NMR (CD3OD) δ 2.97 (t, J = 
7.0 Hz, 2H), 4.35 (t, J = 7.0 Hz, 2H), 6.26 (d, J = 16.0 Hz, 1H), 6.54 (d, J = 11.7 Hz, 1H), 
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6.97 (d, J = 7.2 Hz, 1H), 7.23 (m, 5H), 7.66 (d, J = 16.0 Hz, 1H); 13C NMR (CD3OD) δ 
36.14, 66.22, 103.96 (d, JC-F = 26.4 Hz), 113.82 (d, JC-F = 12.9 Hz), 114.02 (d, JC-F = 3.9 
Hz), 116.98 (d, JC-F =5.4 Hz), 127.52, 129.48, 129.95, 138.87 (d, JC-F = 3.5 Hz), 139.35, 
143.39, 150.79 (d, JC-F = 11.9 Hz), 157.21 (d, JC-F = 245.1 Hz), 168.90; CI-MS m/z 303 
(MH+, 100). HRCI-MS: Calcd for C17H15FO4; 303.1033, Found 303.1023; Anal. Calcd 
for C17H15FO4: C, 67.54; H, 5.00; F, 6.28. Found: C, 67.53; H, 4.97; F, 6.18. 
 
3-(3-Fluoro-4-hydroxy-5-methoxy-phenyl)-acrylic acid phenethyl ester (3a, 
CAPE-3). The 3-fluoro-4-hydroxy-5-methoxy-benzaldehyde (2a, 200 mg, 1.18 mmol) 
was used directly in the Wittig reaction to afford 214 mg (57% yield) of compound 3a as 
an off-white solid after column chromatography and recrystallization from 
EtOAc/hexane:  mp 94 ºC;  1H NMR (CDCl3) δ 3.02 (t, J = 7.0 Hz, 2H), 3.94 (s, 3H), 
4.42 (t, J = 7.0 Hz, 2H), 6.28 (d, J = 16.1 Hz, 1H), 6.83 (d, J = 1.6 Hz, 1H), 6.95 (dd, J = 
10.8, 1.8 Hz, 1H), 7.28 (m, 5H), 7.53 (d, J = 16.1 Hz, 1H); 13C NMR (CDCl3) δ 35.23, 
56.54, 65.03, 106.03, 109.54 (d, JC-F = 19.2 Hz),117.07, 126.11 (d, JC-F =7.8 Hz), 126.60, 
128.55, 128.92, 135.38 (d, JC-F = 13.9 Hz), 137.88, 143.86, 148.30 (d, JC-F = 6.2 Hz), 
150.55 (d, JC-F = 242.6 Hz), 166.77; CI-MS m/z 317 (MH+, 100). HRCI-MS: Calcd for 
C18H17FO4; 317.1189. Found 317.1184; Anal. Calcd for C18H17FO4: C, 68.35; H, 5.42; F, 
6.01. Found: C, 68.24; H, 5.36; F, 5.98. 
 
3-(3-Fluoro-4,5-dihydroxy-phenyl)-acrylic acid phenethyl ester (3b, CAPE-
2). Demethylation of 3-fluoro-4-hydroxy-5-methoxy-benzaldehyde (2a, 200 mg, 1.18  
mmol) with BBr3 (3 ml, 3 mmol) afforded crude 3-fluoro-4,5-dihydroxy-benzaldehyde 
(2b) which was used in the subsequent Wittig reaction with 4 to give 307 mg (86 % 
yield) of 3b as an off-white solid  after column chromatography and recrystallization 
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from EtOAc/CH2Cl2:  mp 135 ºC; 1H NMR (CD3OD) δ 2.98 (t, J = 7.0 Hz, 2H), 4.36 (t, J 
= 7.0 Hz, 2H), 6.25 (d, J = 15.9 Hz, 1H), 6.83 (t, J = 1.5 Hz, 1H), 6.85 (d, J = 2.0 Hz, 
1H), 6.87 (d, J = 2.0 Hz, 1H),  7.24 (m, 5H), 7.45 (d, J = 15.9 Hz, 1H); 13C NMR 
(CD3OD) δ 36.18, 66.22, 108.36 (d, JC-F = 19.8 Hz), 111.84, 116.75, 126.62 (d, JC-F =8.9 
Hz), 127.55, 129.51, 129.97, 137.36, 139.41, 145.92, 148.84 (d, JC-F = 5.9 Hz), 153.43 (d, 
JC-F = 238.1 Hz), 168.76; CI-MS m/z 303 (MH+, 100). HRCI-MS: Calcd for C17H15FO4; 
303.1033, Found 303.1030; Anal. Calcd for C17H15FO4+1/4H2O: C, 66.55; H, 5.09. 
Found: C, 66.76; H, 4.84. 
 
3-(3-Fluoro-4-hydroxy-phenyl)-acrylic acid phenethyl ester (3c, CPAE-5).  
Demethylation of 3-fluoro-4-methoxy-benzaldehyde (1, 200 mg, 1.30 mmol) with BBr3 
(3.3 ml, 3.3 mmol) afforded crude 3-fluoro-4-hydroxy-benzaldehyde (2c) which was used 
in the subsequent Wittig reaction with 4 to give 290.6 mg (78 % yield) of compound 3c 
as an off-white solid after column chromatography and recrystallization from 
EtOAc/hexane: mp 80 ºC; 1H NMR (CDCl3) δ 3.01 (t, J = 7.1 Hz, 2H), 4.42 (t, J = 7.1 
Hz, 2H), 6.27 (d, J = 16.0 Hz, 1H), 6.98 (s, 1H), 7.00 (s, 1H), 7.01 (s, 1H),  7.26 (m, 5H), 
7.55 (d, J = 15.9 Hz, 1H); 13C NMR (CDCl3) δ 35.22, (40.48), 65.10, 114.72 (d, JC-F = 
18.5 Hz), 116.83, 117.71, 125.57 (d, JC-F =3.1 Hz), 126.60, 127.67 (d, JC-F = 6.3 Hz), 
128.54, 128.94, 137.87, 143.66, 145.79 (d, JC-F = 14.7 Hz), 151.16 (d, JC-F = 238.9 Hz), 
167.04; CI-MS m/z 287 (MH+, 100). HRCI-MS: Calcd for C17H15FO3; 287.1083, Found 
287.1089; Anal. Calcd for C17H15FO3+1/4H2O: C, 70.21; H, 5.37; F, 6.53. Found: C, 
70.02; H, 5.27; F, 6.50. 
 
3-(2-Fluoro-4,5-dimethoxy-phenyl)-acrylic acid phenethyl ester (3d, CAPE-
6). This compound was a co-product from the above reaction leading to compound 3f. It 
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was isolated as 69 mg (6 % yield) of an off-white solid after repeated column 
chromatography and recrystallization from CH2Cl2/hexane: mp 86 ºC; 1H NMR (CDCl3) 
δ (ppm): 3.02 (t, J = 7.1 Hz, 2H), 3.88 (s, 3H), 3.89 (s, 3H), 4.43 (t, J = 7.1 Hz, 2H), 6.36 
(d, J = 16.1 Hz, 1H), 6.64 (d, J = 11.6 Hz, 1H), 6.94 (d, J = 6.8 Hz, 1H), 7.26 (m, 5H), 
7.78 (d, J = 16.1 Hz, 1H); 13C NMR (CDCl3) δ (ppm): 35.24, 56.28, 56.40, 64.99, 100.15 
(d, JC-F = 28.0 Hz), 109.42 (d, JC-F = 4.5 Hz), 113.46 (d, JC-F = 12.7 Hz), 117.64 (d, JC-F = 
6.0 Hz), 126.57, 128.53, 128.94, 137.17 (d, JC-F = 3.0 Hz), 137.92, 145.65 (d, JC-F = 2.5 
Hz), 152.01 (d, JC-F = 10.2 Hz), 156.51 (d, JC-F = 248.8 Hz), 166.95; CI-MS m/z 331 
(MH+, 100). HRCI-MS: Calcd for C19H19FO4; 331.1346. Found 331.1354; Anal. Calcd 
for C19H19FO4+1/4H2O: C, 68.15; H, 5.87. Found: C, 68.47; H, 5.70. 
 
3-(2-Fluoro-4–methoxy-5-hydroxyphenyl)-acrylic acid phenethyl ester (3f, 
CAPE-4). Partial demethylation of 2-fluoro-4,5-dimethoxy-benzaldehyde (2d, 600 mg, 
3.26 mmol) was carried out with one equivalent of boron tribromide (3.26 ml, 3.26 
mmol) to give crude monomethyl-2-fluoro-4,5-dihydroxybenzaldehyde (2f) as a mixture 
of 4- and 5-methyl isomers containing some un-reacted 2d. This mixture was used 
directly in the subsequent Wittig reaction with 4 to afford 42 mg (4 % yield) of 
compound 3f as of off-white solid after repeated column chromatography and 
recrystallization from CH2Cl2/hexanes: 1H NMR (CDCl3) δ 3.01 (t, J = 7.1 Hz, 2H), 3.89 
(s, 3H), 4.41 (t, J = 7.1 Hz, 2H), 6.33 (d, J = 16.1 Hz, 1H), 6.61 (d, J = 11.3 Hz, 1H), 7.05 
(d, J = 7.1 Hz, 1H), 7.26 (m, 5H), 7.74 (d, J = 16.1 Hz, 1H); 13C NMR (CDCl3) δ 35.23, 
56.30, 65.02, 99.45 (d, JC-F = 28.5 Hz), 112.38 (d, JC-F = 4.0 Hz), 114.52 (d, JC-F = 13.2 
Hz), 118.02 (d, JC-F =6.2 Hz), 126.56, 128.52, 128.96, 137.04 (d, JC-F = 3.1 Hz), 137.93, 
142.00 (d, JC-F = 2.5 Hz), 149.01 (d, JC-F = 10.2 Hz), 155.76 (d, JC-F = 247.8 Hz), 167.01; 
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CI-MS m/z 317 (MH+, 100). HRCI-MS: Calcd for C18H17FO4; 317.1189. Found 
317.1198; Anal. Calcd for C18H17FO4: C, 68.35; H, 5.42. Found: C, 68.04; H, 5.22. The 
structural assignment for 3f is based on the appearance of the 2-fluorocatechol 4-position 
carbon resonance (J3C-F = 10 Hz) at 149 ppm, which is further downfield than expected 
for the 5-methyl isomer (c.a. 140 ppm). 
 
3.2.3 Cell Culture 
 
HUVEC were cultured the same way as described in Chapter II. 
 
3.2.4 Cell Viability (Alamar Blue Assay) 
 
Stock solutions of MD (0.5 M in PBS) or CAPE analogues (1000x in DMSO) 
were diluted in culture medium and added to plate wells at final concentrations of 10–40 
µM for MD and 5-15 µg/ml for CAPE derivatives, respectively. Cell viability was 
assessed at 24 hours after initiation of treatment versus vehicle (PBS or DMSO) controls 
using Alamar Blue™. Detailed experimental information was described in Chapter II. 
 
3.2.5 In Vitro Cytoprotection Assay 
 
Confluent HUVEC were pretreated with CAPE and its derivatives for 6 hrs. 
Cytotoxic dose of MD was then added to the HUVEC in the presence of testing CAPE 
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analogues and DMSO as vehicle control. After 24 hrs incubation, cell viability was 
measured using the Alamar Blue assay.  
 
3.2.6 Statistical Analysis 
 
Data were represented as the mean ± standard deviation. Differences among the 
groups were analyzed using the one-way analysis of variance combined with Tukey 
(equal variances assumed) or Games-Howell (equal variances not assumed) test. A 
difference of p< 0.05 was considered significant for all statistical analyses. 
 
 




A Wittig coupling approach was taken to elaborate a number of fluorinated 
analogues of CAPE (Table 3.1). The required fluorinated benzaldehydes (2a-f) were 
either commercially available, or easily prepared through demethylation of commercially 
available aldehydes with boron tribromide (Figure 3.1). The demethylated aldehydes 
were applied directly in the subsequent Wittig reaction employing the 
phenethyloxycarbonylmethyl-triphenyl-phosphonium chloride 4, which was prepared as 
described in the literature [148]. As shown in Figure 3.1 and Table 3.1, the preparation of 
the fluorinated CAPE derivatives is relatively straightforward due to the commercial 
availability of a number of fluorinated methoxybenzaldehydes, which can be easily 
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demethylated and immediately subjected to Wittig coupling. The methylated CAPE 
derivatives derived from direct Wittig coupling of these aldehydes were also prepared.  
 In case of 2-fluoro-4,5-dimethoxybenzaldehyde (2d), demethylation with one 
equivalent of boron tribromide afforded a mixture of 4- and 5-monomethylated aldehydes 
along with some remaining 4,5-dimethylated starting material. This mixture was used 
directly in the Wittig reaction to give a low yield of the monomethylated CAPE 
derivative CAPE-4, along with a small amount of the 2-fluoro-dimethyl CAPE analogue 
CAPE-6. The remaining fluorinated CAPE analogues were isolated in good yield after 
column chromatography and recrystallization. All of the isolated CAPE analogues were 
characterized by 1H and 13C NMR and low- and high-resolution mass spectrometry. 
Typical 1H NMR, 13C NMR, and mass spectrometry spectral data in the case of CAPE-1 
are presented in Figure 3.2 – 3.5. All CAPE derivatives gave satisfactory elemental 
analyses. In agreement with the results reported by others [148], the (E)/(Z) ratio of the 
CAPE analogues prepared in this way were generally >9:1, as judged by 1H NMR.   
Two series of CAPE analogues were prepared, those bearing a fluorine at the 3-
position of the caffeic acid catechol ring (CAPE-2, 3, and 5) and those with fluorine at 
the 2-position (CAPE-1, 4, and 6). In addition to variation in the position of fluorination, 
analogues were prepared in which one (CAPE-3 and 4) or both (CAPE-6) of the hydroxyl 
groups of the catechol functionality of CAPE were methylated. We also examined an 










Table 3.1:  Synthesis of fluorinated CAPE analogues.  
 
 
Compound R2 =  R3 = R4 = R5 = Yield 
a H OMe H F 57% 
b H OH H F 86% 
c H H H F 78% 
d F H Me OMe 6%a 
e F H H OH 55% 
f F H Me OH 4% a 
a. Low yields are due to compound losses during repeated chromatography required to 
separate 3d and 3f from the reaction product of crude 2f, which contained some of the 





































































3.3.2 Cytotoxicity of Fluorinated CAPE Analogues Compared to CAPE 
 
CAPE and the fluorinated CAPE analogues were initially assayed for cytotoxic 
effects in HUVEC at the concentrations used in the cytoprotection studies.  HUVEC were 
incubated in the presence of these compounds at 5, 10, and 15 μg/ml for 24 hrs, and the 
extent of cell viability was determined versus vehicle-treated control cells using the 
Alamar Blue assay. Cell viability less than 90% of control was considered toxic.  The 
results, shown in Figure 3.6, demonstrate that, compared to CAPE, CAPE-1, 2, 3, and 4 
were also toxic at the highest concentration examined (15 μg/ml), while the analogues 
CAPE-5 and 6 showed no toxicity at any tested concentrations. The data suggest that the 
cytotoxicity of these CAPE analogs towards HUVEC is not correlated with the position 
of the fluorine substitution. The 2-fluoroCAPE derivative CAPE-1 and the 3-fluoroCAPE 
derivative CAPE-2 are cytotoxic at >10 µg/ml, as is CAPE itself. In contrast, derivatives 
that lack CAPE’s catechol functionality, such as the 2-fluoro-4,5-dimethyl analog CAPE-
6 and the fluorophenol CAPE-5 are less cytotoxic than CAPE at the highest 
concentrations examined. It was found that CAPE-2 was less cytotoxic at 10 μg/ml than 
at 5 and 15 μg/ml. The origin of this phenomenon is not known; however, such non-










Figure 3.6:   The cytotoxicity of CAPE and its derivatives toward HUVEC. HUVEC cells 
were incubated with CAPE at the indicated concentrations for 24 hrs and the 
number of viable cells was determined by Alamar Blue assay. Values are 
reported as mean (n = 3) percent of untreated control with error bars 
showing the standard deviation. Asterisks indicate significant cytotoxicity 












































3.3.3 Cytoprotection of Fluorinated CAPE Derivatives against Menadione-Induced 
Oxidative Stress Compared to CAPE 
 
MD treatment of HUVEC for 24 hrs resulted in a concentration-dependent 
decrease in cell viability as measured by the Alamar Blue assay (Figure 3.7). The lowest 
dose of menadione that reduced cell viability to about 10 % of untreated cells (e.g., 30 
µM) was employed for the cytoprotection assays of CAPE and its analogues. Almost all 
CAPE derivatives showed dose-dependent cytoprotection against MD-mediated 
cytotoxicity in HUVEC to some extent except CAPE-2. The dose-dependent 
cytoprotection profiles for all of the CAPE derivatives are shown in Figure 3.8. 
Compared to CAPE, CAPE analogues CAPE-3, 4, 5, and 6, demonstrated cytoprotective 
effects even at the highest concentrations, 10 or 15 µg/ml, while CAPE-1 only showed 
cytoprotection at 5 µg/ml. Within the same passage of HUVEC, the cytoprotection of 
CAPE and its derivatives at their maximal cytoprotective dose were compared as shown 
in Figure 3.9.  
The cytoprotection data demonstrated that the position of fluorine substitution on 
the CAPE catechol ring can have a significant effect on the ability of these derivatives to 
protect against MD-mediated oxidative stress. The presence of a fluorine at the 2-position 
of the catechol ring (CAPE-1) results in cytoprotection at a similar level to that of CAPE. 
In contrast, the presence of a fluorine at 3-position (CAPE-2) completely abolishes 
cytoprotective activity. The catechol functionality of CAPE and related antioxidants has 
been reported to be involved in cytoprotection through metal ion chelation [88]. In our 
studies, fluorinated CAPE derivatives in which the catechol functionality of CAPE is 
methylated or replaced with a phenol also display cytoprotection. Both 2- and 3-
fluoromonomethyl CAPE derivatives CAPE-3 and 4, respectively, retain cytoprotective 
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activity, although the maximal cytoprotection by these analogs is less than that by CAPE. 
Interestingly, the 2-fluorodimethyl CAPE derivative CAPE-6 and 3-fluoro-4-hydroxy 
CAPE analogue CAPE-5 are also both cytoprotective, and these analogues, which are not 
cytotoxic at higher concentrations, do not show the diminution in cytoprotection at higher 

























Figure 3.7:   MD shows dose-dependent cytotoxicity in HUVEC. HUVEC were 
incubated with MD for 24 hrs at the indicated concentrations and the 
number of viable cells was determined by Alamar Blue assay. Values are 
reported as mean (n = 3) percent of untreated control with error bars 
showing the standard deviation. The lowest dose of MD causing 90 % loss 
in cell viability (e.g., 30 µM) was employed in the cytoprotection assays. 
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Figure 3.8:   Dose-dependent cytoprotection by CAPE derivatives.  HUVEC were 
incubated with CAPE analogs for 6 hrs at the indicated concentrations prior 
to MD treatment. Values are reported as mean (n = 3) percent of untreated 
control with error bars showing the standard deviation. Asterisks indicate 
significant protective effects against MD-caused injury relative to no 




Figure 3.9:   Comparison of CAPE and CAPE analogs maximal cytoprotection against 
MD-induced oxidative stress. CAPE: 5 µg/ml; CAPE-1: 5 µg/ml; CAPE-2: 
10 µg/ml; CAPE-3: 10 µg/ml; CAPE-4: 10 µg/ml; CAPE-5: 10 µg/ml; 
CAPE-6: 15 µg/ml. Values are reported as mean (n = 3) percent of untreated 
control with error bars showing the standard deviation. Asterisks indicate 
significant protective effects against MD-caused injury relative to no 
pretreatment (P< 0.05). Clover signs indicate significant difference relative 











Six new catechol-ring fluorinated CAPE derivatives were synthesized using the 
Wittig reaction and characterized to meet criteria of purity. Their cytoprotection profiles 
were established in the HUVEC-MD model. The results demonstrated that most of the 
fluorinated CAPE analogues examined were as cytoprotective as CAPE in a dose-
dependent manner. CAPE-1 displayed the best cytoprotective effect among the 
derivatives, and was not significantly different from CAPE. CAPE-3 to 6 all protected 
HUVEC from MD-induced oxidative injury to some extent. CAPE-5 and 6 extended the 
beneficial effects to higher dose of 15 μg/ml without exhibiting cytotoxicity. CAPE-2, 
however, showed no cytoprotection at the doses tested. The cytoprotection data described 
here provides some insight into the structural basis for CAPE cytoprotection. Further 
exploration of the mechanism responsible for cytoprotective effects of CAPE and its 













Chapter IV: Mechanism Investigation of Cytoprotection of Caffeic Acid 
Phenethyl Ester and Fluorinated Derivatives: Effects on Heme 




To study caffeic acid phenethyl ester (CAPE) structure and cytoprotective 
relationships, six catechol ring-fluorinated CAPE derivatives were synthesized and 
evaluated for their cytoprotective effects in the human umbilical vein endothelial cells 
(HUVEC)-menadione (MD) model which simulates ischemia/reperfusion injury in vitro 
(Chapter II and III). Gene expression analysis data showed CAPE induced the 
cytoprotective gene heme oxygenase-1 (HO-1), which may play an important role in 
CAPE cytoprotection. That this is the case was suggested by the application of HO-1 
inhibitor SnPPIX. To further elucidate the structural effects on the protective mechanism 
of CAPE, the effect of HO-1 elevation on the cytoprotection of CAPE analogues was 
examined.  
However, antioxidant activity has also been proposed to account for the beneficial 
effects of polyphenolic compounds such as CAPE, curcumin, and resveratrol in I/R 
induced oxidative damage [37, 180, 181]. To investigate whether CAPE cytoprotection is 
due to a transcription-mediated event or pure structure-related antioxidant activity, it was 
necessary to evaluate the free radical scavenging abilities of CAPE and derivatives in 
HUVEC cells, which was achieved by measuring the intracellular ROS production using 
a fluorescent probe 5-(and-6)-chlormethyl-2’,7’-dichlorodihydrofluorescein diacetate 
(CM-H2DCFDA) [182].  
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In this chapter, the hypothesis was tested that the cytoprotective effect of CAPE 
and derivatives on MD-induced oxidative injury in HUVEC is mediated through 
transcriptional activity, mainly the induction of HO-1, rather than their direct antioxidant 
function. 
 
4.2 MATERIALS AND METHODS 
 
4.2.1 Chemicals and Reagents 
 
Caffeic acid and 1 M 4-(2-hydroxyethyl)-1-piperazineethanesulfoic acid (HEPES) 
buffer were obtained from Sigma-Aldrich (Saint Louis, MO). Methyl Caffeate (MC) and 
phenethyl dimethyl caffeate (PEDMC) were from LKT Laboratories (St. Paul, MN). CM-
H2DCFDA and 10× Hanks’ balanced salt solution (no sodium bicarbonate and phenol 
red) were obtained from Invitrogen (Eugene, OR). Cells-to-cDNA kit was from Ambion 
(Austin, TX). 
 
4.2.2 Synthesis of Catechol Ring-Fluorinated CAPE Derivatives 
 
The chemical structures of the Fluorinated CAPE analogues examined in this 
study were reported in Figure 4.1. These compounds were synthesized according to a 
















































































4.2.3 Cell Culture 
 
HUVEC were cultured according to experimental section in Chapter II. 
 
4.2.4 Cell Viability and Toxicity Assay 
 
Cell viability was measured in HUVEC using Alamar Blue assay kit (Chapter II). 
MD was used to induce oxidative injury in HUVEC as previously described (Chapter II). 
 
4.2.5 Cell Protection Assay 
 
CAPE and its derivatives were dissolved in DMSO to 20 mM and diluted 1000-
fold with medium before assay. Confluent HUVEC in 48-well plates were initially 
pretreated with CAPE and its analogues at same concentrations of 20 µM for 6 hrs, and 
the cytotoxic dose of MD was then administered to the HUVEC in the presence of testing 
compounds. After 24-hr incubation, cell viability was measured using the Alamar Blue 
assay. 
 
4.2.6 Determination of Endothelial HO-1 mRNA Levels by Real-time RT-PCR 
 
HUVEC were grown in 48-well plates until confluence and pretreated with 20 
µM CAPE and its derivatives for 6 hrs. cDNA was obtained by reverse transcription from 
cells directly without RNA isolation using the Cells-to cDNA™ II kit according to the 
manufacturer’s instruction (Ambion Inc., Austin, TX).  Real-time PCR was performed on 
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a LightCyclerTM thermal cycler (Idaho Technology, Salt Lake City, UT) with Roche 
LightCycler® TaqMan Master for HO-1 and 18S (Roche Diagnostics, Indianapolis, IN). 
HO-1 and 18S primer sets were from TaqMan® Gene Expression Assays (Applied 
Biosystems, Foster City, CA). HO-1 gene was normalized to the expression level of 18S 
gene for each sample. Relative quantification was acquired by comparative CT method. 
 
4.2.7 Western Blotting 
 
Detailed experimental procedures were described in Chapter II. 
 
4.2.8 HO-1 Inhibition with SnPPIX 
 
Confluent HUVEC were pretreated with CAPE and its fluorinated derivatives at 
20 µM in the presence of different doses of HO-1 inhibitor SnPPIX, respectively, for 6 
hrs before exposing to a toxic dose of MD for additional 24 hrs. SnPPIX was dissolved in 
0.1 M NaOH and diluted 1000-fold with medium. Cell viability was measured using the 
Alamar Blue assay. 
 
4.2.9 Cell-Based Antioxidant Assay 
 
Intracellular ROS production while HUVEC were exposed to 20 µM CAPE and 
derivatives was measured with the fluorescent probe CM-H2DCFDA [182]. In brief, 
HUVEC were seeded onto 96-well plates and grown till confluence. The working buffer 
was prepared by diluting 10× Hanks’ balanced salt solution (without sodium bicarbonate 
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or phenol red; Invitrogen) and 10 mM HEPES buffer in sterile water to make 1× Hanks’ 
HEPES. HUVEC were rinsed twice with prewarmed working buffer, and incubated for 
30min at 37 °C in the incubator with DCFDA (8 µM) premixed in the working buffer. 
HUVEC were then washed twice with prewarmed working buffer and loaded with the 
testing compounds dissolved in the working buffer. The fluorescence released from the 
cells was recorded immediately at 480 nm (excitation) and 520 nm (emission) using 
SpectraMAX® M2 microplate reader at different time intervals over a 2 hr period while 
the HUVEC were incubated at 37 °C within the plate reader. The fluorescent signals were 
normalized to the initial readings at time zero. The relative fluorescence was proportional 
to the ROS production. 
 
4.2.10 Statistical Analysis 
 
Data are presented as mean plus standard deviation. Differences between or 
among the groups were analyzed using the independent samples T test or one-way 
analysis of variance combined with Tukey (equal variances assumed) or Games-Howell 
(equal variances not assumed) test through SPSS statistical software. A difference of p 








4.3 RESULTS AND DISCUSSION 
 
4.3.1 Cytoprotective Comparison of CAPE and Fluorinated Derivatives against 
Oxidative Stress in HUVEC 
 
To further elucidate the molecular mechanisms of CAPE cytoprotection, we first 
compared the cytoprotective effects of CAPE and fluorinated derivatives against MD 
toxicity at the same molar amount. The cytotoxic effect of MD was evaluated in HUVEC 
and a dose of 22.5 μM was selected and applied in the cytoprotection assay (Figure 4.2). 
CAPE and fluorinated analogues at 20 μM ameliorated MD-induced oxidative injury in 
HUVEC to different levels (Figure 4.3). Among all fluorinated derivatives, CAPE-1 
showed maximal cytoprotection resulting in about 60% more cell viability compared to 
MD-treated HUVEC which was not significantly different than that of CAPE itself. 
CAPE-4 and CAPE-5 exhibited similar protective effects which recovered about 45% 
more cells from MD toxicity. CAPE-3 protected HUVEC to a relatively low level and 
about 20% more cells survived from oxidative injury. CAPE-2 and CAPE-6 didn’t 
increase the cell survival significantly compared to MD control at the dose tested. The 
concentration of CAPE-6 at 20 μM is equal to 6.6 μg/ml, which may not reach its 
cytoprotective dose yet (10 μg/ml). The cytoprotection results of CAPE analogues are 





4.3.2 HO-1 mRNA and Protein Expression in HUVEC by CAPE Fluorinated 
Derivatives 
 
We examined whether HO-1 up-regulation is also involved in the beneficial 
effects of CAPE analogues. HUVEC with same batch and passage number as those for 
the cytoprotection assay were employed to determine HO-1 mRNA levels after 6-hr 
pretreatment with 20 μM CAPE and analogues. Almost all CAPE fluorinated analogues 
activated high level of HO-1 mRNA expression compared to the DMSO control except 
CAPE-6 (Figure 4.4). The cytoprotection correlated well with HO-1 activation for most 
CAPE derivatives. CAPE, CAPE-1, 3, 4, and 5 showed both cytoprotection and HO-1 
mRNA induction (> 15 fold). CAPE-6 neither protected HUVEC nor increased HO-1 
expression to the level induced by other analogues. Only CAPE-2 activated HO-1 
transcription but did not ameliorate MD-caused oxidative damage in HUVEC. 
Considering that there may be a nonlinear relationship between HO-1 transcript and 
protein level, it was necessary to check the HO-1 protein level induced by CAPE-2. 
Interestingly, the western blot data showed CAPE-2 did not induce HO-1 protein product 
as CAPE did at 6 hrs (Figure 4.5). A Similar induction of mRNA without a 
corresponding translation into protein product has been observed in other polyphenols 
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Figure 4.2:   Cytotoxicity of MD in HUVEC. Values are represented as means plus 
standard deviation (n=3). MD caused reduction of HUVEC viability in a 
dose-dependent manner. The dose of MD at 22.5 μM was used in the 
cytoprotection assay of CAPE and derivatives. ∗: P<0.05 versus control 




















Figure 4.3:   CAPE and its fluorinated analogs’ cytoprotection against MD-induced injury 
in HUVEC. Values are represented as means plus standard deviation (n=3).  
Pretreatment of HUVEC with CAPE and six synthesized derivatives at 20 
μM showed different cytoprotective effects against 22.5 μM MD-caused 
oxidative injury. CAPE-1 exhibited the best cytoprotection among 
analogues, which was similar to that of CAPE. CAPE-3, 4, and 5 
ameliorated MD-resulted oxidative stress in HUVEC to some extent, while 















Figure 4.4:   HO-1 mRNA induction by CAPE and fluorinated derivatives in HUVEC 
through RT-PCR. Values were represented as means plus standard 
deviations (n=4). After 6 hr incubation, CAPE and most analogues highly 
elevated HO-1 gene expression more than 15 fold compared to DMSO 

















































Figure 4.5:   HO-1 protein expression in HUVEC by CAPE and CAPE-2. CAPE at 20 
μM induced HO-1 protein production about 6 fold compared to DMSO 
control in 24 hrs, while same amount of CAPE-2 didn’t significantly elevate 









4.3.3 Effects of HO-1 Inhibitor on Cytoprotection of CAPE Fluorinated Analogues 
against MD-Induced Oxidative Injury in HUVEC 
 
The application of the HO-1 inhibitor SnPPIX suggested that HO-1 was involved 
in the beneficial effects of those cytoprotective derivatives of CAPE. Different 
concentrations of SnPPIX were coincubated in HUVEC with CAPE and its 
cytoprotective analogues (CAPE-1, 3, 4, and 5) at 20 µM. SnPPIX suppressed the 
cytoprotection of most CAPE derivatives against MD in a dose-dependent manner except 
CAPE-1, where CAPE-1 cytoprotection was completely abolished compared to MD-
treated cells at any dose applied (Figure 4.6). These data further indicated that HO-1 
induction and enzymatic activity played a major role in the cytoprotection mechanisms of 


















Figure 4.6:   The effect of HO-1 inhibitor SnPPIX on CAPE and its cytoprotective 
derivatives at 20 μM against MD-mediated oxidative injury in HUVEC. 
Values are represented as means plus standard deviation (n=3). SnPPIX 
suppressed the cytoprotective effects of CAPE (A) and its analogues 3 (C), 4 
(D), and 5 (E) in a dose-dependent manner against 22.5 μM MD-induced 
oxidative injury, while it completely removed CAPE-1 (B) cytoprotection 
even at 10 μM. The incubation of CAPE derivatives plus 40 μM SnPPIX 
alone with HUVEC was not toxic. ∗: P< 0.01 versus 22.5µM MD alone. 
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4.3.4 Antioxidant Activity Comparison of CAPE and Derivatives in HUVEC by 
Determining the Intracellular ROS Production 
 
Structurally-related antioxidant activity has long been proposed as the major 
beneficial effect of polyphenols. To elucidate the effects of antioxidant properties of 
CAPE and analogues on their potential cytoprotection, we evaluated their free radical 
scavenging abilities in HUVEC through measuring the cellular ROS level with a 
fluorescent probe CM-H2DCFDA. The results showed that HUVEC treated with 20 µM 
CAPE, CAPE-1, and 2 generated ROS less fluorescence than DMSO control, indicating 
that corresponding ROS production was significantly less at 2 hrs time point compared to 
DMSO control. This represented a dampening of endogenous ROS generation that 
normally occurs during metabolism. Interestingly, CAPE-3 and 4 with only one hydroxyl 
group on the aromatic ring resulting from mono-methylation and CAPE-5 with hydrogen 
replacement behaved as pro-oxidants in cell culture that produced greater fluorescence 
than DMSO control. CAPE-6 didn’t change the trend of ROS formation in HUVEC 
(Figure 4.7). By reference to the cytoprotection data of CAPE fluorinated analogues, 
maintaining cell-based antioxidant activity didn’t correlate to cytoprotection of human 
endothelial cells against the detrimental effects of MD. CAPE-2 maintained antioxidant 
activity without being cytoprotective, while CAPE-3, 4, and 5 exhibiting pro-oxidant 
activity were also cytoprotective. CA, a potential CAPE metabolite, MC and PEDMC, 
commercially available CAPE derivatives, were also tested for antioxidant activities in 
HUVEC. CA and MC showed similar antioxidant effect compared to CAPE, while 
PEDMC didn’t change much of ROS production compared to DMSO control as CAPE-6 
did (Figure 4.7). None of these analogues showed any beneficial effects against MD-
caused damage and they didn’t elevate much HO-1 mRNA either compare to CAPE at 20 
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µM (Figure 4.8). The lack of cytoprotection for CA and MC implies the minor role of 
chemical antioxidant activity in cytoprotection, and the loss of HO-1 induction by those 
compounds indicates the important role of HO-1 activation indirectly.  
The cytoprotection, HO-1 induction, and intracellular ROS scavenging data of 
CAPE analogues have provided some insights into their structure-activity relationships. 
In the case of CAPE-6 and PEDMC, the blockage of both hydroxyl groups of CAPE 
catechol ring by methylation hindered the transcriptional activation of HO-1 gene 
expression and caused loss of cytoprotection, which was not influenced by the presence 
of 2-fluorine introduction. The only one hydroxyl methylation of CAPE (CAPE-3 and 4) 
provided some cytoprotection and elevated HO-1 mRNA as well, where the incorporation 
of fluorine at different position caused small difference in activities. The presence of only 
one hydroxyl group accompanied with an ortho-fluorine as CAPE-5 also showed 
beneficial effect correlated with HO-1 induction. The maintenance of the catechol ring of 
CAPE was not required for cytoprotection. The phenethyl ester group was a prerequisite 
feature in CAPE structure necessary to up-regulate HO-1 and provided protection since 
the replacement by H group for CA or methyl ester for MC abolished both HO-1 
induction and cytoprotection of CAPE. The introduction of fluorine at different position 
of the CAPE catechol ring, however, altered cytoprotection. 2-fluoro-CAPE (CAPE-1) 
showed maximal cytoprotection among other analogs, while 3-fluoro-CAPE (CAPE-2) 
didn’t protect HUVEC against oxidative damage by MD. Although CAPE-2 also induce 
HO-1 mRNA expression, the lack of HO-1 protein product supported the correlation 
between cytoprotection and HO-1 induction for CAPE derivatives. The cell-based 
antioxidant assay indicates the maintenance of 3, 4-dihydroxyl groups on the aromatic 
ring ensures the antioxidant function of CAPE and analogues, the total methylation of 
those groups abolishes their ROS scavenging ability, and the presence of one hydroxyl 
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group and fluorine on the catechol ring induced more ROS production. However, their 












Figure 4.7:   Direct antioxidant activities of CAPE and analogs in HUVEC demonstrated 
by measuring the alteration of intracellular ROS level. The ROS level of 
DMSO control was represented as a smooth line connecting all the data 
points (A and B). ROS level after the treatment of CA, MC, CAPE, CAPE-
1, and CAPE-2 was decreased compared to that of control in a time-
dependent manner, while the incubation of CAPE-6 and PEDMC generated 
similar ROS level as DMSO (A). The treatment of CAPE-3, 4, and 5 
increased ROS level to different extent instead (B). The different ROS level 
at 2 hrs was shown in panel C, which reflected the antioxidant abilities of 
CAPE and analogs. 
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Figure 4.8:   The cytoprotection and HO-1 induction profiles of 20 μM CA, MC, and 
PEDMC in HUVEC compared to CAPE. Values are represented as means 
plus standard deviation (n=3). Neither of CA, MC, or PEDMC protected 
HUVEC from MD-induced cytotoxicity (A), nor did they induce much HO-





The cytoprotection, HO-1 induction, and cell-based antioxidant profiles of CAPE 
and derivatives at the same molar concentration of 20 μM were determined. The 
alteration of HO-1 at the transcriptional level correlated with the cytoprotective effects of 
most CAPE analogues except CAPE-2, which up-regulated HO-1 transcript but showed 
no protection. This was explained by the failure to produce HO-1 protein levels compared 
to that of DMSO control and CAPE. The application of the HO-1 inhibitor SnPPIX 
resulted in loss of protection of CAPE derivatives, which further indicated the importance 
of HO-1 induction in cytoprotection. CAPE analogues that showed antioxidant activity in 
HUVEC but didn’t yield cytoprotective effects such as CAPE-2, CA, and MC did not 
induce HO-1. On the other hand, CAPE derivatives with pro-oxidant properties (CAPE-3, 
4, and 5) could also protect HUVEC from oxidative stress. In conclusion, transcriptional 
activation of antioxidant enzyme HO-1 contributed an important portion to CAPE 













Chapter V: Stability of Caffeic Acid Phenethyl Ester and Fluorinated 




Plasma stability is a very important issue in drug development. It has a direct 
impact on drug performance in vivo and serves as a criterion for drug candidates 
screening at early stage of preclinical study. In addition, further degradation of drugs in 
post-collecting samples could compromise the results of subsequent studies such as 
pharmacokinetics. Samtani et al have demonstrated this issue in the analysis of 
corticosteroid prodrugs betamethasone sodium phosphate and dexamethasone sodium 
phosphate from plasma samples [184, 185].  
Although CAPE exhibits many beneficial effects in animal models, its stability in 
biological media has not been well studied. In addition, our previous studies showed one 
of the CAPE derivatives, 3-(2-fluoro-4,5-dihydroxyphenyl)-acrylic acid phenethyl ester 
(CAPE-1 or FCAPE), showed good cytoprotective activity in the in vitro HUVEC-MD 
model and ability to induce HO-1 expression as CAPE (Chapter III and IV). Since this 
structural modification may result in different stability and rate of metabolism, it may 
have some advantage over CAPE in protective potency and display different 
pharmacokinetic profile in vivo.  
The purpose of this study was to investigate the stability of CAPE and FCAPE in 
rat plasma in the presence and absence of sodium fluoride at pH 6.  
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FCAPE was synthesized and characterized previously (Chapter III). Taxifolin, 
sodium fluoride, and formic acid were obtained from Aldrich and Sigma Chemical Co. 
(St. Louis, MO). Heparinized male Sprague Dawley rat plasma was purchased from 





HPLC was performed on a Varian HPLC system equipped with a 9010 pump, a 
9050 UV detector, a 9065 diode array detector, and a 9100 autosampler fitted with a 20μl 
sample injection loop. Instruments were controlled by a Varian Star 4.5 work station 
(Varian Inc., Palo Alto, CA). Column equilibration was performed prior to analysis. 
 
5.2.3 Chromatographic Conditions 
 
The HPLC analysis was performed on a RP Luna C18(2) column (250 × 3.00mm 
i.d.; 5 μm, 100 Å) coupled with a security guard C18 cartridge system (4.0 × 2.0mm i.d.; 
5 μm, 100 Å) (Phenomenex, Torrance, CA).The mobile phase consisted of A: 0.5% 
formic acid in acetonitrile and B: 0.5% formic acid in water. Before analysis, the mobile 
phase was filtered and degassed. The flow rate was maintained at 0.4 ml/min and the 
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detection wavelengths were set at 325 and 330 nm for CAPE and FCAPE, respectively. 
The sample volume injected was 20 µl. The temperatures of column and autosampler 
were controlled at room temperature of 25 °C and 4 °C, respectively. The gradient system 
was illustrated in Table 5.1. At 15 minutes, the gradient system was changed back to the 
beginning level (15% A and 85% B) before next run.  
 
Table 5.1: The gradient system for CAPE and FCAPE 
Time (min) Gradient (CAPE) Gradient (FCAPE) 
 (%)A (%)B (%)A (%)B 
0 15 85 15 85 
2 15 85 15 85 
3 75 25 55 45 
10 100 0 100 0 
15 100 0 100 0 
A: acetonitrile with 0.5% formic acid. 
B: water with 0.5% formic acid. 
 
 
5.2.4 Sample Preparation 
 
The method was based on the extraction of CAPE and FCAPE from plasma with 
ethyl acetate. Blank rat plasma was spiked with freshly made working solutions of 
CAPE, FCAPE, and taxifolin in acetonitrile for the preparation of CAPE or FCAPE 
calibration standard samples. Two hundred microliters of spiked rat plasma samples were 
transferred to a 1.5-ml centrifuge microtube. Six hundred microliters of ethyl acetate was 
added to the plasma samples, vortexed for 15 minutes, and centrifuged at 5,000 × g for 15 
minutes at 4ºC. The supernatant (organic phase) was transferred to a 2-ml centrifuge 
microtube. The residue was extracted with 600 µl of ethyl acetate one more time, and the 
supernatant was collected, pooled, evaporated under a nitrogen stream at room 
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temperature, and stored at -20 ºC. Samples were reconstituted with 200 µl of mobile 
phase A: B (50:50, v/v) immediately prior to analysis. After vortexing for 15 minutes and 
a 15-min centrifugation at 5,000 × g at 4 ºC, the supernatant was transferred to 
autosampler microvials to be analysed. All plasma samples were handled on ice during 
the extraction process. 
 
5.2.5 Method Validation 
 
Blank rat plasma was spiked with freshly prepared working solutions (100 μg/ml) 
of CAPE, FCAPE, and taxifolin (internal standard, IS) to obtain calibration standards of 
0.25, 0.5, 1, 5, and 10 μg/ml CAPE or FCAPE in the presence of 10 μg/ml IS. The HPLC 
method was validated by analyzing six replicates of each calibration standard for three 
consecutive days. Quantitative determination of CAPE and FCAPE was obtained from 
the standard curve where the peak height ratios (CAPE/taxifolin or FCAPE/taxifolin) 
were plotted against corresponding nominal concentrations of CAPE or FCAPE. A linear 
relationship was observed over the standard curve range from 0.25 to 10 μg/ml. The 
linear regression equations for the standard curve were found to be Y=0.711X – 0.048 for 
CAPE and Y=0.551X + 0.031 for FCAPE (Y, peak height ratio; X, nominal 
concentration). The coefficient of correlation (r2) was 0.9994 for CAPE and 0.9999 for 
FCAPE. Method precision and accuracy were represented as percentage relative standard 
deviation (%R.S.D.) and percentage deviation (%Deviation), respectively, which ≤ 15% 
was acceptable for most calibration standards except the lower limit of quantification 
(LLOQ). LLOQ refers to the smallest quantifiable concentration also known as the 
lowest concentration point on the calibration curve for which precision and accuracy ≤ 
20% were acceptable. The LLOQ was 0.25 µg/ml for both CAPE and FCAPE. The limit 
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of detection (LOD) regarding as the lowest concentration discriminate from baseline was 
also determined at signal/noise ratio of 3. CAPE and FCAPE were stable during the 
three-day analyses in the 4°C autosampler.  
The recovery was evaluated as absolute recovery of CAPE or FCAPE at 
concentrations of 0.25, 1 and 10 μg/ml in the presence of 10 μg/ml IS. The absolute 
recovery of the extraction procedure was measured by comparing the peak heights of 
extracted plasma samples with those of neat standards. The absolute recovery of IS was 
also determined.  
 
5.2.6 Stability Studies 
 
The described reverse-phase HPLC assay was applied to determining CAPE or 
FCAPE in rat plasma from an in vitro stability study. This study was designed to 
determine the activation energy of CAPE or FCAPE hydrolysis in rat plasma. The 
stability study was evaluated at five time points (0.5, 1, 2, 6, and 24 hrs), three 
temperatures (4, 25, and 37 °C), and two concentrations (0.5 and 5 μg/ml) in the presence 
and absence of 0.4% sodium fluoride and 0.1 M acetate buffer at pH 6. The blank rat 
plasma was first spiked with the freshly made working solutions of CAPE or FCAPE (1 
mg/ml) and taxifolin (2 mg/ml) to yield a final concentration of 0.5 or 5 μg/ml CAPE or 
FCAPE in the presence of 10 μg/ml taxifolin without the addition of sodium fluoride and 
pH adjustment. Aliquots of 200 μl of this bulk solution were placed in 1.5-ml centrifuge 
microtubes, and these microtubes were then tightly capped and incubated in the 37 °C 
incubator, at room temperature of 25 °C, and 4 °C in a refrigerator. The plasma samples 
were extracted with ethyl acetate at different time points following the extraction 
procedure described above. In addition, blank rat plasma was first mixed with 4% sodium 
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fluoride and acetate buffer (5 M, pH 5) to generate the final concentrations of 0.4% and 
0.1 M, respectively. The pretreated rat plasma was then spiked with CAPE or FCAPE 
and IS to achieve the same concentrations examined above. Aliquots of 200 μl of this 
bulk solution were stored in a 4 °C refrigerator and extracted at the same time points.   
The ability of NaF and pH adjustment to maintain the integrity of CAPE or 
FCAPE during three freeze-thaw cycles (FTCs), short-term (bench top, 24 hrs) storage, 
and long-term (-20 °C, four weeks) storage was examined. Two batches of blank rat 
plasma were mixed with NaF and acetate buffer. One batch was spiked with a low 
concentration of CAPE or FCAPE plus IS at 10 μg/ml and the other was spiked with a 
high concentration of CAPE or FCAPE plus IS. Three 200-μl aliquots of plasma samples 
at each concentration of CAPE or FCAPE were extracted and analyzed immediately 
serving as the control samples (t = 0). For the three FTCs stability study, three 200-μl 
aliquots of each concentration (0.5 or 5 μg/ml) were stored at -20 °C for 24 hrs and 
thawed at room temperature. When thawed completely, the aliquots were refrozen for 12 
to 24 hrs. After repeating two more times of this cycle, the aliquots were extracted and 
analyzed. For the short-term storage study, three aliquots of each concentration (0.25 or 
10 μg/ml) were kept at the bench top for 24 hrs before being processed for HPLC assay. 
For the long-term storage, three aliquots of each concentration (0.5 or 5 μg/ml) were 
stored at -20°C for four weeks, and processed for analysis. Stability was represented as 
percent recovery of CAPE or FCAPE by comparing the observed concentrations of 





5.2.7 Data Analysis 
 
The data obtained from the stability study in the absence of 0.4% sodium fluoride 
and 0.1 M acetate buffer were plotted as natural logarithm (Ln) of the percentage 
remaining of CAPE or FCAPE versus time. The first-order rate constant for the 
hydrolysis of CAPE or FCAPE were calculated from the slope of the linear fit of the 
experimental data.  
The energy of activation (EA) known as the minimum energy required for the 
occurrence of a reaction was obtained using the Arrhenius equation at 4, 25, and 37°C. 
The Arrhenius equation is giving by equation 5.1: 
 
                       lnk = lnA – EA/RT                            (5.1) 
 
Where k is the first order decomposition rate constant, A is the Arrhenius frequency 
factor, R represents the ideal gas constant, T is the absolute temperature, and EA is the 
Energy of Activation.  
The effect of 0.4% Sodium fluoride and 0.1 M acetate buffer on the kinetics of 
hydrolysis of CAPE or FCAPE from rat plasma was evaluated by analysis of variance 








5.3 RESULTS AND DISCUSSION 
 
5.3.1 Assay Validation 
 
To facilitate the stability study of CAPE and its fluorinated derivative FCAPE, we 
developed a simple HPLC assay with UV detection. The chromatographic separation was 
specific for CAPE and FCAPE, and no endogenous substances interfered with their 
determinations. Representative chromatograms for CAPE and FCAPE were shown in 
Figure 5.1. The retention time was 9.1 minutes for CAPE and 7.3 minutes for IS, and 
11.0 minutes for FCAPE and 7.9 minutes for IS over a 15-min run, respectively. The 
assays were linear over the range of 0.25 – 10 µg/ml for CAPE and FCAPE (r2 > 0.999, 
n=3). The linear regression parameters, method precision, and accuracy for CAPE and 
FCAPE were reported in Table 5.2, 5.3, and 5.4, respectively. In brief, the precision 
ranged from 0.7 to 13.7% for CAPE, and 0.4 to 10.4% for FCAPE. Accuracy ranged 
from -2.8 to 12.4% for CAPE and -0.6 to 6.8% for FCAPE. The LOD was set at 0.1 
µg/ml for both CAPE and FCAPE. The absolute recovery was 84% - 96% (%R.S.D. ≤ 
9.7) for CAPE, and 86.8% (%R.S.D. = 13.6) for IS (n=18). The absolute recovery was 
89% - 100% (%R.S.D. ≤ 7.9) for FCAPE, and 95.6% (%R.S.D. = 9.4) for IS (n=18). The 




Figure 5.1:   Typical chromatograms of (A) CAPE (10 μg/ml) and (B) FCAPE (10 μg/ml) 
from rat plasma in the presence of 10 μg/ml Taxifolin as internal standard. 







Table 5.2: Linear regression parameters. 
  CAPE standard curve parameters 
Statistics Linear slope  Intercept  r2 
 0.7192 -0.0618 0.9994 
 0.7264 -0.0659 0.9987 
 0.6867 -0.0160 1.0000 
Mean              0.711          -0.048 0.9971 
SD              0.021           0.028 0.0014 
%R.S.D.              3.0       -57.8    0.1 
 FCAPE standard curve parameters 
 0.5671 0.0214 1.0000 
 0.5530 0.0435 1.0000 
 0.5319 0.0278 0.9996 
Mean              0.551          0.031 0.9999 
SD              0.018          0.011 0.0002 












Table 5.3: CAPE analytical method validation. 
                        Nominal  concentration (μg/ml)  
  0.25 0.5 1 5 10 
                       Observed concentration (μg/ml) 
Day1 0.281 0.505 0.986 4.574     10.65 
 0.285 0.506 1.045 4.857     10.39 
 0.302 0.551 0.979 4.664   9.966 
 0.290 0.576 1.035 4.835   9.927 
 0.305 0.521 1.027 4.768  9.751 
 0.298 0.522 1.031 5.260  9.804 
      
Day2 0.309 0.525 1.112 4.650   9.673 
 0.312 0.533 1.075 4.620     10.66 
 0.326 0.553 0.993 4.483     10.19 
 0.314 0.549 0.958 4.985   9.891 
 0.299 0.541 1.039 4.893   9.911 
 0.310 0.536 1.050 4.785     10.42 
      
Day3 0.245 0.461 1.021 4.946     10.21 
 0.246 0.463 1.015 4.934   9.726 
 0.244 0.502 1.042 4.963   9.783 
 0.236 0.477 1.026 5.048     10.36 
 0.229 0.487 1.056 5.181   9.747 
  0.227 0.479 1.038 4.963     10.15 
Mean 0.281 0.516 1.029 4.856     10.07 
SD 0.033 0.033 0.036 0.207 0.32 
%R.S.D.  11.7    6.4    3.5    4.3       3.2 
%Deviation a  12.4    3.2    2.9   -2.9       0.7 
          
 
 






Table 5.4: FCAPE analytical method validation. 
                        Nominal  concentration (μg/ml)  
  0.25 0.5 1 5 10 
                       Observed concentration (μg/ml) 
Day1 0.274 0.446 0.987 4.852   9.920 
 0.244 0.543 1.000 5.182   9.869 
 0.228 0.558 1.007 4.953     10.90 
 0.245 0.539 0.945 5.067   9.725 
 0.235 0.506 1.007 5.007   9.792 
 0.230 0.519 0.963 4.979   9.783 
      
Day2 0.248 0.379 1.002 4.886     10.19 
 0.255 0.457 1.004 5.199     10.25 
 0.318 0.480 0.983 5.118   9.813 
 0.293 0.525 1.017 5.197     10.07 
 0.209 0.502 0.963 4.723   9.922 
 0.242 0.513 0.991 5.100   9.654 
      
Day3 0.214 0.414 1.025 4.755   9.643 
 0.304 0.512 1.054 4.926     10.33 
 0.360 0.530 0.951 5.058   9.999 
 0.334 0.457 0.936 4.934     10.64 
 0.325 0.569 0.971 4.729   9.447 
  0.244 0.525 1.199 4.791     10.32 
Mean 0.267 0.499 1.000 4.970     10.01 
SD 0.045 0.051 0.058 0.159 0.37 
%R.S.D.  16.9  10.2    5.8    3.2       3.7 
%Deviation a    6.8   -0.2    0.0   -0.6       0.1 
            
 
 





Table 5.5: Absolute recovery of CAPE and FCAPE. 
Nominal concentration         CAPE                 FCAPE 
 Absolute recovery (% recovery) 
0.25 μg/ml 81.1   83.6 
 85.6   88.7 
 81.9 101.8 
 83.7   94.1 
 79.9   88.1 
  99.8   83.2 
Mean 85.3   89.9 
SD   7.3     7.1 
%R.S.D.   8.6     7.9 
   
1 μg/ml 80.5   92.3 
 81.2 102.9 
 94.3   92.5 
 77.5 106.9 
 81.1 106.4 
  92.1   94.0 
Mean 84.5   99.2 
SD   7.0     7.0 
%R.S.D.   8.3     7.1 
   
10 μg/ml 82.7   88.3 
        105.5 100.5 
 85.8   88.5 
        102.2   95.7 
 95.1   96.1 
         101.2   81.4 
Mean 95.4   91.8 
SD   9.3     7.0 




5.3.2 Stability Study 
 
5.3.2.1 Temperature effect 
 
The effect of temperature on the degradation of CAPE and FCAPE in rat plasma 
was investigated at 4, 25, and 37 °C. Decomposition of CAPE occurred spontaneously in 
plasma samples at room temperature, was enhanced at 37 °C and slowed down at 4 °C 
(Table 5.6 and 5.7 for CAPE, and Table 5.8 and 5.9 for FCAPE). Since CAPE and 
FCAPE at a low dose of 0.5 μg/ml disappeared dramatically and couldn’t be quantified at 
37 °C, Their degradation at 5 μg/ml was plotted as the natural logarithm of percent 
remaining versus time (Figure 5.2 and 5.3). Linear relationships were observed for CAPE 
and FCAPE at three temperatures tested with the correlation coefficients greater than 
0.95. This indicated that CAPE and FCAPE in rat plasma underwent first-order 
degradation kinetics within the conditions studied. The slope of the plot represented the 
first-order degradation rate constant (k), which were summarized in Table 5.10. The 
effect of temperature on the observed rate constant for a uni- or bimolecular reaction 
could indicate an empirical relation described by Arrhenius equation. In this study, linear 
Arrhenius plots were observed for the degradation of CAPE and FCAPE (Figure 5.4), 
which indicated that the hydrolysis mechanism were the same within the temperature 
range tested. The energy of activation (Ea value) for the hydrolysis reaction of CAPE and 
FCAPE in rat plasma was calculated from the slope of the Arrhenius plot. The half-lives 
(t1/2) of CAPE and FCAPE at the temperatures studied were determined by equation 5.2: 
  
                            t1/2 = 0.693 / k                   (5.2) 
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 Where k is the first order decomposition rate constant and t1/2 is the half-life. The 
calculated Ea, k, and t1/2 were shown in Table 5.10. 
 
Table 5.6:    Stability of 0.5 μg/ml CAPE in spiked rat plasma at 37 °C, 25 °C, and 4 °C 
in the absence of NaF∗.  
 0 (control) 0.5 hr 1 hr 2 hr 6 hr 24 hr 
                  Stability (% recovery) 
37 °C  BLOQ BLOQ BLOQ ND ND 
  BLOQ BLOQ BLOQ ND ND 
    BLOQ BLOQ BLOQ BLOQ ND 
  BLOQ BLOQ BLOQ ND ND 
       
25 °C   96.9 56.9 BLOQ BLOQ ND ND 
 100.8 60.2 BLOQ BLOQ ND ND 
  102.1 61.7 BLOQ BLOQ ND ND 
Mean 99.9 59.6 BLOQ BLOQ ND ND 
SD   2.7   2.4     
%R.S.D.   2.7   4.0     
       
4 °C  87.0 71.0 88.6 49.7 BLOQ 
  80.7 73.9 71.4 55.4 BLOQ 
    88.2 90.4 64.8 54.4 BLOQ 
Mean  85.3 78.5 74.9 53.2 BLOQ 
SD    4.0 10.5 12.3   3.0  
%R.S.D.     4.7 13.4 16.4   5.6   
             
             BLOQ: below lower limit of quantification.  
             ND: not detectable. 






Table 5.7:    Stability of 5 μg/ml CAPE in spiked rat plasma at 37 °C, 25 °C, and 4 °C in 
the absence of NaF∗.  
 0 (control) 0.5 hr 1 hr 2 hr 6 hr 24 hr 
          Stability (% recovery) 
37 °C  27.3 14.4 ND ND ND 
  25.6 14.0 BLOQ ND ND 
    24.6 13.6 BLOQ ND ND 
Mean  25.9 14.0 BLOQ ND ND 
SD    1.4   0.4    
%R.S.D.    5.4   2.9    
       
25 °C 101.2 58.3 29.2 14.8 BLOQ ND 
   97.1 52.4 29.8 12.3 BLOQ ND 
  101.7 52.4 30.6 16.7 BLOQ ND 
Mean 100.0 54.4 29.9 14.6 BLOQ ND 
SD     2.6   3.4   0.7   2.2   
%R.S.D.     2.6   6.3   2.3 15.1   
       
4 °C  77.6 72.6 73.7 49.7 18.1 
  74.7 69.0 72.2 45.9 16.8 
    75.1 70.4 64.4 54.6 14.5 
Mean  75.8 70.7 70.1 50.1 16.5 
SD    1.5   1.8   5.0   4.4   1.8 
%R.S.D.     2.0   2.5   7.1   8.8 10.9 
           
           BLOQ: below lower limit of quantification.  
           ND: not detectable. 







Table 5.8:    Stability of 0.5 μg/ml FCAPE in spiked rat plasma at 37 °C, 25 °C, and 4 °C 
in the absence of NaF∗.  
 0 (control) 0.5 hr 1 hr 2 hr 6 hr 24 hr 
           Stability (% recovery) 
37 °C  BLOQ BLOQ BLOQ ND ND 
  BLOQ BLOQ BLOQ ND ND 
    BLOQ BLOQ BLOQ ND ND 
  BLOQ BLOQ BLOQ ND ND 
       
25 °C 104.2 82.7 71.8 BLOQ BLOQ ND 
   96.0 78.5 81.7 BLOQ BLOQ ND 
    99.8 87.5 69.3 BLOQ BLOQ ND 
Mean 100.0 82.9 74.3 BLOQ BLOQ ND 
SD     4.1   4.5   6.6    
%R.S.D.     4.1   5.4   8.9    
       
4 °C    95.5 86.5 92.2 78.7 BLOQ 
    93.4 95.1 87.2 71.1 BLOQ 
    106.1 96.1 92.4 79.3 BLOQ 
Mean    98.3 92.6 90.6 76.4 BLOQ 
SD      6.8   5.3   2.9   4.6  
%R.S.D.       6.9   5.7   3.2   6.0   
           
           BLOQ: below lower limit of quantification.  
           ND: not detectable. 








Table 5.9:    Stability of 5 μg/ml FCAPE in spiked rat plasma at 37 °C, 25 °C, and 4 °C in 
the absence of NaF∗.  
 0 (control) 0.5 hr 1 hr 2 hr 6 hr 24 hr 
          Stability (% recovery) 
37 °C  53.5 22.5 BLOQ ND ND 
  53.0 23.0 BLOQ ND ND 
    51.2 21.3 BLOQ ND ND 
Mean  52.6 22.3 BLOQ ND ND 
SD    1.2   0.9    
%R.S.D.    2.3   4.0    
       
25 °C   99.6 80.4 63.6 43.1 10.6 ND 
   99.2 84.5 58.1 42.3 10.6 ND 
  101.2 83.6 65.1 42.8 10.9 ND 
Mean 100.0 82.8 62.3 42.7 10.7 ND 
SD     1.1   2.2   3.7   0.4   0.2  
%R.S.D.     1.1   2.7   5.9   0.9   1.9  
       
4 °C  96.3 91.6 90.1 74.8 45.5 
  95.8 95.6 92.3 74.3 45.3 
    95.3 96.2 94.6 77.0 50.8 
Mean  95.8 94.5 92.4 75.3 47.2 
SD    0.5   2.5   2.2   1.4   3.1 
%R.S.D.     0.5   2.6   2.4   1.9   6.6 
           
           BLOQ: below lower limit of quantification.  
           ND: not detectable. 









Figure 5.2:   First-order hydrolysis kinetics of CAPE at 5 μg/ml in rat plasma at 4, 25, 
and 37 °C. The linear regression equation at each temperature is shown as 
follows. 4 °C: y = -0.0679x + 4.406, r2 = 0.9725; 25 °C: y = -0.954x + 








































Figure 5.3:   First-order hydrolysis kinetics of FCAPE at 5 μg/ml in rat plasma at 4, 25, 
and 37 °C. The linear regression equation at each temperature is shown as 
follows. 4 °C: y = -0.0307x + 4.574, r2 = 0.9853; 25 °C: y = -0.369x + 








































Figure 5.4:   Arrhenius plots for the activation energy determination of CAPE (♦) and 
FCAPE ( ). The Arrhenius equations are shown as follows. CAPE: y = - 

































Table 5.10:  The kinetic parameters of hydrolysis of CAPE and FCAPE at 5 μg/ml in rat 
plasma at 4, 25, and 37 °C in the absence of NaF∗. 
    CAPE   
Temperature (°C) 37 25 4 
k (h-1) 1.97 0.954 0.0679 
t1/2 (h) 0.35 0.73 10.21 
Ea (Kcal/mol)  17.9  
    FCAPE   
Temperature (°C) 37 25 4 
k (h-1) 1.50 0.369 0.0307 
t1/2 (h) 0.46 1.88 22.57 
Ea (Kcal/mol)   20.1   









5.3.2.2 Effects of sodium fluoride and pH 
 
The application of an enzyme inhibitor and maintenance of a weak acid 
environment are common ways to keep target compounds stable in plasma samples [158]. 
In the presence of 0.4% sodium fluoride, a reversible esterase inhibitor, and pH 
adjustment to 6 with acetate buffer (5 M, pH 5), the hydrolysis of CAPE and FCAPE was 
completely inhibited at 4 °C. The stability of CAPE and FCAPE as percent of control at 
each time point was not significantly different from each other at a significance level of 
p<0.05 (Figure 5.5). This was also confirmed by the fact that no degradation product 
peak appeared on the chromatograms. The ability of NaF and pH reduction to preserve 
the integrity of CAPE or FCAPE in rat plasma was evaluated in the study of freeze-thaw, 
short-term, and long-term stability. These stability experiments reflect the conditions that 
may occur during routine sample handling, storage, and analysis. The data showed that 
the stability of all samples tested was above 85% of the corresponding controls (Table 
5.11), which indicated that 0.4% NaF addition and pH adjustment together effectively 
inhibited the hydrolysis of CAPE or FCAPE. 
These results indicated that FCAPE appeared to be more stable than CAPE as 
reflected by the higher energy of activation. The Ea value estimated for FCAPE was 13% 
higher than that of CAPE. The potential to limit the metabolism of FCAPE and other 
fluorinated derivatives may allow them to exert their protective effect longer than CAPE 
in vivo. The addition of 0.4% sodium fluoride and 0.1 M acetate buffer provides a 
feasible way to prevent the degradation of CAPE and FCAPE for the purpose of 
establishing their pharmacokinetic profiles and ensures their stability in rat plasma after 





Figure 5.5:   Stability of CAPE (A) and FCAPE (B) at 0.5 and 5 μg/ml in rat plasma in 
the presence of 0.4% Sodium fluoride and 0.1 M acetate buffer at 4 °C. 
Value were reported as mean (n=3) percent of control (t = 0 hr) with error 
bars showing the standard deviation. No statistically significant differences 
were observed at each time point compared to control for the same dose of 



















































Table 5.11:  Stability of CAPE and FCAPE in rat plasma containing sodium fluoride and 
acetate buffer, expressed as mean % recovery. 
  CAPE  FCAPE  
 0.5 μg/ml 5 μg/ml 0.5 μg/ml 5 μg/ml 
Freeze-thaw (three cycles) 102.8 84.3 99.5 95.8 
 109.0 87.2 99.9 99.4 
  101.9 83.7 96.1 98.1 
Mean 104.5 85.1 98.5 97.8 
SD     3.9   1.9   2.1   1.9 
% R.S.D.     3.7   2.2   2.1   1.9 
     
Long-term storage a   99.2 101.9   99.6 104.1 
 104.3   96.1 104.6 101.1 
    97.8 101.4 106.8   97.8 
Mean 100.5 99.8 103.7 101.0 
SD     3.4   3.2     3.7     3.2 
% R.S.D.     3.4   3.2     3.6     3.2 
     
 0.25μg/ml 10 μg/ml 0.25μg/ml 10 μg/ml 
Room temperature (24 hrs) 87.5  95.3 95.1 99.0 
 89.1    101.0 82.9 94.7 
  95.7  91.7 88.9 97.0 
Mean 90.7  96.0 89.0 96.9 
SD   4.4    4.7   6.1   2.1 
% R.S.D.   4.8    4.9   6.9   2.2 








A simple HPLC-UV analytical method was developed and validated for the 
determination of CAPE and FCAPE in rat plasma. The stability profiles of CAPE and 
FCAPE in rat plasma at 4, 25, and 37 °C were established. The data suggested that both 
CAPE and FCAPE underwent first-order hydrolysis in rat plasma, enhancing at 37 °C 
and slowing down at 4 °C compared to 25 °C. The calculated energy of activation from 
arrhenius plot was 17.9 Kcal/mol for CAPE and 20.1 Kcal/mol for FCAPE, respectively. 
This result indicates that FCAPE is more difficult to undergo hydrolysis in rat plasma 
than CAPE. The relatively longer half-lives of FCAPE at each temperature suggested that 
FCAPE is more stable than CAPE in the conditions tested.  
The effects of the esterase inhibitor NaF and pH adjustment were examined. The 
data suggested that the addition of NaF at 0.4% and acetate buffer at 0.1 M in rat plasma 
could maintain the integrity of CAPE and FCAPE after three freeze and thaw cycles, at 
room temperature for 24 hrs, and for at least four weeks at -20 °C.  
In conclusion, the chemical modification of CAPE seems to provide a better drug 
candidate with better stability and longer half-life. The application of sodium fluoride and 









Chapter VI: Quantitative Determination of Caffeic Acid Phenethyl 
Ester and Fluorinated Derivative FCAPE from Sprague Dawley Rat 





The quantitative determination of CAPE and FCAPE in a biological medium is 
essential for establishing their pharmacokinetic profiles. A literature search showed that 
only a limited number of quantitative analyses of CAPE have been performed. Ceschel et 
al. reported an HPLC-UV method for the quantification of CAPE in propolis extracts. 
The separation was performed on a Nova-Pak C18 column at room temperature with 
mobile phase consisting methanol/acetonitrile (50:50, v/v). The UV detection wavelength 
was set at 325 nm. Detailed quantitative information, however, was not available from 
the paper [159]. Del Boccio and Rotilio employed an HPLC system coupled a quadrupole 
mass spectrometer detector to measure CAPE from crude propolis [160]. Ethyl acetate 
was used to extract CAPE from propolis and the chromatographic separation was 
achieved on a Luna RP-C18 column at room temperature with a linear gradient consisting 
of acetonitrile and water with 0.5% formic acid in both solvents. The analyses were 
performed by Selected Ion Monitoring mode, monitoring deprotonated molecule peak of 
CAPE at m/z 283. The external standard method was applied to define a linear 
quantification range of 0.125 – 80 ng/ml. On the basis of Del Boccio and Rotilio’s 
method, Celli et al. were able to determine CAPE in rat plasma and urine by liquid 
chromatography/tandem mass spectrometric analysis with similar separation conditions 
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[161]. Taxifolin was used as the internal standard. The linear range was validated from 5 
to 1000 ng/ml for CAPE. The lower limit of detection was set at 1ng/ml.  
In this chapter, a method using ultra-performance liquid chromatography with 
electrospray ionization tandem mass spectrometry (UPLC-ESI-MS/MS) for the 
quantification of CAPE and FCAPE in male Sprague Dawley rat plasma was developed. 
Methyl caffeate (MC, Figure 4.1) was used as the internal standard (IS). This method was 
validated according to the acceptance criteria for bioanalytical method validation 
described in the FDA guidelines [186].  
 
 




CAPE, FCAPE, MC, NaF, formic acid, and heparinized male Sprague Dawley rat 
plasma were obtained as described in previous chapters. All reagents used were of the 




The quantitative analysis was performed on a Waters® ACQUITY™ TQD tandem 
quadrupole UPLC-MS/MS system, which consists of an ACQUITY Ultra Performance™ 
liquid chromatography system and an ACQUITY TQ detector (Waters, Milford, MA). 
This UPLC-MS/MS system was controlled by MassLynx™ 4.1 software. 
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6.2.3 UPLC-MS/MS Conditions 
 
The UPLC separation was performed on a Waters ACQUITY ethylene-bridged 
(BEH™) C18 column (1.7 µm, 2.1 × 50 mm) at 60 °C. The mobile phase consisted of 
(A) water with 0.2% formic acid and (B) acetonitrile with 0.1% formic acid at a flow rate 
of 0.4 ml/min. A gradient elution was applied (Table 6.1). The sample injection volume 
was 10 µl. The sample temperature was controlled at 4 °C prior to analysis. The total 
UPLC run time was 2.7 min.  
 
 





(ml/min) (%) A (%) B 
1 0.00 0.4 75.0 25.0 
2 0.12 0.4 75.0 25.0 
3 0.50 0.4   2.0 98.0 
4 2.00 0.4   2.0 98.0 
5 2.10 0.4 75.0 25.0 
6 2.70 0.4 75.0 25.0 
A: water with 0.2% formic acid. 






All MS optimization experiments were performed in MS scan mode and product 
scan mode. The mass spectrometer was operated in multiple reaction monitoring (MRM) 
mode using electrospray ionization in negative ion mode. For MRM data collection, the 
capillary voltage was 2800 V, the cone voltage was 40 V, the source temperature was 125 
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°C, the desolvation temperature was 350 °C, the cone gas flow was 70 L/Hr, the 
desolvation gas flow was 650 L/hr, the MS inter-scan delay was 0.01 sec, the 
polarity/mode switch inter-scan delay was 0.03 sec, the inter-channel delay was 0.01 sec, 
and the dwell time was 0.1 sec. The MRM transitions for the analytes were: m/z 283.00 > 
m/z 134.90 for CAPE, m/z 301.00 > m/z 152.90 for FCAPE, and m/z 192.90 > m/z 133.80 
for MC. 
 
6.2.4 Preparation of Stock Solutions, Calibration Standards, and Quality Control 
Samples 
 
Stock solutions of CAPE and FCAPE in acetonitrile were prepared at 1 mg/ml for 
making spiking solutions with the calibration standards. Separate stock solutions of 
CAPE and FCAPE were used to prepare spiking solutions for the quality control (QC) 
samples. A stock solution of MC at 1 mg/ml was prepared to generate an IS working 
solution at a nominal concentration of 20 µg/ml in acetonitrile. Spiking solutions of 
CAPE and FCAPE were added to SD rat blank plasma (containing 0.4% sodium fluoride 
and 0.1 M acetate buffer) to obtain the required concentrations for calibration standards 
ranging from 10 to 10000 ng/ml and QC samples at low (25 ng/ml), medium (4500 
ng/ml), and high (9000 ng/ml) concentrations for either CAPE or FCAPE. 
 
6.2.5 Sample Extraction Procedure 
 
Two hundred microliters of plasma sample in the presence of 0.4% NaF and 0.1 
M acetate buffer were transferred to a 1.5-ml centrifuge microtube with the addition of 50 
µl of the IS working solution. Six hundred microliters of ethyl acetate were applied to the 
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extracted plasma sample as previously described (Chapter V). In brief, after a 15-minute 
vortexing and a 15-minute centrifuging at 4 °C, the supernatant from both extractions 
was pooled and collected in a 2 ml centrifuge microtube. After evaporation to dryness 
under a nitrogen flow at room temperature, the resulting residues were stored at – 80 °C 
until analyzed. Prior to analysis, the extracted residues were reconstituted and diluted in 2 
ml water/methanol (50:50, v/v), mixed, and centrifuged. Ten microliters of each sample 
was injected into the UPLC-MS/MS system. 
 
6.2.6 Assay Validation 
 
Assay validation included determinations of specificity, sensitivity, accuracy, 
precision, concentration-response function (calibration), recovery, and stability. The 
calibration curve was obtained by plotting the peak ratios (CAPE/IS or FCAPE/IS) 
against the nominal concentrations of the analyte (CAPE or FCAPE) and best fitted using 
a quadratic regression model with 1/X weighting. In order to obtain the appropriate MS 
detection, the calibration curve was developed within the range from 1 to 1000 ng/ml by 
reconstitution of the calibration standards in 10-fold dilution after extraction. The limit of 
detection (LOD) was determined at a signal-to-noise (S/N) ratio of 3. The lower limit of 
quantification was measured at a minimum S/N ratio of 10. Accuracy was determined by 
comparing the mean observed concentration to the theoretical concentration and 
expressed as the ratio in percentage (% theoretical). Precision was presented as the 
percent coefficient of variation (%CV). The inter-day and intra-day accuracy and 
precision of QC samples were evaluated in three-day core validation runs. Each 
validation run consisted of calibration standards in triplicate and six replicates of QC 
samples at three different concentrations plus a minimum of two blank plasma samples 
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without IS and two with IS (not used in the regression). The recovery of CAPE or 
FCAPE and IS was determined by comparing the peak area of extracted plasma samples 
to that of the pure standard samples in solvent at three QC concentrations (n=3 for CAPE 
or FCAPE and n=9 for IS). The stability of CAPE or FCAPE in the presence of NaF and 
acetate buffer was represented as percent recovery and accessed after three freeze and 
thaw cycles, 24 hrs at room temperature, and at least one month in -30 °C at three 
concentrations of QC samples in triplicate. The carry-over effect was evaluated by 
comparing the level of CAPE or FCAPE at upper limit of quantification (ULOQ) to a 
blank sample which followed and represented as a percentage of the ratio of the peak area 
of the target analyte in the blank run versus that of the previous ULOQ sample. A carry-
over of less than 1% was considered to be acceptable.  
 
 
6.3 RESULTS AND DISCUSSION 
 
6.3.1 Method Development 
 
A validated method for quantification analysis of CAPE and FCAPE in biological 
fluid is a prerequisite for investigation of accurate pharmacokinetics. We previously 
reported an HPLC-UV method used for determination of the stability of CAPE and 
FCAPE (chapter V). Due to the limit of UV detection, a more sensitive method was 
required for in vivo quantification. We tried an HPLC tandem mass spectrometric method 
first that was capable of quantitative measurement of CAPE and FCAPE down to a lower 
limit of 1 ng/ml. However, the carryover effect of more than 6% which compromised the 
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accuracy of the measurement. The application of an UPLC system solved this problem by 
minimizing the carryover to less than 1% for both CAPE and FCAPE. The tandem MS 
detector provided the required sensitivity. The full-scan and product ion mass spectra 
were performed using the electrospray negative ionization mode since CAPE, FCAPE, 
and internal standard MC are all polyphenols and readily lost one proton forming 
deprotonated [M-H]¯ ion peaks. The full-scan mass spectra of CAPE, FCAPE, and MC 
showed abundant deprotonated molecular ion peak at m/z = 283.00, 301.00, and 192.90, 
respectively (Figure 6.1A). The consequent product ion mass spectra for CAPE, FCAPE, 
and IS exhibited major fragment ions at m/z = 134.90, 152.90, and 133.80, respectively 
(Figure 6.1B). The chromatographic separation was optimized and achieved in 2.7 min 
using an ACQUITY BEH™ C18 column with 1.7 µm particle size and gradient elution. 
Representative chromatograms for CAPE, FCAPE, and IS in rat plasma are shown in 
Figure 6.2. No endogenous interference was found in the area of interest from different 
sources of blank rat plasma. Sample clean-up procedures were adopted from our previous 
described method (chapter V). The addition of 0.4% NaF and pH adjustment of the rat 
blank plasma was necessary to maintain the integrity of CAPE and FCAPE during the 
preparation of calibration standards and QC samples. This step was necessary to assure 
the quality of the data to establish the pharmacokinetic profiles of CAPE and FCAPE. 
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                                                                     A 
 
 
                                                                       B 
Figure 6.1:   Full scan mass spectra for CAPE, FCAPE, and MC (A) and product ion 
mass spectra where product ions m/z 135, m/z 153, and m/z 134 were 
monitored for CAPE, FCAPE, and MC, respectively (B). 
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                                                                      A 
 
                                                                       B 
 
Figure 6.2:   Typical MRM chromatograms of CAPE, FCAPE, and MC at 100 ng/ml (A) 





6.3.2 Method Validation 
 
For calibration purposes, the standard curves were obtained over the 
concentration range of 1 -1,000 ng/ml after 10-fold dilutions of CAPE or FCAPE by 
plotting CAPE or FCAPE to IS peak area ratios against their nominal concentrations with 
weighted regression analysis. A quadratic regression with 1/X weighting gave the best fit 
for the concentration/detector response relationship for CAPE and FCAPE in rat plasma. 
The mean quadratic calibration equations for the validation runs were: Y= -0.0007830X2 
+ 2.112X + 0.696 for CAPE and Y= -0.0006568X2 + 1.769X + 0.509 for FCAPE. The 
mean coefficients of determination (r2) for the validation runs were 0.9971 for CAPE and 
0.9969 for FCAPE. The parameters were present in Table 6.2. Linear regression of the 
data was also performed but with much lower r2 (<0.9900) than that obtained using a 
quadratic regression. For the LC-MS(/MS) analysis, especially with ESI, calibration 
curves with a dynamic range over 2 orders of magnitude is not always linear possibly due 
to the concentration-sensitive behavior of ESI. The analyte ion signal can become 
saturated with an increase of sample concentration [187]. The lower limit of 
quantification (LLOQ) refers to the lowest calibration standard, which is 1 ng/ml for both 
CAPE and FCAPE. The typical chromatograms for CAPE and FCAPE at LLOQ were 
shown in Figure 6.3. The limit of detection was set at 0.1ng/ml for both CAPE and 
FCAPE. The calibration curves for CAPE and FCAPE were acceptable according to the 
validation criteria as the back-calculated values were within ± 15% of the nominal 
concentrations (± 20% at the LLOQ) in the three-day validation (Table 6.3 and Table 
6.4). 
For the QC samples, the inter-day and intra-day accuracy (% theoretical) of 
CAPE ranged from 91.6 to 113.2, and the inter-day and intra-day precision (%CV) was 
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less than 14.2 (Table 6.5); the inter-day and intra-day accuracy (% theoretical) of FCAPE 
ranged from 92.3 to 110.0, and the inter-day and intra-day precision (%CV) was less than 
9.5 (Table 6.6).  
The recovery of CAPE and FCAPE was estimated using QC samples by 
comparing the peak area of spiked plasma samples that were extracted versus neat 
samples. The mean absolute recovery ranged from 80.2% to 100.7% (%R.S.D. < 12.7) 
for CAPE and 49.9% to 86.3% (%R.S.D. < 9.5) for FCAPE, respectively (Table 6.7). The 
mean absolute recovery for I.S. was 98.7% (%R.S.D. = 3.1, n = 9). The stability issue of 
CAPE and FCAPE has been addressed in our previous study (Chapter V). The addition of 
NaF and pH adjustment prevented degradation of CAPE and FCAPE after three freeze-
thaw cycles (-30 °C to 20 °C), 24 hr at room temperature (20 °C), and at least one month 








































Table 6.2: Quadratic regression parameters. 
                      CAPE calibration curve parameters   
Statistics Quadratic slope (a) a Linear slope (b) a Intercept (c) a r2 
 -7.460E-04 1.916 0.9232 0.9975 
 -7.382E-04 2.148 0.5417 0.9982 
 -8.648E-04 2.272 0.6226 0.9955 
Mean -7.830E-04 2.112 0.6958 0.9971 
SD 7.095E-05 0.181 0.2010 0.0014 
%R.S.D.         9.1            8.6     28.9  0.14 
                     FCAPE calibration curve parameters  
 -6.468E-04 1.635 0.7309 0.9971 
 -5.884E-04 1.772 0.4665 0.9966 
 -7.352E-04 1.899 0.3280 0.9969 
Mean -6.568E-04 1.769 0.5085 0.9969 
SD 7.391E-05 0.132 0.2047 0.0003 
%R.S.D.       11.3            7.5     40.3  0.03 













Table 6.3: CAPE calibration curve validation. 
                                  Nominal  concentration (ng/ml)  
 1 5 10 100 500 1000 
                                  Observed  concentration (ng/ml)   
Day1 0.914 5.893 12.42 107.1 478.4 1023 
 0.807 6.165 11.26 109.3 456.5 1127 
 0.670 5.311 10.68 108.5 479.9     989.0 
       
Day2 0.857 6.108 11.05 102.6 485.8 1039 
 0.962 5.253 11.22 111.3 497.5 1051 
 0.909 5.098 10.84 106.0 454.5      975.4 
       
Day3 0.891 5.978 12.11 111.3 436.4 1097 
 0.860 5.088 11.76 117.9 487.7 1171 
  0.701 5.265 10.82 105.0 470.4     929.2 
Mean 0.841 5.573 11.35 108.8 471.9 1045 
SD 0.099 0.451   0.61     4.5   19.4    77 
%R.S.D.  11.8    8.1 5.4     4.1     4.1         7.4 















Table 6.4: FCAPE calibration curve validation. 
                                  Nominal  concentration (ng/ml)    
 1 5 10 100 500 1000 
                                  Observed  concentration (ng/ml)   
Day1 0.810 6.041 12.39 109.7 471.0 1038 
 0.830 6.030 11.21 110.2 461.5 1178 
 0.653 5.252 11.08 107.5 474.1      974.1 
       
Day2 0.707 6.189 10.84 103.0 481.3 1001 
 0.951 4.710 12.24 119.1 500.0 1070 
 0.960 5.106 10.78 106.1 437.0 1010 
       
Day3 0.797 5.498 11.39 102.5 479.6      972.4 
 0.891 5.023 10.70 111.2 497.6 _b 
  0.962 5.313 10.46 107.1 458.5      892.0 
Mean 0.840 5.462 11.23 108.5 473.4 1017 
SD 0.112 0.517   0.67     5.0   19.6     84 
%R.S.D.  13.3    9.5      6.0     4.6     4.1         8.3 
%Deviation -16.0    9.2 12.3     8.5    -5.3         1.7 











Table 6.5: Intra/inter-day precision and accuracy for CAPE QC samples.  
Nominal concentration  Intra-day  Inter-day (n=18)  
 Day1 Day2 Day3  
2.5ng/ml Observed concentration (ng/ml)  
1 2.486 2.554 2.378  
2 2.698 2.795 2.877  
3 2.796 2.744 2.822  
4 2.518 2.639 3.043  
5 2.320 2.596 2.757  
6 2.338 2.447 3.075   
Mean 2.526 2.629 2.825           2.660 
SD 0.191 0.127 0.252           0.224 
%CV     7.56     4.83     8.92           8.42 
% theoretical a 101.04 105.16 113.00       106.40 
450ng/ml     
1 445.8 463.3 450.8  
2 440.4 420.0 436.0  
3 414.7 434.7 444.6  
4 387.7 414.1 424.6  
5 387.3 412.4 426.2  
6 397.9 419.8    292.7 b   
Mean   412.30   427.38    436.44 426.84 
SD     25.90     19.27      11.38   21.67 
%CV       6.28       4.51        2.61     5.08 
% theoretical     91.62     94.98      96.98   94.85 
900 ng/ml     
1 790.0 805.5 897.7  
2   1091.4 850.5 965.8  
3 982.1 849.9 877.8  
4 779.5 812.6 772.0  
5 809.0 863.4 889.7  
6 865.1 834.7 907.3  
Mean   886.18   836.10   885.05 869.11 
SD   125.18     22.95     63.29   80.74 
%CV     14.13       2.74       7.15     9.29 
% theoretical     98.46     92.90     98.34   96.57 
     b Rejected as an outlier. 
 
 
a % theoretical = Mean Nominal × 100
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Table 6.6: Intra/inter-day precision and accuracy for FCAPE QC samples. 
Nominal concentration  intraday  interday (n=18) 
 Day1 Day2 Day3  
2.5ng/ml Observed concentration (ng/ml)  
1 2.960 2.974 2.631  
2 2.501 2.781 2.738  
3 2.671 2.688 2.897  
4 2.744 2.946 2.731  
5 2.692 2.523 2.668  
6 2.536 2.642 2.840   
Mean 2.684 2.759 2.751           2.731 
SD 0.165 0.177 0.101           0.146 
%CV     6.15     6.42     3.67           5.35 
% theoretical a 107.36 110.36 110.04       109.24 
450ng/ml     
1 447.4 452.7 411.4  
2 435.9 442.6 369.0  
3 453.2 439.6 462.2  
4 450.3 424.5 433.9  
5 430.8 428.9 399.3  
6 443.3 438.5    193.7 b   
Mean   443.48   437.80   415.16 432.11 
SD       8.66     10.05     35.21   24.02 
%CV       1.95       2.30       8.48     5.56 
% theoretical     98.56     97.29     92.27   96.02 
900 ng/ml     
1 919.6 823.3 926.5  
2 972.3 873.7 916  
3 880.4 854.4 871.4  
4 804.5 786.7 821.2  
5 882.8 912.3 879.6  
6   1056.0 847.4 909.2  
Mean   919.27   849.63   887.32 885.41 
SD     86.63     42.87     38.78   63.62 
%CV       9.42       5.05       4.37     7.19 
% theoretical   102.14     94.40     98.59   98.38 
     b Rejected as an outlier. 
 





Table 6.7: Recovery of CAPE and FCAPE. 
Nominal concentration        CAPE                   FCAPE 
  Absolute recovery (% recovery) 
2.5 μg/ml 77.0 48.7 
 91.5 54.6 
  72.2 46.3 
Mean 80.2 49.9 
SD 10.1   4.3 
%R.S.D. 12.6   8.6 
   
450 μg/ml 89.3 74.9 
 92.5 72.8 
  92.7 70.7 
Mean 91.5 72.8 
SD   1.9   2.1 
%R.S.D.   2.1   2.9 
   
900 μg/ml 97.2 83.0 
       101.7 91.3 
        103.1 84.5 
Mean       100.7 86.3 
SD   3.1   4.4 











Table 6.8: Stability of CAPE in rat plasma expressed as mean % recovery.  
Storage conditions Nominal concentrations (ng/ml) 
  2.5 450 900 
Room temperature (24hrs) 104.4 105.3 109.7 
   90.9 107.7 109.2 
   90.9 109.8 104.3 
Mean   95.4 107.6 107.7 
SD     7.8     2.3     3.0 
% R.S.D.     8.2     2.1     2.8 
    
Freeze-thaw (three cycles)   97.6 104.4   93.9 
 104.4 103.3 100.3 
    90.9   99.7   94.4 
Mean   97.6 102.5   96.2 
SD     6.7     2.4     3.5 
% R.S.D.     6.9     2.3     3.6 
    
Long-term storage a 101.0 104.2   98.5 
   87.5 100.6   96.5 
   90.9 103.8   94.6 
Mean   93.2 102.9   96.5 
SD     7.0     2.0     1.9 
% R.S.D.     7.5     1.9     2.0 










Table 6.9: Stability of FCAPE in rat plasma expressed as mean % recovery.  
Storage conditions Nominal concentrations (ng/ml) 
  2.5 450 900 
Room temperature (24hrs) 110.5 102.3 100.0 
   96.3 102.5 106.7 
 _b 106.2 105.1 
Mean 103.4 103.7 103.9 
SD   10.0     2.2     3.5 
% R.S.D.     9.7     2.1     3.4 
    
Freeze-thaw (three cycles)   99.2   97.4   96.4 
   90.7 102.3 105.6 
    85.0   98.8   92.7 
Mean   91.6   99.5   98.2 
SD     7.1     2.5     6.6 
% R.S.D.     7.8     2.5     6.7 
    
Long-term storage a   87.8   99.1   91.7 
   82.2   98.7   92.7 
 _b   98.2   95.1 
Mean   85.0   98.6   93.2 
SD     4.0     0.4     1.8 
% R.S.D.     4.7     0.4     1.9 
                    a For one month at -30 °C 








A rapid and sensitive UPLC-ESI-MS/MS method was developed, validated, and 
applied to the quantitative determination of CAPE and FCAPE in male Sprague Dawley 
rat plasma. The chromatographic separation within 3 minutes allowed a fast sample 
analysis time and high-throughput capability favoring a high sample load. The calibration 
curve showed best fit over the concentration range of 1-1,000 ng/ml using a quadratic 
regression with 1/concentration weighting. The intra and inter-day accuracy and precision 
for QC samples were all within the FDA suggested acceptance criteria. CAPE and 
FCAPE were stable in rat plasma with the addition of 0.4% NaF and 0.1 M acetate buffer 
under the storage conditions. These results support an acceptable and reliable method for 















Chapter VII: Pharmacokinetics of caffeic acid phenethyl ester and its 
fluorinated derivative FCAPE after intravenous bolus administration to 




Data from previous stability studies demonstrated that caffeic acid phenethyl ester 
(CAPE) and 3-(2-fluoro-4,5-dihydroxyphenyl)-acrylic acid phenethyl ester (FCAPE) are 
subject to rapid hydrolysis in male Sprague Dawley rat plasma and determined that 
further degradation in post-collected biological samples could be prevented by the 
addition of 0.4% NaF and 0.1 M acetate buffer (Chapter V). The quantitative 
determination of CAPE and FCAPE in male Sprague Dawley rat plasma was established 
by liquid chromatography with electrospray ionization tandem mass spectrometry and 
validated to provide sufficient sensitivity and selectivity provided (Chapter VI). Both 
studies supported the determination of the pharmacokinetic (PK) profiles of CAPE and 
FCAPE in rats.  
Three doses of CAPE were administered to determine if CAPE follows linear 
pharmacokinetics in male Sprague Dawley rats after intravenous administration. The 
non-compartmental PK analyses and bi-exponential fit of the plasma concentration (Cp) 









Helix silastic tubing (0.02 × 0.37) and St. Gobain Tygon tubing (0.02 × 0.06) 
were from VWR International (West chester, PA). Cannula guides (22 Guage) and 
stainless steel screws were from Plastics One (Roanoke, VA). Ethicon silk sutures and 




Male Sprague Dawley (SD) rats weighing 300 ± 50 grams were purchased from 
Harlan (Indianapolis, IN). Rats were housed 2-3 per cage in a temperature-controlled 
animal room under a 12:12 light: dark cycle (lights on 0700h) and allowed to acclimate 
for 1 week with food and water provided at libitum prior to surgery. Rats were housed 
individually after the surgery. The following experimental protocols were approved by 
University of Texas at Austin Animal Resource Center and met the Institutional Animal 
Care and Use Committee (IACUC). 
 
7.2.3 Surgical Procedures 
 
The rats were subjected to jugular vein catheterization surgery. During the whole 
surgical process, rats were deeply anesthetized with isoflurane gas (Henry Schein) 
through a gas anesthesia machine (induction at 4% and maintenance at 2%). Aseptic 
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procedures were performed in an isolated area dedicated for surgery. All surgical tools 
were sterilized prior to use. The surgical area including the skull and neck on each rat 
was shaved and cleaned with iodine followed by 70% alcohol and treated with 2% 
xylocaine (Henry Schein). An incision was made on the skin of the skull with a scalpel. 
Then, the jugular vein was located on the neck and a small incision was made. The 
jugular vein was isolated, hemisected and a sterile catheter introduced and secured with 
sutures. After verifying the blood flow, the catheter was pulled routed subcutaneously 
from the neck to the skull. The neck incision was sutured and cleaned with betadyne 
followed by wound powder. The animal was stabilized with a stereotax equipped with an 
isoflurane breathing adaptor. Four small holes were drilled into the skull to allow sterile 
screws to be inserted for the purpose of fixing cranioplast dental cement. Both cannula 
and jugular catheter tubing were secured on the skull with dental cement. The surgical 
area was cleaned and treated post-operatively. The catheter was flushed daily with 0.1 ml 
filtered heparinized saline (200 U/ml) till the end of the experiment. The catheterized rats 
were allowed at least 5-day to recover before the start of pharmacokinetic study. 
 
7.2.4 Pharmacokinetic Study 
 
Male Sprague Dawley rats weighing 300 ± 50 grams were randomly divided into 
four groups, each containing 5 rats. Different group of rats were intravenously 
administered CAPE at doses of 5, 10, or 20 mg/kg and FCAPE at a dose of 20mg/kg. 
CAPE or FCAPE was dissolved in 15% ethanol, 45% propylene glycol, and 40% sterile 
saline and prepared freshly before each experiment. The Rats were administered 0.5 ml 
of drug solution via the jugular vein catheter over a 30-second period. The cannula and 
catheter were immediately flushed with a small volume of isotonic heparinized saline to 
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ensure complete drug delivery. Blood samples (400 µl) were collected at 0 (pre-dose), 
and at 5, 10, 20, 40, 60, 90, 120, and 180 minutes post administration. The blood samples 
were immediately transferred to heparinized vials containing 0.4% sodium fluoride and 
0.1 M acetate buffer and placed on ice. Plasma samples were harvested by centrifugation 
at 10,000 g for one minutes and stored at -80 °C until assayed. 
 
7.2.5 Sample Extraction 
 
Two hundred microliters of plasma sample were transferred to a 1.5 ml centrifuge 
microtube with the addition of 50 µl of the IS working solution. Six hundred microliters 
of ethyl acetate were applied twice to extract the plasma sample as previously described 
in chapter VI. 
 
7.2.6 Quantitative Analysis of CAPE or FCAPE in Rat Plasma 
 
The concentration of CAPE or FCAPE was determined by the validated analytical 
procedure using UPLC-ESI-MS/MS described in chapter VI.  
 
7.2.7 Data Analysis 
 
Non-Compartmental Analysis (NCA) was performed using WinNonlin 
professional Edition version 2.1 (Pharsight Cooperation, Mountain View, CA). The data 
points within the terminal phase were chosen to determine the terminal elimination rate 
constant λz. The area under the plasma concentration time curve (AUC) was estimated 
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using linear trapezoidal rule. AUC from the time of last measurable concentration (tlast) to 
infinity was calculated as Clast/λz, where Clast is the drug concentration at tlast. The AUC 
from time zero to infinity (AUC∞) was calculated using equation 7.1. The area under the 
product of the concentration and time versus time curve is referred to the area under the 
first moment curve (AUMC). The AUMC from time zero to tlast was estimated using the 
linear trapezoidal rule. The AUMC from tlast to infinity was computed as the sum of 
Clast×tlast/λz and Clast /λz2. The computation of the AUMC∞ was achieved using equation 
7.2. Total body clearance (CL), volume of distribution (Vd), elimination phase half-life 
(t1/2-λz), mean residence time (MRT), and volume of distribution at steady state (Vss) were 














































The plasma concentration time data of CAPE or FCAPE, which declined in an 
apparent bi-exponential trend after intravenous bolus administration, were also fitted by 
non-linear regression to the equation (7.8). 
 
                             Cp = A⋅e-α⋅t + B⋅e-β⋅t                   (7.8)  
 
Parameters A, B, α, and β were estimated graphically from the slopes and 
intercepts by methods of residuals, and used to fit the plasma concentration time data by 
WinNonlin. The calculation of the AUC, AUMC, Vd, and half life (t½) was achieved 
using equations 7.9 to 7.12, respectively. The computation of parameters such as Cl, 










7.2.8 Statistical Analysis 
 
Differences between or among the mean value for each group were analyzed 
using the independent samples t-test or one-way analysis of variance using SPSS for 






















7.3 RESULTS AND DISCUSSION 
 
7.3.1 Pharmacokinetics of CAPE 
 
 The plasma concentrations (normalized by individual dose in mg) of CAPE after 
intravenous bolus administration to male Sprague Dawley rats at doses of 5, 10, and 20 
mg/kg of CAPE are summarized in Table 7.1 – 7.3. The validated calibration curve 
ranged from 10 to 10,000 ng/ml of CAPE. Therefore, concentration values less than 80% 
of LLOQ (10 ng/ml) were considered below lower limit of quantification (BLOQ) and 
not applied in pharmacokinetic analysis. Plasma samples with concentration over 10,000 
ng/ml of CAPE were diluted and reanalyzed in order to ensure that the corresponding 
concentrations after dilution fall within the calibration curve range. The plasma 
concentrations of CAPE following intravenous administration of 20 mg/kg CAPE at 5 
minutes were determined after 10-fold dilution. The graphic representations of CAPE 
plasma concentration-time profiles in semi-log scale are illustrated in Figure 7.1 – 7.3. 
CAPE shows a rapid distribution phase reflected by the rapid decline of the plasma 
concentrations from 5 to 15 minutes after 5, 10, and 20 mg/kg CAPE administered 
intravenously. The average CAPE plasma concentration-time profiles after three 








Table 7.1: Observed plasma concentrations normalized by individual dose (ng/ml⋅mg) of 
CAPE following intravenous bolus administration of 5 mg/kg CAPE to male 
Sprague Dawley rats. 
Time (min) rat1 rat2 rat3 rat4 rat5 Mean SD 
5 1570.9 679.2 797.7 464.1 1404.1 983.2 479.3 
10 200.5 107.6 62.0 44.7 131.6 109.3 61.7 
20 53.9 32.6 22.9 19.1 20.5 29.8 14.5 
40 23.4 8.0 11.1 10.4 7.9 12.1 6.4 
60 13.3 7.3 7.5 5.2 5.6 7.8 3.2 
 90 NU BLOQ BLOQ NU BLOQ   
120  NU BLOQ BLOQ BLOQ BLOQ   
180  BLOQ BLOQ BLOQ BLOQ BLOQ   
        
Dose (mg) 1.65 1.61 1.54 1.695 1.52 1.60 0.03 
Weight (kg) 0.330 0.322 0.308 0.339 0.304 0.321 0.015 
NU: not usable for pharmacokinetic analysis. 
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Figure 7.1:   Semi logarithmic representation of the individual normalized plasma 
concentration (Cp) time profile of CAPE after intravenous bolus 








Table 7.2: Observed plasma concentrations normalized by individual dose (ng/ml⋅mg) of 
CAPE following intravenous administration of 10 mg/kg CAPE to male 
Sprague Dawley rats. 
Time (min) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
5 1092.1 2778.0 1422.8 1251.2 1887.8 1686.4 679.0 
10 143.3 570.7 329.6 86.5 195.1 265.0 193.1 
20 41.5 180.9 59.4 22.0 44.0 69.6 63.7 
40 11.4 133.7 45.7  NU 14.9 51.0 49.4 
60 NU 152.1  NU 5.2  NU  NU  
90 2.7 88.4 10.4 3.8 3.4 21.7 37.4 
120 BLOQ NU NU BLOQ NU   
180  BLOQ NU NU BLOQ BLOQ   
        
Dose (mg) 3.57 3.23 2.67 3.51 3.78 3.35 0.43 
Weight (kg) 0.357 0.323 0.267 0.351 0.378 0.335 0.043 
NU: not usable for pharmacokinetic analysis. 
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Figure 7.2:   Semi logarithmic representation of the individual normalized plasma 
concentration (Cp) time profile of CAPE after intravenous bolus 









Table 7.3: Observed plasma concentrations normalized by individual dose (ng/ml⋅mg) of 
CAPE following intravenous administration of 20 mg/kg CAPE to male 
Sprague Dawley rats. 
Time (min) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
5 3675.5a 3988.8a 3175.7a 3976.2a 3251.2a 3613.5 387.0 
10 280.4 278.2 306.1 558.2 619.8 408.6 166.5 
20 71.7 49.3 106.8 432.2 355.7 203.1 177.4 
40 45.9 32.9 48.3 173.9 116.2 83.4 60.1 
60 23.6 21.2 37.8 76.8 67.7 45.4 25.5 
90 7.0 13.5 24.0 30.4 NU 25.0 16.8 
120 NU NU NU 18.4 NU NU  
180 NU NU NU NU NU NU  
        
Dose (mg) 5.78 5.88 5.72 6.36 5.2 5.79 0.41 
Weight (kg) 0.289 0.294 0.286 0.318 0.260 0.289 0.021 
a Plasma concentrations were determined after 10-fold dilution. 
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Figure 7.3:   Semi logarithmic representation of the individual normalized plasma 
concentration (Cp) time profile of CAPE after intravenous bolus 
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Figure 7.4:   Superposition of dose-normalized average plasma concentrations (Cp) of 
CAPE as a function of time after intravenous bolus administration of 5, 10, 




Non-Compartmental Analysis Following Intravenous Bolus Administration of CAPE 
 
Non-Compartmental Analysis (NCA) of the blood plasma concentration time data 
for CAPE at three doses was performed. The pharmacokinetic parameters obtained from 
the individual rat data are summarized in Table 7.4 – 7.6. The average of the 
pharmacokinetic parameters obtained from the individual plasma time curve were 
compared to the pharmacokinetic parameters obtained from the mean plasma 
concentration time curve for 5, 10, and 20 mg/kg of CAPE, respectively, in Table 7.7. 
Good agreement exists between the average of pharmacokinetic parameters obtained 
from the individual plasma concentration time data and from the pharmacokinetic 
parameters obtained from the mean plasma concentration time curve.  
One-way analysis of variance (ANOVA) test comparing the mean PK parameters 
obtained following three doses of CAPE administration intravenously to Sprague Dawley 
rats were performed and the results were summarized in Table 7.8. There were 
statistically significant differences found in body weight normalized AUC∞, total body 
clearance Cl, and volume of distribution Vd (P < 0.05). There were no statistically 
significant differences found in the terminal elimination rate constant (λz), elimination 
phase half-life (t1/2-λz), mean residence time (MRT), and volume of distribution at steady 
state (Vss) (P > 0.05).  
Figure 7.5 illustrates the relationship between dose and the area under the plasma 
concentration time curve from time zero to infinity (AUC∞). It can be observed that as the 
dose increases the AUC∞ does not increase proportionally. It can be concluded from the 
data that dose proportionality does not exist in dose range studied in this investigation. 









Table 7.4: Pharmacokinetic parameters of CAPE obtained following intravenous bolus 
administration of 5 mg/kg CAPE to male Sprague Dawley rats (non-
compartmental analysis). 
PK parameter Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
AUC∞(μg⋅min/ml⋅kg) 209.6 80.4 155.1 77.0 230.8 150.6 71.2 
Cl (ml/min⋅kg) 72.3 193.2 104.7 191.4 71.3 126.6 61.5 
Vd (ml/kg) 2066 5163 3751 5886 2197 3813 1717 
λZ  (min-1) 0.035 0.037 0.028 0.033 0.032 0.033 0.004 
λZ half-life (min) 19.8 18.5 24.8 21.3 21.4 21.2 2.4 
MRT (min) 3.1 4.2 2.3 3.0 1.7 2.9 0.9 
Vss (ml/kg) 225.7 805.4 238.2 579.4 118.1 393.4 288.2 
        
Weight (kg) 0.330 0.322 0.308 0.339 0.304 0.321 0.015 


















Table 7.5: Pharmacokinetic parameters of CAPE obtained following intravenous bolus 
administration of 10 mg/kg CAPE to male Sprague Dawley rats (non-
compartmental analysis). 
PK parameter Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
AUC∞(μg⋅min/ml⋅kg) 285.0 721.9 232.2 697.8 579.3 503.3 230.5 
Cl (ml/min⋅kg) 98.3 42.9 161.3 40.8 45.7 77.8 52.5 
Vd (ml/kg) 2651 4706 6255 1574 1296 3297 2129 
λZ  (min-1) 0.037 0.009 0.026 0.026 0.035 0.027 0.011 
λZ half-life (min) 18.7 76.1 26.9 26.7 19.7 33.6 24.0 
MRT (min) 2.8 35.4 7.7 1.6 2.0 9.9 14.5 
Vss (ml/kg) 279.4 1520.0 1247.6 63.9 90.6 640.3 690.5 
        
Weight (kg) 0.357 0.323 0.267 0.351 0.378 0.335 0.043 

















Table 7.6: Pharmacokinetic parameters of CAPE obtained following intravenous bolus 
administration of 20 mg/kg CAPE to male Sprague Dawley rats (non-
compartmental analysis). 
PK parameter Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
AUC∞(μg⋅min/ml⋅kg) 2876 3357 2112 2172 1470 2398 732 
Cl (ml/min⋅kg) 24.1 20.3 33.1 29.0 52.3 31.7 12.5 
Vd (ml/kg) 715 1087 1645 1034 1262 1148 340 
λZ  (min-1) 0.034 0.019 0.020 0.028 0.042 0.028 0.010 
λZ half-life (min) 20.6 37.2 34.4 24.7 16.7 26.7 8.8 
MRT (min) 1.7 1.9 4.1 6.8 6.9 4.3 2.5 
Vss (ml/kg) 40.3 38.1 134.4 198.0 359.7 154.1 133.2 
        
Weight (kg) 0.289 0.294 0.286 0.318 0.260 0.289 0.021 

















Table 7.7: Average of the pharmacokinetic parameters obtained from the individual 
plasma time curve and pharmacokinetic parameters obtained from the mean 
plasma concentration time curve at 5, 10, and 20 mg/kg of CAPE (non-
compartmental analysis). 















AUC∞(μg⋅min/ml⋅kg) 150.6 144.2 503.3 419.2 2398 2162 
Cl (ml/min⋅kg) 126.6 108.3 77.8 71.2 31.7 32.0 
Vd (ml/kg) 3813 3233 3297 4253 1148 1087 
λZ  (min-1) 0.033 0.034 0.027 0.017 0.028 0.029 
λZ half-life (min) 21.2 20.7 33.6 41.4 26.7 23.6 
MRT (min) 2.9 2.7 9.9 9.5 4.3 4.2 
Vss (ml/kg) 393.4 289.1 640.3 674.6 154.1 134.8 

















Table 7.8: ANOVA results comparing the mean values of pharmacokinetic parameters of 
CAPE obtained following intravenous bolus administration of CAPE at 5 
mg/kg, 10 mg/kg, and 20 mg/kg to Sprague Dawley rats.  
Pharmacokinetic 5 mg/kg 10 mg/kg 20 mg/kg ANOVA 
parameters Mean ± SD Mean ± SD Mean ± SD P value 
AUC∞(μg⋅min/ml⋅kg) 150.6 ± 71.2 503.3 ± 230.5 2398 ± 732   0.000* 
Cl (ml/min⋅kg) 126.6 ± 61.5 77.8 ± 52.5 31.7 ± 12.5   0.026* 
Vd (ml/kg) 3813 ± 1717 3297 ± 2129 1148 ± 340   0.048* 
λZ  (min-1) 0.033 ± 0.004 0.027 ± 0.011 0.028 ± 0.010 0.513 
λZ half-life (min) 21.2 ± 2.4 33.6 ± 24.0 26.7 ± 8.8 0.439 
MRT (min) 2.9 ± 0.9 9.9 ± 14.5 4.3 ± 2.5 0.410 
Vss (ml/kg) 393.4 ± 288.2 640.3 ± 690.5 154.1 ± 133.2 0.103 
* P value < 0.05 was considered significantly different.  















Figure 7.5:   Relationship of the area under the plasma concentration time curve versus 



























Bi-Exponential Fit Following Intravenous Bolus Administration of CAPE 
 
The individual blood plasma concentration time data for CAPE at three doses 
were fitted by non-linear regression to a bi-exponential equation (7.8). The individual 
pharmacokinetic parameters obtained from the individual plasma concentration time 
profile are summarized in Table 7.9 – 7.11. The average of the pharmacokinetic 
parameters obtained from the individual plasma time curve were compared to the 
pharmacokinetic parameters obtained from the mean plasma concentration time curve for 
5, 10, and 20 mg/kg of CAPE, respectively, and shown in Table 7.12. There is a 
relatively good agreement between the average of the individual pharmacokinetic 
parameters and the pharmacokinetic parameters obtained from the mean plasma 
concentration time curve. The fit of the mean plasma concentration time curves for the 5, 
10, and 20 mg/kg CAPE is represented in Figure 7.6 to 7.8, respectively. The average of 
the individual pharmacokinetic parameters and the pharmacokinetic parameters from the 
mean plasma concentration time curve both obtained from the bi-exponential fit were 
compared to those both obtained from the non-compartmental analysis (NCA). The 
results are shown in Table 7.13. The data suggest that the PK parameters estimated from 
both NCA and bi-exponential fit are relatively in good agreement. Some of the 
differences may be attributable to the large variance observed in the individual data. 
Figure 7.9 illustrates the relationship between dose and the area under the plasma 
concentration time curve from time zero to infinity (AUC∞). It can be observed that as the 
dose increases the AUC∞ does not increase proportionally. It can be concluded from the 
data that dose proportionality does not exist in the dose range studied in this 
investigation. The observed square of the correlation coefficient is 0.7715, which 








Table 7.9: Pharmacokinetic parameters of CAPE obtained following intravenous bolus 
administration of 5 mg/kg CAPE to male Sprague Dawley rats (bi-
exponential fit). 
PK parameter Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
AUC (μg⋅min/ml⋅kg) 192.8 72.6 150.9 86.3 180.8 136.7 54.7 
Cl (ml/min⋅kg) 78.6 214.0 107.6 171.0 90.9 132.4 57.8 
Vd (ml/kg) 2068 5632 3587 5344 2674 3861 1584 
t1/2 (min) 18.5 18.5 23.1 22.0 20.4 20.5 2.1 
MRT (min) 3.9 4.7 3.0 3.6 2.8 3.6 0.8 
Vss (ml/kg) 307.8 1012.2 324.1 610.9 256.1 502.2 317.0 
A (μg/ml⋅kg) 88.2 28.8 91.6 50.8 90.2 69.9 28.6 
B (μg/ml⋅kg) 0.558 0.275 0.205 0.180 0.196 0.283 0.158 
α (min−1) 0.496 0.441 0.636 0.631 0.515 0.544 0.086 
β (min−1) 0.038 0.038 0.030 0.032 0.034 0.034 0.003 
        
Weight (kg) 0.330 0.322 0.308 0.339 0.304 0.321 0.015 















Table 7.10: Pharmacokinetic parameters of CAPE obtained following intravenous bolus 
administration of 10 mg/kg CAPE to male Sprague Dawley rats (bi-
exponential fit). 
PK parameter Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
AUC (μg⋅min/ml⋅kg) 254.0 677.7 207.1 567.9 492.8 439.9 202.8 
Cl (ml/min⋅kg) 110.3 45.7 180.9 50.2 53.7 88.1 58.1 
Vd (ml/kg) 2981 4570 7236 1859 1492 3628 2346 
t1/2 (min) 18.7 69.3 27.7 25.7 19.3 32.1 21.1 
MRT (min) 3.9 34.0 8.6 2.8 3.2 10.5 13.3 
Vss (ml/kg) 434.0 1554.0 1560.2 139.4 171.4 771.8 725.9 
A (μg/ml⋅kg) 112.0 177.3 58.4 333.9 243.3 185.0 108.4 
B (μg/ml⋅kg) 0.692 2.187 0.787 0.491 0.869 1.005 0.675 
α (min−1) 0.476 0.386 0.333 0.607 0.519 0.464 0.108 
β (min−1) 0.037 0.010 0.025 0.027 0.036 0.027 0.011 
        
Weight (kg) 0.357 0.323 0.267 0.351 0.378 0.335 0.043 
















Table 7.11: Pharmacokinetic parameters of CAPE obtained following intravenous bolus 
administration of 20 mg/kg CAPE to SD rats (bi-exponential fit). 
PK parameter Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
AUC (μg⋅min/ml⋅kg) 2480 2507 1907 2733 2264 2378 311 
Cl (ml/min⋅kg) 27.9 27.1 36.7 23.0 34.0 29.7 5.5 
Vd (ml/kg) 846 1426 1748 821 791 1126 436 
t1/2 (min) 21.0 35.7 33.0 24.4 16.1 26.0 8.2 
MRT (min) 2.7 3.2 5.1 6.8 5.0 4.6 1.6 
Vss (ml/kg) 74.9 86.7 187.9 155.9 170.9 135.3 51.1 
A (μg/ml⋅kg) 1439 1404 984 1389 1191 1281 192 
B (μg/ml⋅kg) 2.92 1.43 2.91 11.85 15.55 6.93 6.35 
α (min−1) 0.602 0.577 0.556 0.600 0.625 0.592 0.026 
β (min−1) 0.033 0.019 0.021 0.028 0.043 0.029 0.010 
        
Weight (kg) 0.289 0.294 0.286 0.318 0.260 0.289 0.021 















Table 7.12: Average of the pharmacokinetic parameters obtained from the individual 
plasma time curve and pharmacokinetic parameters obtained from the mean 
plasma concentration time curve at 5, 10, and 20 mg/kg of CAPE (bi-
exponential fit). 















AUC (μg⋅min/ml⋅kg) 136.7 131.7 439.9 379.5 2378 2639 
Cl (ml/min⋅kg) 132.4 118.5 88.1 78.6 29.7 26.2 
Vd (ml/kg) 3861 3118 3628 4913 1126 819 
t1/2 (min) 20.5 18.1 32.1 44.1 26.0 21.7 
MRT (min) 3.6 3.4 10.5 11.9 4.6 4.2 
Vss (ml/kg) 502.2 402.3 771.8 932.9 135.3 108.7 
A (μg/ml⋅kg) 69.9 65.2 185.0 138.1 1281 1509 
B (μg/ml⋅kg) 0.283 0.314 1.005 0.930 6.93 7.27 
α (min−1) 0.544 0.528 0.464 0.431 0.592 0.626 
β (min−1) 0.034 0.038 0.027 0.016 0.029 0.032 














Figure 7.6:   The typical bi-exponential fit obtained from the mean plasma concentration 














Figure 7.7:   The typical bi-exponential fit obtained from the mean plasma concentration 
















Figure 7.8:   The typical bi-exponential fit obtained from the mean plasma concentration 












Table 7.13: Comparison of average of the pharmacokinetic parameters obtained from the 
individual plasma concentration (Cp) time curve and pharmacokinetic 
parameters obtained from the mean Cp time curve at 5, 10, and 20 mg/kg of 
CAPE by non-compartmental analysis (NCA) and bi-exponential fit. 
 Average of Individual 
Pharmacokinetic 5 mg/kg 10 mg/kg 20 mg/kg 
parameters NCA fit NCA fit NCA fit 
AUC∞(μg⋅min/ml⋅kg) 150.6 136.7 503.3 439.9 2398 2378 
Cl (ml/min⋅kg) 126.6 132.4 77.8 88.1 31.7 29.7 
Vd (ml/kg) 3813 3861 3297 3628 1148 1126 
t1/2 (min) 21.2 20.5 33.6 32.1 26.7 26.0 
MRT (min) 2.9 3.6 9.9 10.5 4.3 4.6 
Vss (ml/kg) 393.4 502.2 640.3 771.8 154.1 135.3 
 Mean Cp 
 NCA fit NCA fit NCA fit 
AUC∞(μg⋅min/ml⋅kg) 144.2 131.7 419.2 379.5 2162 2639 
Cl (ml/min⋅kg) 108.3 118.5 71.2 78.6 32.0 26.2 
Vd (ml/kg) 3233 3118 4253 4913 1087 819 
t1/2 (min) 20.7 18.1 41.4 44.1 23.6 21.7 
MRT (min) 2.7 3.4 9.5 11.9 4.2 4.2 































Figure 7.9:   Relationship of the area under the plasma concentration time curve versus 








7.3.2 Pharmacokinetics of FCAPE 
 
The plasma concentrations (normalized by individual dose in mg) of FCAPE after 
intravenous bolus administration to male Sprague Dawley rats at dose of 20 mg/kg of 
FCAPE are summarized in Table 7.14. The graphic representation of FCAPE plasma 
concentration-time profile in semi-log scale is illustrated in Figure 7.10. FCAPE shows a 
rapid distribution phase reflected by the rapid decline of the plasma concentrations from 




Table 7.14: Observed plasma concentrations normalized by individual dose (ng/ml⋅mg) 
of FCAPE following intravenous administration of 20 mg/kg FCAPE to 
male Sprague Dawley rats. 
Time (min) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
5 1310.6 1053.4 683.8 1351.0 877.2 1055.2 283.9 
10 196.6 227.8 113.8 NA 174.2 178.1 48.2 
20 54.9 125.1 25.7 281.2 72.3 111.9 101.3 
40 30.9 70.4 14.3 212.6 26.5 70.9 82.0 
60 26.6 44.8 7.7 117.8 15.0 42.4 44.4 
90 15.5 23.1 4.3 75.3 NU 26.4 28.1 
120 12.3 15.7 NU 51.0 NU 19.4 18.0 
180 NU NU NU NU NU NU  
        
Dose (mg) 5.1 5.84 5.52 6.18 5.76 5.68 0.40 
weight (kg) 0.255 0.292 0.276 0.309 0.288 0.284 0.020 
NA: not available. 
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Figure 7.10: Semi logarithmic representation of the individual normalized plasma 
concentration (Cp) time profile of FCAPE after intravenous bolus 




Non-Compartmental Analysis Following Intravenous Administration of FCAPE 
 
Non-Compartmental Analysis (NCA) of the blood plasma concentration time data 
for FCAPE was performed. The pharmacokinetic parameters obtained from the 
individual rat data are summarized in Table 7.15. The average of the pharmacokinetic 
parameters obtained from the individual plasma time curve were compared to the 
pharmacokinetic parameters obtained from the mean plasma concentration time curve for 
FCAPE in Table 7.16. The comparison showed that the majority of PK parameters 
obtained from both analyses appear to be in good agreement.  
Independent Samples t-test comparing the PK parameters of CAPE versus 
FCAPE at 20 mg/kg dose was performed and the results are summarized in Table 7.17. 
Statistically significant differences were found in body weight normalized AUC∞, total 
body clearance Cl, volume of distribution Vd, and volume of distribution at steady state 
(Vss) (P < 0.05). There were no statistically significant differences found in the terminal 
elimination rate constant (λz), elimination phase half-life (t1/2-λz), and mean residence time 
(MRT) (P > 0.05). The results suggest that total body clearance for FCAPE is 
significantly greater than that of CAPE, probably indicating that the change in clearance 















Table 7.15: Pharmacokinetic parameters of FCAPE obtained following intravenous bolus 
administration of 20 mg/kg FCAPE to rats (non-compartmental analysis). 
PK parameter Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
AUC∞(μg⋅min/ml⋅kg) 672.5 504.8 312.8 744.9 377.6 522.5 185.2 
Cl (ml/min⋅kg) 116.6 135.7 231.7 86.9 183.9 150.9 57.3 
Vd (ml/kg) 9492 6520 9013 4933 4677 6927 2244 
λZ  (min-1) 0.012 0.021 0.026 0.018 0.039 0.023 0.010 
λZ half-life (min) 56.4 33.3 27.0 39.4 17.6 34.7 14.5 
MRT (min) 11.7 16.7 5.4 35.4 6.3 15.1 12.2 
Vss (ml/kg) 1367.2 2267.9 1239.7 3078.5 1163.6 1823.4 830.2 
        
Weight (kg) 0.255 0.292 0.276 0.309 0.288 0.284 0.020 



















Table 7.16: Average of the pharmacokinetic parameters obtained from the individual 
plasma time curve and pharmacokinetic parameters obtained from the mean 
plasma concentration time curve at 20 mg/kg of FCAPE (non-
compartmental analysis). 
Pharmacokinetic parameters Mean of Individual Mean Cp  
AUC∞ (μg⋅min/ml⋅kg) 522.5 571.6 
Cl (ml/min⋅kg) 150.9 123.2 
Vd (ml/kg) 6927 6977 
λZ  (min-1) 0.023 0.018 
λZ half-life (min) 34.7 39.3 
MRT (min) 15.1 17.3 
Vss (ml/kg) 1823.4 2129.1 


















Table 7.17: Independent Samples t-test results of pharmacokinetic parameters of CAPE 
and FCAPE obtained following intravenous bolus administration of CAPE 
and FCAPE at 20 mg/kg to rats, respectively.  
Pharmacokinetic FCAPE CAPE t-test 
parameters Mean ± SD Mean ± SD P value 
AUC∞ (μg⋅min/ml⋅kg) 522.5 ± 185.2 2398 ± 732   0.004* 
Cl (ml/min⋅kg) 150.9 ± 57.3 31.7 ± 12.5   0.008* 
Vd (ml/kg) 6927 ± 2244 1148 ± 340   0.004* 
λZ  (min-1) 0.023 ± 0.010 0.028 ± 0.010 0.415 
λZ half-life (min) 34.7 ± 14.5 26.7 ± 8.8 0.323 
MRT (min) 15.1 ± 12.2 4.3 ± 2.5 0.089 
Vss (ml/kg) 1823.4 ± 830.2 154.1 ± 133.2   0.010* 
          * P value < 0.05 was considered significantly different.  










Bi-Exponential Fit Following Intravenous Bolus Administration of FCAPE 
 
The individual blood plasma concentration time data for FCAPE were fitted by 
non-linear regression to a bi-exponential equation (7.8). The individual pharmacokinetic 
parameters obtained from the individual plasma concentration time profile are 
summarized in Table 7.18. The average of the pharmacokinetic parameters obtained from 
the individual plasma time curve were compared to the pharmacokinetic parameters 
obtained from the mean plasma concentration time curve for 20 mg/kg of FCAPE and 
shown in Table 7.19. There is a good agreement between the average of the individual 
pharmacokinetic parameters and the pharmacokinetic parameters obtained from the mean 
plasma concentration time curve. The fit of the mean plasma concentration time curve for 
20 mg/kg of FCAPE is represented in Figure 7.11. The average of the individual 
pharmacokinetic parameters and the pharmacokinetic parameters from the mean plasma 
concentration time curve both obtained from bi-exponential fit were compared to those 
both obtained from non-compartmental analysis (NCA) in Table 7.20. The data suggest 
that the PK parameters estimated from both NCA and bi-exponential fit are relatively in 
good agreement. Some of the differences may be attributable to the large variance 















Table 7.18: Pharmacokinetic parameters of FCAPE obtained following intravenous bolus 
administration of 20 mg/kg FCAPE to male Sprague Dawley rats (bi-
exponential fit). 
PK parameter Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
AUC (μg⋅min/ml⋅kg) 597.0 592.1 278.4 751.9 430.3 530.0 180.8 
Cl (ml/min⋅kg) 131.4 115.7 260.3 86.1 161.4 151.0 66.9 
Vd (ml/kg) 7729 4628 9641 4783 3587 6074 2520 
t1/2 (min) 41.1 28.0 25.7 38.2 15.5 29.7 10.3 
MRT (min) 10.3 12.5 6.3 33.6 5.7 13.7 11.5 
Vss (ml/kg) 1351.6 1450.9 1632.2 2889.1 919.8 1648.7 741.2 
A (μg/ml⋅kg) 226.5 215.8 102.3 102.6 173.9 164.2 59.7 
B (μg/ml⋅kg) 1.41 4.01 0.84 8.00 3.50 3.552 2.826 
α (min−1) 0.442 0.502 0.413 0.330 0.493 0.436 0.070 
β (min−1) 0.017 0.025 0.027 0.018 0.045 0.026 0.011 
        
Weight (kg) 0.255 0.292 0.276 0.309 0.288 0.284 0.020 
















Table 7.19: Average of the pharmacokinetic parameters obtained from the individual 
plasma time curve and pharmacokinetic parameters obtained from the mean 
plasma concentration time curve at 20 mg/kg of FCAPE (bi-exponential fit). 
Pharmacokinetic parameters Mean of Individual  Mean Cp  
AUC (μg⋅min/ml⋅kg) 530.0 761.3 
Cl (ml/min⋅kg) 151.0 92.5 
Vd (ml/kg) 6074 4205 
t1/2 (min) 29.7 32.2 
MRT (min) 13.7 10.8 
Vss (ml/kg) 1648.7 999.0 
A (μg/ml⋅kg) 164.2 363.5 
B (μg/ml⋅kg) 3.552 3.347 
α (min−1) 0.436 0.600 
β (min−1) 0.026 0.022 















Figure 7.11: The typical bi-exponential fit obtained from the mean plasma concentration 
















Table 7.20: Comparison of average of the pharmacokinetic parameters obtained from the 
individual plasma time curve and pharmacokinetic parameters obtained 
from the mean plasma concentration (Cp) time curve at 20 mg/kg of FCAPE 
by non-compartmental analysis (NCA) and bi-exponential fit. 
Pharmacokinetic Mean of Individual  Mean Cp 
parameters NCA fit NCA fit 
AUC∞(μg⋅min/ml⋅kg) 522.5 530.0 571.6 761.3 
Cl (ml/min⋅kg) 150.9 151.0 123.2 92.5 
Vd (ml/kg) 6927 6074 6977 4205 
t1/2 (min) 34.7 29.7 39.3 32.2 
MRT (min) 15.1 13.7 17.3 10.8 












The pharmacokinetic profiles of CAPE and FCAPE were characterized following 
single intravenous bolus administration of 5, 10, and 20 mg/kg of CAPE and 20 mg/kg of 
FCAPE to male Sprague Dawley rats, respectively. The plasma concentrations of both 
CAPE and FCAPE at the doses tested declined very fast with approximate distribution 
half life of 1.31 min and 1.16 min for CAPE and FCAPE, respectively. The 
pharmacokinetic parameters estimated from the bi-exponential fit are relatively in good 
agreement with those obtained from non-compartmental analysis.  
The total body clearance of CAPE decreased significantly as the doses of CAPE 
increased followed by a significant increase in area under the plasma concentration time 
curve, which suggests a possible saturation process. The data showed that dose 
proportionality dose not exist within the dose range studied in this investigation for 
CAPE, which is in agreement with the change of clearance among the doses examined. 
The dose-normalized average plasma concentrations of CAPE were not superimposable 
suggesting non-linearity. The change in the clearance appears to be due to the change in 
volume of distribution. It should be noted that the elimination half life is not significantly 
different within three dose group of CAPE.   
The elimination half life was found not to be significantly different between 
CAPE and FCAPE (P > 0.05). However, there are significant differences (P < 0.05) 
between the clearance of FCAPE and CAPE suggesting that the volume of distribution of 
these compounds is different. Thus, further investigation is needed to elucidate the 
cause(s) of the differences observed in the total body clearance of these compounds. It 
can be postulated that differences in plasma protein binding and/or tissue binding and/or 
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Chapter VIII: Conclusions 
 
Ischemia/reperfusion (I/R) injury is a serious pathological condition associated 
with cardiovascular diseases, surgical procedures, and traumatic injury, which may lead 
to death. Recently, caffeic acid phenethyl ester (CAPE), a plant-derived polyphenolic 
compound, has been shown to ameliorate I/R injury in organs and tissues in a variety of 
different animal models. In this dissertation, to better understand the mechanism of 
cytoprotection by CAPE, an in vitro model simulating I/R injury was developed and 
investigated. The structure cytoprotective relationships of CAPE and its fluorinated 
derivatives (FCAPEs) were also investigated, and the pharmacokinetic profiles of CAPE 
and its most cytoprotective analogue FCAPE were determined in rats.  
 
CAPE cytoprotection mechanism investigation: 
 
An in vitro model was developed using menadione (MD)-induced oxidative stress 
to human umbilical vein endothelial cells (HUVEC). This model produced an oxidant 
stress that simulated I/R injury. Good dose-dependent cytoprotection of CAPE was 
observed against MD cytotoxicity in HUVEC after 6 hr pretreatment. CAPE at 5 μg/ml 
exhibited the best cytoprotection. Gene expression analysis was performed to examine 
the alteration of endothelial cell gene transcription induced by 5 μg/ml CAPE for 6 hrs. 
Heme oxygenase-1 (HO-1) was found to be significantly upregulated in its expression by 
microarray analysis. This result was confirmed by real time RT-PCR and western blot. 
The importance of HO-1 induction for CAPE cytoprotection was suggested by the HO-1 
inhibitor SnPPIX, which dose-dependently abrogated the cytoprotective effect of CAPE. 
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CAPE structure cytoprotection relationship: 
 
Six new CAPE derivatives fluorinated on the catechol ring were prepared with the 
Wittig reaction. The cytotoxicity profiles of these derivatives in HUVEC and their 
cytoprotection profiles in the HUVEC-MD model were established.  CAPE-1, 2, 3, and 4 
showed cytotoxicity at the highest dose (15 μg/ml) tested, similar to CAPE. CAPE-5 and 
6 did not show any cytotoxicity at any tested dose. Most fluorinated derivatives of CAPE 
showed dose-dependent cytoprotection except CAPE-2. At equimolar concentrations (20 
μM), CAPE-1 (FCAPE) showed the greatest cytoprotection with no significant difference 
from CAPE. 
 
Further mechanism investigation: HO-1 induction versus antioxidant activity: 
 
Cell-based antioxidant activities of CAPE and derivatives at 20 μM were 
examined by measuring the alteration of ROS level in HUVEC. HO-1 mRNA induction 
by 20 μM CAPE and derivatives was performed by real time RT-PCR. The correlation 
between cytoprotection by CAPE derivatives and antioxidant activity could not be 
confirmed. The best correlation of structure and cytoprotection was with HO-1 mRNA 
induction for most CAPE derivatives except CAPE-2. It was able to induce HO-1 
mRNA, but was not cytoprotective. The lack of HO-1 protein production by CAPE-2 
may account for its failure to be cytoprotective. The results suggested that CAPE and 
most of its derivatives are cytoprotective against oxidative stress in human endothelial 
cell culture, and this in vitro beneficial effects correlate with their ability to induce HO-1 
rather than their directly antioxidant activity.  
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Stability of CAPE and FCAPE in rat plasma: 
 
It was useful to obtain in vivo information of how CAPE and its most 
cytoprotective derivative FCAPE were distributed and eliminated as a function of time in 
animals following intravenous administration, which may provide some insight into their 
beneficial effects in vivo. Before pharmacokinetic characterization, however, the stability 
of CAPE and FCAPE in plasma needed to be addressed to prevent their further 
degradation in post-collection plasma samples as degradation of the compound could 
compromise the pharmacokinetic results. First-order hydrolysis kinetics of CAPE and 
FCAPE were observed in male Sprague Dawley rat plasma at 4, 25, and 37 °C. The 
activation energy for CAPE and FCAPE hydrolysis was estimated with Arrhenius 
equation and found to be 17.9 and 20.1 kcal/mol, respectively, suggesting that FCAPE is 
more stable than CAPE in rat plasma. The addition of the esterase inhibitor sodium 
fluoride (0.4%) and pH adjustment to 6 with 0.1 M acetate buffer retained the integrity of 
CAPE and FCAPE in rat plasma within the time period required.  
 
Quantitative determination of CAPE and FCAPE in rat plasma: 
 
An analytical method using ultra-performance liquid chromatography with 
electrospray ionization tandem mass spectrometry was developed for the quantitative 
determination of CAPE and FCAPE in rat plasma. This method was selective for the 
quantification of CAPE and FCAPE, and no endogenous interference was found in the 
area of interest. The method was validated over the calibration curve range of 1 to 1000 
ng/ml CAPE or FCAPE, which was fitted using quadratic regression with 1/concentration 
weighting. Three-day validation results showed inter/intraday precision and accuracy for 
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CAPE and FCAPE were within 15 % variability. Stability and recovery studies were 
performed, and results were acceptable. This fast, sensitive, and reliable quantitative 
method was applied for the determination of pharmacokinetics of CAPE and FCAPE in 
rats. 
 
Pharmacokinetic characterization of CAPE and FCAPE: 
 
Pharmacokinetic (PK) profiles of CAPE and FCAPE was established following 
intravenous bolus administration of CAPE at 5, 10, and 20 mg/kg, and 20 mg/kg FCAPE 
to jugular vein catheterized male Sprague Dawley rats, respectively. Primary 
pharmacokinetic parameters of CAPE and FCAPE were estimated from non-
compartmental analysis and bi-exponential fit. Relatively good agreement was observed 
for the PK parameters obtained from both analyses. At the doses used, dose 
proportionality of CAPE was not established. This was supported by the observed change 
of clearance and non-superimposable dose-normalized average plasma concentrations of 
CAPE. Statistically significant differences in total body clearance were observed between 
CAPE and FCAPE at the 20 mg/kg dose, which may be attributable to the differences in 
volume of distribution. It should be noted that the elimination half lives for CAPE and 
FCAPE were not statistically different. 
 
In conclusion, the cytoprotective effect of CAPE against oxidative stress in 
human endothelial cells was attributed to its ability to alter transcriptional event of cells, 
especially the induction of cytoprotective gene heme oxygenase-1. The selective 
chemical modifications of CAPE provided insight into receptor binding for HO-1 
induction, and further confirmed the importance of HO-1 induction for CAPE 
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cytoprotection. A direct antioxidant activity of CAPE for its cytoprotective effect was not 
supported by comparison to other derivatives that were not cytoprotective. One 
fluorinated derivative (FCAPE) with similar cytoprotective effect as CAPE in cell culture 
exhibited better stability in rat plasma. Pharmacokinetic results suggest that dose 
proportionality was not apparent for CAPE within the doses tested in Sprague Dawley 
rats. FCAPE may distribute more extensively into tissue than CAPE due to observed 
higher volume of distribution for FCAPE, which may indicate that FCAPE could exert its 
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